



(86) Date de dépôt PCT/PCT Filing Date: 2013/05/02

(87) Date publication PCT/PCT Publication Date: 2013/11/07

(85) Entrée phase nationale/National Entry: 2014/10/30

(86) N° demande PCT/PCT Application No.: IB 2013/001027

(87) N° publication PCT/PCT Publication No.: 2013/164689

(30) Priorités/Priorities: 2012/05/02 (US61/641,756);
2013/04/05 (US61/809,159)

(51) Cl.Int./Int.Cl. *C07K 16/28* (2006.01),
A61K 39/395 (2006.01), *A61P 35/00* (2006.01),
C07K 16/32 (2006.01)

(71) Demandeur/Applicant:
SYMPHOGEN A/S, DK


(72) Inventeurs/Inventors:
ANDERSEN, KIM VILBOUR, DK;
ANDERSEN, PETER SEJR, DK;
STRANDH, MAGNUS, SE;
KOEFOED, KLAUS, DK;
NIELSEN, LARS SOGAARD, DK;
PEDERSEN, MIKKEL WANDAHL, DK;
...

(74) Agent: BORDEN LADNER GERVAIS LLP

(54) Titre : COMPOSITIONS D'ANTICORPS PAN-HER HUMANISES

(54) Title: HUMANIZED PAN-HER ANTIBODY COMPOSITIONS

Figure 1



(57) Abrégé/Abstract:

The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one



(72) **Inventeurs(suite)/Inventors(continued):** JACOBSEN, HELLE, DK; KRAGH, MICHAEL, DK; KJAER, IDA, DK; POULSEN, THOMAS TUXEN, DK; LANTTO, JOHAN, SE

(57) **Abrégé(suite)/Abstract(continued):**

humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

CORRECTED VERSION

WIPO/PCT



(10) International Publication Number
WO 2013/164689 A8

- KOEFOED, Klaus**; Tom Kristensens Vej 42, 7 Tv, DK-2300 København S (DK). **NIELSEN, Lars, Sogaard**, Nivapark 58, DK-2990 Niva (DK). **PEDERSEN, Mikkel, Wandahl**; Forelvej 17, DK-3450 Alleroed (DK). **JACOBSEN, Helle**; Frugthegnet 66, DK-2830 Virum (DK). **KRAGH, Michael**; Laessoesgade 1a, 5tv, DK-2200 Copenhagen (DK). **KJAER, Ida**; Hildursgade 7, 1. Tv., DK-2100 Copenhagen (DK). **POULSEN, Thomas, Tuxen**; Broedrevej 12, DK-2870 Dyssegaard (DK).

- (74) Agents: GUNNISON, Jane, T. et al.; Ropes & Gray LLP, 1211 Avenue of the Americas, New York, NY 10036 (US).**

- (81) Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,

[Continued on next page]

- (54) Title:** HUMANIZED PAN-HER ANTIBODY COMPOSITIONS

1277_CDR _{grafted} -H	EVQLVESGGGLVDPGGSLRLSCAASG	CDR'1	GFAPSYISMSWVROAPGKGL	45
10292			R	45
10460 & 11294			R	45
1277_CDR _{grafted} -H	EWVSYS	CDR2	MSFAGDYLFYSDTVKGRFTISRDNAKNSLYLQMNSLRAED	90
10292			V	90
10460 & 11294			V	90
1277_CDR _{grafted} -H	TAVYYC	CDR3	VRHRDVAIDYAGGGTTVTVSS	117
10292			117	
10460 & 11294			117	
1277_CDR _{grafted} -L	DIQMTQSPSSLSASVGDRVTITCRSS	CDR1	QSIVISNGNTYIHWFQQKP	45
10292			A.....	45
1277_CDR _{grafted} -L	GKAPKLLIYKYSNRFS	CDR2	GVPSRFGSGSGTDFTLTISISLPEDFAT	90
10292				90
1277_CDR _{grafted} -L	YYCS	CDR3	QSITHTPTFGGGTKVEIK	111
10292			F.....111	
1277A_CDR _{grafted} -L	DVVMTQSPSLSPVTLGQPASISCRSS	CDR1	QSIVISNGNTYIHWFQGRP	45
10460			Y.....	45
11294			L.....Y.....	45
1277A_CDR _{grafted} -L	GGSPRRLIYKYSNRFS	CDR2	GVPSRFGSGSGTDFTLISRVEAEQGV	90
10460			L.....	90
11294			L.....	90
1277A_CDR _{grafted} -L	YYCS	CDR3	QSITHTPTFGGGTKVEIK	111
10460	F.....		111	
11294	F.....		111	

- (57) Abstract:** The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies.

WO 2013/164689 A8

- TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
13 March 2014

(48) Date of publication of this corrected version:
16 October 2014

(15) Information about Correction:
see Notice of 16 October 2014

HUMANIZED PAN-HER ANTIBODY COMPOSITIONS

Cross References to Other Applications

This application claims priority from U.S. Provisional Application 61/641,756, filed May 2, 2012, and from U.S. Provisional Application 61/809,159, filed April 5, 2013. The disclosures of those applications are incorporated by reference herein in their entirety.

Field of the Invention

The present invention relates to novel humanized recombinant antibodies targeting the epidermal growth factor receptor (EGFR) family and compositions comprising two or more of these antibodies for use in cancer therapy.

Background of the Invention

The epidermal growth factor receptor family (EGFR or ErbB/HER family) is a subgroup of the receptor tyrosine kinases (RTKs) and includes four members: EGFR/ErbB, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. The members of the EGFR family are closely related single-chain modular glycoproteins with an extracellular ligand binding region, a single transmembrane domain and an intracellular tyrosine kinase domain. In normal physiological settings the ErbB family regulates key events in coordination of cell growth, differentiation and migration. EGFR, HER2 and HER3 are believed to play crucial roles in the malignant transformation of normal cells and in the continued growth of cancer cells. EGFR and HER2 have been found to be overexpressed by many epithelial cancers. Overexpression of EGFR and HER2 has furthermore been linked to disease progression, reduced survival, poor response and chemotherapy resistance in several human epithelial cancers. The role of HER4 in malignant transformation and cancer progression is controversial and will not be discussed further here.

EGFR and HER2 are validated cancer targets and both monoclonal antibodies and small molecule inhibitors of their tyrosine kinase have been approved for the treatment of various cancers. HER3 is currently being explored as a potential therapeutic target. However, patients who initially respond to these therapies often relapse due to evolution of acquired resistance. Pre-clinical research points to the involvement of the one or both of the non-targeted receptors in the development of resistance. Thus, it appears that the ErbB receptors have the ability to replace one another in order to maintain growth stimulatory signaling and a malignant phenotype. Simultaneous targeting of two or all three receptors could therefore be a more efficient way of inhibiting cancer cells with ErbB family dependency.

EGFR is a 170kDa cell surface glycoprotein consisting of a single polypeptide chain of 1186 amino acid residues as originally determined and described by cloning and sequencing of human cDNAs from a human vulval carcinoma cell line. EGFR contains three major domains: an extracellular domain, a transmembrane domain and an intracellular domain containing the tyrosine kinase. The catalytic activity of EGFR resides in the tyrosine kinase domain (residues 685-953) and is activated upon ligand binding.

The EGFR exists in two different conformations, namely a tethered conformation (closed) and an extended conformation (open). The receptor shifts between the two conformations. In the tethered conformation domains II and IV of the extracellular region of EGFR interact, leaving the receptor in an autoinhibited state. Furthermore, domain III is held at a significant distance from domain I, whereby binding of EGF to both domains simultaneously is impossible. In the extended conformation of EGFR, domains I, II and III are sterically arranged in a C shape, giving room for EGF binding. Furthermore, the conformational changes induce exposure of a β -hairpin consisting of a 20 residue region in domain II, also known as the "dimerization arm". The dimerization arm extending from domain II of the EGFR makes extensive contacts with the domain II of another EGFR, thereby forming an EGFR homodimer.

Dimerization brings the active cytoplasmic tyrosine kinase domains of the receptors close enough for phosphorylation of the tyrosine residues in the regulatory regions of the receptors. Furthermore, the juxtamembrane regions of the two receptors form an antiparallel dimer which has been found to be important in stabilizing the tyrosine kinase dimer. The "receptor-mediated" dimerization mechanism is unique for the ErbB family compared to other tyrosine kinase receptors where "ligand-mediated" dimerization is the more common theme .

A number of modes of activation of the intracellular tyrosine kinase domain of EGFR have been suggested. Unlike other receptor tyrosine kinases, the EGFR tyrosine kinase domain by default adopts a conformation normally observed only in phosphorylated and activated kinases. This indicates that the kinase domain of EGFR is constitutively active. Regulation of a constitutive tyrosine kinase would thus occur through the delivery of a dimerization partner's C-terminal regulator region for trans-phosphorylation. Another possibility is that activation of the tyrosine kinase domain involves displacement of inhibitory interactions that have not been visualized in crystallographic studies. However, crystal structure analyses of the juxtamembrane and tyrosine kinase of EGFR have revealed that an asymmetric dimer of tyrosine kinases formed upon dimerization of two EGFRs is important for regulation of the tyrosine kinase activity. In this asymmetric homodimer one of the tyrosine kinases plays the receiver while the other tyrosine kinase plays the donor. Only the receiver kinase domain has catalytic activity and proceeds to phosphorylate tyrosine residues in the C-terminal tail of the receptor (whether in *cis* or *trans*, or both is unknown).

The clathrin-mediated endocytosis is the most important mechanism of down-regulation of EGFR. The destiny of EGFR depends on the stability of the ligand-receptor complex. Upon EGF binding to EGFR the EGFR homodimer is rapidly targeted to clathrin-coated pits and internalized through ligand-induced endocytosis. Simultaneously, EGFR is heavily ubiquitinated by the attachment of both monoubiquitin and polyubiquitin. The ubiquitin ligase Cbl is responsible for the ubiquitination of EGFR. Cbl binds either directly or indirectly through an adaptor protein such as Grb2 to phosphorylated tyrosine residues at the regulatory region of EGFR. The binding of Cbl to EGFR via Grb2 is necessary for receptor internalization. Esp15 also plays a role in EGFR internalization. The exact role of Esp15 is however still controversial. The ubiquitination is involved in endocytotic downregulation of EGFR and endosomal sorting of EGFR to lysosomes. The ubiquitin chains are recognized by the endosomal sorting complex required for transport (ESCRT) and the Hrs/STAM, which retains ubiquitinated proteins in the membrane of early endosomes, thereby hindering recycling of EGFR. Subsequently, EGFR is sorted into intra luminal vesicles (ILVs), which leads to delivery of EGFR to the late endosome and finally degradation in the lysosomes.

In contrast to the degradation of EGFR when bound to EGF, TGF- α binding allows receptor recycling. The TGF- α ligand dissociates rapidly from EGFR in the early endosome due to the acidic environment, leading to receptor dephosphorylation, de-ubiquitination and thereby recycling of the receptor back to the cell surface.

Human epidermal growth factor receptor 2 (HER2, ErbB2 or Neu) was first described in 1984 by Schechter et al. HER2 consists of 1234 amino acids and is structurally similar to EGFR with an extracellular domain consisting of four subdomains I-IV, a transmembrane domain, a juxtamembrane domain, an intracellular cytoplasmic tyrosine kinase and a regulatory C-terminal domain.

The domain II-IV contact that restricts the domain arrangement in the tethered EGFR is absent in HER2. Three of the seven conserved residues important for stabilizing the tether in the unactivated EGFR are different in HER2. HER2 thus resembles EGFR in its extended (open) form with the dimerization arm exposed and apparently poised to drive receptor-receptor interactions. The absence of a tethered HER2 conformation indicates that the receptor lacks autoinhibition as seen for the other members of the ErbB family. A stable interface of subdomain I-III seems to keep HER2 in the extended configuration similar to the extended configuration of the EGFR-EGF complex. The interaction between domains I and III involves regions corresponding to ligand-binding sites in domains I and III of EGFR, leaving no space sterically for ligands, rendering HER2 incapable of binding ligands. Domains II and IV form two distinct interfaces that stabilize the heterodimer formation of HER2 and another member of the ErbB family.

Biophysical studies have failed to detect significant HER2 homodimerization in solution or in crystals. The residues of domain II of EGFR and HER2 are similar. However, Arg285 at the dimer interface is not conserved between EGFR and HER2. In HER2 residue 285 is Leu. Mutation studies indicate that Leu at this position is partly responsible for the absence of HER2 homodimers in solution. Dimerization of intact HER2 *in vivo* may require additional interactions of sites in the transmembrane domain of HER2.

HER2 is the only member of the ErbB family that does not bind known ligands. HER2 is instead activated via formation of heteromeric complexes with other ErbB family members and thereby indirectly regulated by EGFR and HER3 ligands. HER2 is the preferred heterodimerization partner of the three other ErbB receptors. HER2 enhances the affinity of the other ErbB receptors for their ligands by slowing down the rate of ligand-receptor complex dissociation, whereby HER2 enhances and prolongs signaling. The ability of HER2 to enhance the ligand affinity of other ErbB receptors may reflect the promiscuous behavior of HER2 as a heterodimerization partner. Heterodimerization of HER2 and another ligand-bound receptor of the ErbB family induces cross-phosphorylation, leading to phosphorylation of the C-terminal tyrosine residues. The most active HER2 heterodimer is the HER2-HER3 complex. HER2 complements the kinase-deficient HER3 by providing an active kinase.

In contrast to EGFR, HER2 is internalization resistant when overexpressed. Overexpression of HER2 has further been reported to inhibit endocytosis of the other ErbB family members. Two mechanisms by which HER2 escapes lysosomal degradation and thereby remains at the plasma membrane have been suggested. Either HER2 avoids internalization or it becomes efficiently recycled from endosomes back to the plasma membrane. Studies using labeled antibodies have shown that HER2 is constantly internalized and recycled. Other studies in contrast failed to identify intracellular HER2 in cells treated with compounds known to inhibit recycling.

It has been proposed that the carboxyl terminus of HER2 does not possess all signals required for internalization or that it contains an inhibitory signal essential for clathrin-mediated endocytosis. Additionally, studies have shown that HER2 heterodimers are not delivered to endosomes. A Cbl docking site like the one found on EGFR has also been identified on HER2 (Y1112). Cbl can thereby be recruited to HER2, leading to ubiquitination of HER2, but the actual binding efficiency of Cbl is unclear. It has been proposed that HER2 is internalization resistant due to its association with membrane protrusions. Finally, other studies have shown that the endocytosis resistance of HER2-EGFR heterodimers is associated with inefficient EGF-induced formation of clathrin-coated pits.

The third member of the ErbB family, known as human epidermal growth factor receptor 3 (HER3, ErbB3) was identified in 1989 by Kraus M. H. et al. The HER3 gene encodes a protein

of 1342 amino acids with striking structural similarities to EGFR and HER2. Features such as overall size, four extracellular subdomains (I-IV) with two cysteine clusters (domains II and IV), and a tyrosine kinase domain show structural similarities to EGFR and HER2. The tyrosine kinase domain of HER3 shows 59% sequence homology to the tyrosine kinase domain of EGFR.

Just like EGFR, HER3 exists in a tethered conformation and an extended conformation. In the tethered conformation the dimerization arm is buried by interactions with domain IV, leaving domains I and III too far apart for efficient ligand binding. Ligand binding to the extracellular domains I and III occurs in the extended conformation of HER3 and leads to heterodimerization with other members of the ErbB family. No HER3 homodimers are formed upon ligand binding. The extended and ligand-bound HER3 molecule preferentially heterodimerizes with HER2.

In contrast to EGFR and HER2, the tyrosine kinase of HER3 has impaired catalytic activity, insufficient for any detectable biological response. Two amino acid residues which are highly conserved in the catalytic domains of protein kinases are altered in the catalytic domain of HER3. These are the substitution of asparagine for aspartic acid at residue 815 and substitution of histidine for glutamate at residue 740. The two amino acid substitutions may be the reason why HER3 lacks catalytic activity of its tyrosine kinase domain. Because of the impaired intrinsic kinase activity of HER3 the receptor needs to heterodimerize with another ErbB family member in order to respond to its own ligand binding.

Little is known about endocytosis of HER3. Moreover, different studies have suggested that HER3 is endocytosis impaired to the same extent as HER2. In agreement with this, the HER3-NRG1 complex was found to be internalized less efficiently and slower than the EGFR-EGF complex, supporting the view that HER3 is not endocytosed as efficiently as EGFR. However, when the C-terminal tail of EGFR was replaced with the C-terminal tail of HER3, EGFR became endocytosis impaired, suggesting that a region in the C-terminus of HER3 protects the receptor against internalization. It has also been suggested that NRG1 does not efficiently target HER3 to degradation due to the dissociation of the ligand-receptor complexes in endosomes, as it is observed when EGF is activated by TGF α .

Targeting the ErbB family has been intensely pursued in the last decade as a cancer treatment strategy. Different treatment modalities have been explored, such as tyrosine kinase inhibitors (TKIs), monoclonal antibodies (mAbs) and ligand-traps. An advantage of monoclonal antibodies for treatment of cancer is target specificity, ensuring a low toxicity compared to conventional cytotoxic cancer chemotherapy. Monoclonal antibodies have been approved for the treatment of solid tumors with abnormally high levels of EGFR or HER2, and numerous mAbs targeting EGFR or HER2 are in clinical trials. TKIs inhibit receptor signaling by binding to

the ATP-binding site in the tyrosine kinase domain of EGFR and HER2. Erlotinib/Tarceva® inhibits tyrosine kinases of EGFR while lapatinib/Tykerb® inhibits tyrosine kinases of both EGFR and HER2. Both erlotinib and lapatinib are FDA approved TKIs for use in the treatment of non-small lung cancer (NSCLC) and HER2 overexpressing metastatic breast cancer, respectively.

However, despite the clinical usefulness of monoclonal antibody therapy and TKIs, development of acquired resistance to the treatment is an increasing issue. Combination therapy of mAbs and conventional cytotoxic chemotherapy is one of the approaches being carried out in order to increase treatment efficacy. Furthermore, several strategies are being explored to increase the efficacy of monoclonal antibodies, including enhancement of effector functions, and direct and indirect arming of the antibodies with radionuclides or toxins.

Thus, a need exists for additional drugs to treat EGFR family-related diseases in patients, including patients who have developed resistance to existing treatments. These additional drugs also should have a low risk of provoking an undesirable immune response when used to treat human patients.

Summary of the invention

We have discovered that simultaneous targeting of two or more members of the EGFR-family (e.g., EGFR, HER2, and HER3) with humanized antibodies leads to effective inhibition of cancer growth. We have also discovered that compositions targeting multiple EGFR-family members can be used to treat cancer, such as pancreatic, bone, colon, endometrial, or urinary tract cancer, including cancer that has acquired resistance to drug therapies targeting only one EGFR-family member.

Accordingly, the present invention is directed to humanized antibodies directed against EGFR, HER2 and HER3, as well as compositions comprising two or more humanized antibodies directed against two or more of these targets. The invention is further directed to the use of the antibodies and compositions for human cancer therapy.

One aspect of the invention relates to a recombinant antibody composition comprising at least one humanized anti-EGFR antibody or an antigen-binding fragment thereof, at least one humanized anti-HER2 antibody or an antigen-binding fragment thereof, and at least one humanized anti-HER3 antibody or an antigen-binding fragment thereof.

A humanized anti-EGFR antibody of the invention may be selected from an antibody comprising the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:3 or SEQ ID NO:2, and an antibody comprising the

heavy chain variable region sequence of SEQ ID NO:4 and the light chain variable region sequence of SEQ ID NO:5. In one embodiment, the anti-EGFR antibody may comprise a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44 and Val83, and a light chain variable region sequence (SEQ ID NO:2) comprising Ala19 and Phe92; a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44, Val83 and Ile104, and a light chain variable region sequence (SEQ ID NO:3) comprising Tyr41, Leu51 and Phe92; or a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44, Val83 and Ile104, and a light chain variable region sequence (SEQ ID NO:3) comprising Leu34, Tyr41, Leu51 and Phe92. In another embodiment, the anti-EGFR antibody may comprise a heavy chain variable region sequence (SEQ ID NO:4) comprising Leu20, Ile48 and Ala68, and a light chain variable region sequence (SEQ ID NO:5) comprising Val75 and Phe87; or a heavy chain variable region sequence (SEQ ID NO:4) comprising Leu20, Ile48, Leu56, and Ala68, and a light chain variable region sequence (SEQ ID NO:5) comprising Val75 and Phe87.

In some embodiments, the invention encompasses a humanized anti-EGFR antibody whose heavy and light chain amino acid sequences comprise: SEQ ID NOs:43 and 44, respectively, SEQ ID NOs:38 and 39, respectively, SEQ ID NOs:41 and 42, respectively, SEQ ID NOs:45 and 46, respectively, or SEQ ID NOs:47 and 48, respectively, or an antigen-binding fragment thereof.

A humanized anti-HER2 antibody of the invention may be selected from an antibody comprising the heavy chain variable region sequence of SEQ ID NO:6 and the light chain variable region sequence of SEQ ID NO:7, and an antibody comprising the heavy chain variable region sequence of SEQ ID NO:8 and the light chain variable region sequence of SEQ ID NO:9. In one embodiment, the anti-HER2 antibody may comprise a heavy chain variable region sequence (SEQ ID NO:6) comprising Ser55, Leu70, Val72, Lys74 and Ala79, and a light chain variable region sequence (SEQ ID NO:7) comprising Val44, Met48 and Tyr70; or a heavy chain variable region sequence (SEQ ID NO:6) comprising Ser55 and Val72, and a light chain variable region sequence (SEQ ID NO:7) comprising Met48 and Tyr70. In another embodiment, the anti-HER2 antibody may comprise a heavy chain variable region sequence (SEQ ID NO:8) comprising Ala49, Ile74 and Ser77, and a light chain variable region sequence (SEQ ID NO:9) comprising Thr56, Tyr71, Ser85 and Leu104.

In some embodiments, the invention encompasses a humanized anti-HER2 antibody whose heavy and light chain amino acid sequences comprise: SEQ ID NOs:51 and 52, respectively, SEQ ID NOs:49 and 50, respectively, or SEQ ID NOs:53 and 54, respectively, or an antigen-binding fragment thereof.

A humanized anti-HER3 antibody of the invention may be selected from an antibody comprising the heavy chain variable region sequence of SEQ ID NO:10 and the light chain variable region sequence of SEQ ID NO:11, and an antibody comprising the heavy chain

variable region sequence of SEQ ID NO:12 and the light chain variable region sequence of SEQ ID NO:13. In one embodiment, the anti-HER3 antibody may comprise a heavy chain variable region sequence (SEQ ID NO:10) comprising Met49, Ser55 and Ile68, or Asn44, Ser55 and Thr93, and a light chain variable region sequence (SEQ ID NO:11) comprising Phe36, Val44, Phe49 and Ile85, or Phe36, Phe49 and Leu73. In another embodiment, the anti-HER3 antibody may comprise a heavy chain variable region sequence (SEQ ID NO:12) comprising Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence (SEQ ID NO:13) comprising Val21, Val44 and Phe87, and optionally Thr29; or a heavy chain variable region sequence (SEQ ID NO:12) comprising Phe41, Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence (SEQ ID NO:13) comprising Val21, Val44, Tyr71, Phe87 and Leu104.

In some embodiments, the invention encompasses a humanized anti-HER3 antibody whose heavy and light chain amino acid sequences comprise: SEQ ID NOs:55 and 56, respectively, SEQ ID NOs:57 and 58, respectively, SEQ ID NOs:59 and 60, respectively, or SEQ ID NOs:61 and 62, respectively, or an antigen-binding fragment thereof.

The invention also encompasses antibody compositions comprising two, three, four, five or six of the antibodies described above. In some embodiments, the antibody composition may comprise (i) 11294 and/or 11302; (ii) 11249 and/or 11145; and (iii) 10738 and/or 11052. In one embodiment, the composition comprises all six antibodies.

The antibody composition may comprise (a) anti-EGFR antibody 10292, 10460, or 11294; (b) anti-EGFR antibody 10560 or 11302; (c) anti-HER2 antibody 10704 or 11249; (d) anti-HER2 antibody 11145; (e) anti-HER3 antibody 10738 or 10810; and (f) anti-HER3 antibody 11006 or 11052. In a preferred embodiment, the antibody composition comprises anti-EGFR antibodies 11294 and 11302, anti-HER2 antibodies 11249 and 11145, and anti-HER3 antibodies 10738 and 11052. Antibody 10292, 10460, 11294, 10560, 11302, 10704, 11249, 11145, 10738, 10810, 11006, or 11052 may comprise at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4.

In one embodiment, the antibody composition may comprise (a) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:43 and the light chain variable region sequence of SEQ ID NO:44; (b) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:47 and the light chain variable region sequence of SEQ ID NO:48; (c) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:51 and the light chain variable region sequence of SEQ ID NO:52; (d) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:53 and the light chain variable region sequence of SEQ ID NO:54; (e) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:55 and the light chain variable region sequence of SEQ ID NO:56; and (f) an

antibody comprising the heavy chain variable region sequence of SEQ ID NO:61 and the light chain variable region sequence of SEQ ID NO:62.

Further aspects of the invention relate to a method for producing antibodies and antibody compositions of the invention; a pharmaceutical composition comprising an antibody or an antibody composition of the invention and a pharmaceutically acceptable diluent, carrier, or excipient; a method for treating cancer in a human or other mammal comprising administering to a subject in need thereof a therapeutically effective amount of a recombinant antibody composition or pharmaceutical composition of the invention; use of a recombinant antibody composition or a pharmaceutical composition of the invention for preparing a medicament for the treatment of cancer; and a recombinant antibody composition or pharmaceutical of the invention for use as a medicament for treatment of cancer. For human treatment, the antibodies preferably are directed to human HER family members. In some embodiments, each of these compositions comprises more than one monoclonal antibody, each binding to a different epitope in the targeted HER. In some embodiments, at least one of the antibodies is conjugated to an anti-cancer agent, e.g., a cytotoxic agent, a cytokine, a toxin, or a radionuclide.

Cancer treatable by the methods of the invention includes, without limitation, pancreatic cancer (including pancreatic cancer facilitated by a KRAS mutation), head and neck cancer, breast cancer, bone cancer, colon (including colorectal cancer) cancer, endometrial cancer, urinary tract cancer, skin cancer, lung cancer, prostate cancer, gastric cancer, esophageal cancer, ovarian cancer, other epidermal cancer, and cancers with a dependency on one or more of EGFR, HER2, and HER3.

The patient may have been treated for cancer previously. For example, the patient may have been treated with a drug targeting a single EGFR-family member and have acquired resistance to the drug (e.g., cetuximab, trastuzumab, or pertuzumab).

The invention also relates to a nucleic acid molecule comprising a nucleotide sequence encoding any of the antibody heavy or light chains or heavy or light variable regions described herein. The invention also relates to an expression vector comprising such nucleic acid molecules and a host cell comprising such nucleic acid molecules or vectors. The host cell may be capable of expressing any of the antibodies described herein.

Brief Description of the Drawings

Figure 1: Amino acid sequence alignment of variable chains of the anti-EGFR humanized monoclonal antibodies 10292, 10460, and 11294 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity,

whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chains of 10292 (SEQ ID NO:38), 10460 (SEQ ID NO:40), and 11294 (SEQ ID NO:42) aligned to CDR grafted sequence (1277_CDRgrafted-H; SEQ ID NO:62). Middle: Variable light chain of 10292 (SEQ ID NO:39) aligned to CDR grafted sequence (1277_CDRgrafted-L; SEQ ID NO:63). Bottom: Variable light chains of 10460 (SEQ ID NO:41) and 11294 (SEQ ID NO:43) aligned to CDR grafted sequence (1277A_CDRgrafted-L; SEQ ID NO:64).

Figure 2: Amino acid sequence alignment of variable chains of the anti-EGFR humanized monoclonal antibodies 10560 and 11302 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity, whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chains of 10560 (SEQ ID NO:44) and 11302 (SEQ ID NO:46) aligned to CDR grafted sequence (1565_CDRgrafted-H; SEQ ID NO:65). Bottom: Variable light chains of 10560 (SEQ ID NO:45) and 11302 (SEQ ID NO:47) aligned to CDR grafted sequence (1565_CDRgrafted-L; SEQ ID NO:66).

Figure 3: Amino acid sequence alignment of variable chains of the anti-HER2 humanized monoclonal antibodies 10704 and 11249 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity, whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chains of 10704 (SEQ ID NO:48) and 11249 (SEQ ID NO:50) aligned to CDR grafted sequence (4384_CDRgrafted-H; SEQ ID NO:67). Bottom: Variable light chains of 10704 (SEQ ID NO:49) and 11249 (SEQ ID NO:51) aligned to CDR grafted sequence (4384_CDRgrafted-L; SEQ ID NO:68).

Figure 4: Amino acid sequence alignment of variable chains of the anti-HER2 humanized monoclonal antibody 11145 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity, whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chain of 11145 (SEQ ID NO:52) aligned to CDR grafted sequence (4517_CDRgrafted-H; SEQ ID NO:69). Bottom: Variable light chain of 11145 (SEQ ID NO:53) aligned to CDR grafted sequence (4517_CDRgrafted-L; SEQ ID NO:70).

Figure 5: Amino acid sequence alignment of variable chains of the anti-HER3 humanized monoclonal antibodies 10738 and 10810 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity, whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chains of 10738 (SEQ ID NO:54) and 10810 (SEQ ID NO:56) aligned to CDR grafted sequence (5038_CDRgrafted-H; SEQ ID

NO:71). Bottom: Variable light chains of 10738 (SEQ ID NO:55) and 10810 (SEQ ID NO:57) aligned to CDR grafted sequence (5038_CDRgrafted-L; SEQ ID NO:72).

Figure 6: Amino acid sequence alignment of variable chains of the anti-HER3 humanized monoclonal antibodies 11006 and 11052 with the *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions. Dots denote identity, whereas differing positions are marked with their one letter amino acid abbreviation. Shaded areas indicate CDRs as defined by IMGT. Top: Variable heavy chains of 11006 (SEQ ID NO:58) and 11052 (SEQ ID NO:60) aligned to CDR grafted sequence (5082_CDRgrafted-H; SEQ ID NO:73). Bottom: Variable light chains of 11006 (SEQ ID NO:59) and 11052 (SEQ ID NO:61) aligned to CDR grafted sequence (5082_CDRgrafted-L; SEQ ID NO:74).

Figure 7: *In vitro* activity of humanized anti-EGFR antibody variant 10292 in combination with its chimeric anti-EGFR partner antibody. A431NS cells (top panel) and H358 cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 8: *In vitro* activity of humanized anti-EGFR antibody variant 10460 in combination with its chimeric anti-EGFR partner antibody. A431NS cells (top panel) and H358 cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 9: *In vitro* activity of humanized anti-EGFR antibody variant 10560 in combination with its chimeric anti-EGFR partner antibody. A431NS cells (top panel) and H358 cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 10: *In vitro* activity of humanized anti-HER2 antibody variant 10704 in combination with its chimeric anti-HER2 partner antibody. OE19 cells (top panel) and BT474 cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 11: *In vitro* activity of humanized anti-HER2 antibody variant 11145 in combination with its chimeric anti-HER2 partner antibody. OE19 cells (top panel) and BT474 cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 12: *In vitro* activity of humanized anti-HER3 antibody variant 10738 in combination with its chimeric anti-HER3 partner antibody. MBA-MD-175 VII cells (top panel) and MCF-7 cells (in the presence of 1 nM heregulin beta; bottom panel) were treated with different

concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 13: *In vitro* activity of humanized anti-HER3 antibody variant 10810 in combination with its chimeric anti-HER3 partner antibody. MBA-MD-175 VII cells (top panel) and MCF-7 cells (in the presence of 1 nM heregulin beta; bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 14: *In vitro* activity of humanized anti-HER3 antibody variant 11006 in combination with its chimeric anti-HER3 partner antibody. MBA-MD-175 VII cells (top panel) and MCF-7 cells (in the presence of 1 nM heregulin beta; bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 15: *In vitro* activity of humanized anti-HER3 antibody variant 11052 in combination with its chimeric anti-HER3 partner antibody. MBA-MD-175 VII cells (top panel) and MCF-7 cells (in the presence of 1 nM heregulin beta; bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 16: Cross-reactivity pattern of chimeric and humanized antibodies with human, cynomolgus and murine HER family antigens. The OD signal from 40 nM antibody, measured at 450 nm using an ELISA reader, was scored from negative (-; OD<0.1) to strongly positive (+++; OD>2.5).

Figure 17: *In vitro* activity of humanized anti-EGFR antibody variant 11294 in combination with its chimeric anti-EGFR partner antibody. A431NS cells (top panel) and FaDu cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 18: *In vitro* activity of humanized anti-EGFR antibody variant 11302 in combination with its chimeric anti-EGFR partner antibody. A431NS cells (top panel) and FaDu cells (bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 19: *In vitro* activity of humanized anti-HER2 antibody variant 11249 in combination with its humanized anti-HER2 partner antibody 11145. OE19 cells (top panel) and BT474 cells

(bottom panel) were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 20: *In vitro* activity of a mixture of humanized antibodies (variants 11294, 11302, 11249, 11145, 10738 and 11052; humanized Pan-HER) and a mixture of chimeric antibodies (1277, 1565, 4384, 4517, 5038 and 5082; chimeric Pan-HER). The indicated cell lines were treated with different concentrations of the indicated antibody mixtures for 96 hours. Data are presented as means $\pm$ SEM.

Figure 21A is a schematic illustrating the interaction of Pan-HER with its EGFR (left), HER2 (middle) and HER3 (right) target proteins.

Figure 21B is a series of charts showing the effects of treatment with EGFR (left), HER2 (middle) and HER3 (right) antibodies on the metabolic activity of A431NS, HCC202, and MDA-MB-175-VII cell lines, respectively. The figure legend in the left panel lists from top to bottom: Negative control, 1277, 1565, 1277+1565. The figure legend in the center panel lists from top to bottom: Negative control, 4384, 4517, 4384+4517. The figure legend in the right panel lists from top to bottom: Negative control, 5038, 5082, 5038+5082.

Figure 21C is a series of Western blot images showing the levels EGFR (left), HER2 (middle), and HER3 (right) in the total cell lysates of A431NS, HCC202 and MDA-MB-175-VII cancer cells, respectively, that had been treated with the indicated antibodies and antibody mixtures.

Figure 22 is an image showing the receptor phosphorylation levels of EGFR (left), HER2 (middle), and HER3 (right) in 73 cancer cell lines treated with Pan-HER (1277, 1565, 4384, 4517, 5038 and 5082; chimeric Pan-HER).

Figure 23 is a table showing maximal metabolic activity as a percentage of untreated (no Heregulin or EGF) control cells (set to 100%) after treatment with Pan-HER mixture (1277, 1565, 4384, 4517, 5038 and 5082; chimeric Pan-HER), Pan-HER subcomponents and a negative control antibody.

Figure 24 is a table showing maximal metabolic activity as a percentage of untreated control cells in the absence of ligand (set to 100%) after treatment with Pan-HER (1277, 1565, 4384, 4517, 5038 and 5082; chimeric Pan-HER), Pan-HER subcomponents and a negative control antibody in the presence of 5 nM Heregulin. Cells were exposed to medium containing antibodies and ligands for 96 hours. (i.e. ligand and antibody was added simultaneously to the cells).

Figure 25 is a table showing maximal metabolic activity as a percentage of untreated control cells in the absence of ligand (set to 100%) after treatment with Pan-HER (1277, 1565, 4384, 4517, 5038 and 5082; chimeric Pan-HER), Pan-HER subcomponents and a negative control antibody in the presence of 1 nM EGF. Cells were exposed to medium containing antibodies and ligands for 96 hours. (i.e. ligand and antibody was added simultaneously to the cells).

Figure 26 is an image showing the mutation status of genes listed across the top of the image of seven pancreatic cancer cell lines (CAPAN-1, PK-1, CFPAC-1, BxPC3, ASPC1, CAPAN-2, Pan08.13, PANC-1, KP4, MiaPaca-2 and PSN1).

Figure 27 is a series of graphs showing the dose-response of the CAPAN-1 cell line to Pan-HER treatment in the absence (left) or presence of Heregulin (middle) and EGF (right) ligands.

"Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Figure 25 is a series of graphs showing the effects of Pan-HER and reference antibodies on the metabolic activity of parental cell lines (top) and the corresponding resistant clones that have acquired resistance to cetuximab, trastuzumab or pertuzumab (bottom). "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. The figure legend in the left top panel lists from top to bottom: Pan- HER, cetuximab, Neg. control. The figure legend in the center top panel lists from top to bottom: Pan-HER, trastuzumab, Neg. control. The figure legend in the right top panel lists from top to bottom: Pan-HER, pertuzumab, Neg. control.

Figure 28 is a series of graphs showing the effects of Pan-HER and reference antibodies on the metabolic activity of parental cell lines (top) and the corresponding resistant clones that have acquired resistance to cetuximab, trastuzumab or pertuzumab (bottom). "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. The figure legend in the left top panel lists from top to bottom: Pan- HER, cetuximab, Neg. control. The figure legend in the center top panel lists from top to bottom: Pan-HER, trastuzumab, Neg. control. The figure legend in the right top panel lists from top to bottom: Pan-HER, pertuzumab, Neg. control.

Figure 29 is a series of Western blot images showing the levels of EGFR, HER2 and HER3 in whole cell lysates of H292 (top) and OVCAR-8 (bottom) cell lines after antibody treatment.

"Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Figure 30 is a graph showing the effects of treatment with Pan-HER or its subcomponents on tumor volume in the BxPC-3 xenograft model. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384,

and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082.

Figure 31 is a series of images showing EGFR and HER2 immunolabeled sections of tumors resected from vehicle and Pan-HER treated BxPC-3 xenografts three days after withdrawal of treatment. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Figure 32 is a graph showing the effects of treatment with Pan-HER or its subcomponents on tumor volume in the Calu-3 xenograft model. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082.

Figure 33 (top) is a series of Western blot images showing the levels of EGFR, HER2, HER3 and a β -actin loading control in BxPC-3 tumor lysates after antibody treatment. The relative quantification of EGFR, HER2, and HER3 levels in the Western blot band intensities is shown in a series of charts in Fig. 30 (bottom). "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082.

Figure 34 is a series of graphs showing the effects of Pan-HER on tumor volume in ST191, ST204, ST383, STS021, ST179, ST385, STS064, ST334, STS059, and STS058 patient-derived tumor xenograft models of KRAS mutated pancreatic cancer. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Figure 35 is a series of graphs showing the effects of treatment with Pan-HER or its subcomponents on tumor volume in ST179 and ST383 patient-derived tumor xenograft models of KRAS mutated pancreatic cancer. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082.

Figure 36 is a schematic illustrating the development and cloning of acquired cetuximab resistant HN5 clones.

Figure 37 is a graph showing the dose-response effects of cetuximab treatment on parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14.

Figure 38 is a graph showing the binding curve of cetuximab to fixed parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14.

Figure 39 is a graph showing the relative surface levels of EGFR found by fluorescence flow cytometry in parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14.

Figure 40 is a series of Western blot images showing the total levels of EGFR, phosphorylated EGFR species, and a β -actin loading control in cell lysates from parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 that were either untreated (left) or stimulated with EGF (right).

Figure 41 is a series of Western blot images showing the total levels of EGFR, AKT, pAKT (Ser473), ERK1/2, pERK1/2(Thr202/Tyr204), and a β -actin loading control in cell lysates from parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 that were either untreated (left) or stimulated with EGF (right).

Figure 42 is a graph showing the viability of parental HN5 cells and cetuximab resistant clones HN5 CR2 and HN5 CR14 treated with EGFR-LNA, cetuximab, EGFR-2mix (antibodies 1277 and 1565) or controls.

Figure 43 is a series of Western blot images showing the total levels of EGFR in parental HN5 cells and cetuximab resistant clones HN5 CR2 and HN5 CR14 treated with EGFR-LNA, cetuximab, EGFR-2mix (antibodies 1277 and 1565) or controls.

Figure 44 is a graph showing the viability of parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 treated with the indicated EGFR antibodies.

"EGFR 2mix" refers to a mixture of antibodies 1277 and 1565. "Her3 2mix" refers to a mixture of antibodies 5038 and 5082.

Figure 45 is a series of graphs showing the dose-response of parental HN5 cells (Fig. 45A) and cetuximab resistant clones HN5 CR2 (Fig. 45B) viability to treatment with the indicated antibodies. "EGFR 2mix" refers to a mixture of antibodies 1277 and 1565. "Her3 2mix" refers

to a mixture of antibodies 5038 and 5082. "EGFR+HER3 4mix" refers to a mixture of antibodies 1277, 1565, 5038 and 5082.

Detailed description of the invention

While some monoclonal antibodies (e.g., cetuximab, trastuzumab, and pertuzumab) have
5 been used to treat EGFR-family-related diseases, these treatments are not effective for all
patients. Additionally, patients often develop resistance to such drugs after initial use. This
invention is based on our discovery of new humanized antibodies targeting EGFR-family
members EGFR, HER2, and HER3 and that mixtures of such humanized antibodies (a
humanized pan-HER antibody composition) can effectively down-regulate the targets and
10 inhibit growth of a variety of cancer cell lines. We have also discovered that antibody mixtures
targeting EGFR-family members EGFR, HER2, and HER3 effectively suppress tumor growth in
multiple xenograft models of human cancer, including hard-to-treat patient-derived models of
pancreatic cancer. We have also shown that antibody mixtures targeting more than one
EGFR-family member retain their inhibitory effect in cells that have acquired resistance to
15 therapeutic monoclonal antibodies such as cetuximab, trastuzumab, and pertuzumab.

Humanized Antibodies

One aspect of the invention relates to humanized antibodies that bind the EGFR-family
members EGFR, HER2, and HER3. The term "antibody" or "antibody molecule" describes a
20 functional component of serum and is often referred to either as a collection of molecules
(antibodies or immunoglobulin) or as one molecule (the antibody molecule or immunoglobulin
molecule). An antibody is capable of binding to or reacting with a specific antigenic
determinant (the antigen or the antigenic epitope), which in turn may lead to induction of
immunological effector mechanisms. An individual antibody is usually regarded as
25 monospecific, and a composition of antibodies may be monoclonal (i.e., consisting of identical
antibody molecules) or polyclonal (i.e., consisting of two or more different antibodies reacting
with the same or different epitopes on the same antigen or even on distinct, different
antigens). Each antibody has a unique structure that enables it to bind specifically to its
corresponding antigen, and all natural antibodies have the same overall basic structure of two
30 identical light chains and two identical heavy chains. Antibodies are also known collectively as
immunoglobulins.

Unless otherwise indicated, the terms "antibody" or "antibodies" as used herein are intended
to include single chain antibodies as well as binding fragments of antibodies, such as Fab,
35 F(ab')₂, Fv fragments or single chain Fv (scFv) fragments, and multimeric forms such as
dimeric IgA molecules or pentavalent IgM. In the present description and claims, references to
an "antibody" or "antibodies" are therefore intended to encompass, in particular, binding

fragments and single chain antibodies, unless it is indicated otherwise or apparent from the context that this is not the case.

Each heavy chain of an antibody typically includes a heavy chain variable region (VH) and a heavy chain constant region. The heavy chain constant region typically includes three domains, referred to as CH1, CH2 and CH3. Each antibody light chain typically includes a light chain variable region (VL) and a light chain constant region. The light chain constant region typically includes a single domain, referred to as CL. The VH and VL regions may be further subdivided into regions of hypervariability ("hypervariable regions", which may be hypervariable in sequence and/or in structurally defined loops). The "hypervariable" regions found in the variable domains of an antibody that are primarily responsible for determining the antibody's binding specificity. These are also referred to as complementarity determining regions (CDRs), which are interspersed with regions that are more conserved, termed framework regions (FRs). Each of the heavy and light chains of an antibody contains three CDR regions, referred to as CDR1, CDR2 and CDR3, of which CDR3 shows the greatest variability. Each VH and VL typically includes three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The amino acid residues in the variable regions are often numbered using a standardized numbering method known as the Kabat numbering scheme (Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, USA), although other numbering schemes such as Chothia and IMGT also exist.

The term "recombinant antibody" refers to an antibody that is expressed from a cell or cell line transfected with an expression vector (or possibly more than one expression vector, e.g. two expression vectors) comprising the coding sequence of the antibody, where said coding sequence is not naturally associated with the cell.

The four-digit antibody numbers used herein, i.e. 1277, 1565, 4384, 4517, 5038 and 5082, refer to the chimeric parent antibodies disclosed in WO 2012/059857, from which the humanized antibodies of the invention are derived. Table 1 below shows the SEQ ID NOs, as set forth in Table 8, for the DNA and amino acid sequences of the heavy chain variable regions (VH) and the light chains (LC) of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Table 1: SEQ ID NOs for the DNA and amino acid sequences of the heavy chain variable regions and light chains of chimeric antibodies

Antibody Number	Antigen	V _H DNA seq.	V _H amino acid seq.	light chain DNA seq.	light chain amino acid seq.
1277	EGFR	14	15	16	17
1565	EGFR	18	19	20	21
4384	HER2	22	23	24	25
4517	HER2	26	27	28	29
5038	HER3	30	31	32	33
5082	HER3	34	35	36	37

The specificity of an antibody's interaction with a target antigen resides primarily in the amino acid residues located in the six CDRs of the heavy and light chain. The amino acid sequences within CDRs are therefore much more variable between individual antibodies than sequences outside of CDRs. Because CDR sequences are responsible for most antibody-antigen interactions, it is possible to express recombinant antibodies that mimic the properties of a specific naturally occurring antibody, or more generally any specific antibody with a given amino acid sequence, by constructing expression vectors that express CDR sequences from the specific antibody grafted into framework sequences from a different antibody. As a result, it is possible to "humanize" a non-human antibody and still substantially maintain the binding specificity and affinity of the original antibody. A more detailed discussion of humanization is provided below.

A "chimeric antibody" refers in its broadest sense to an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies, typically an antibody that is partially of human origin and partially of non-human origin, i.e. derived in part from a non-human animal, for example a mouse, rat or other rodent, or an avian such as a chicken. Chimeric antibodies are preferred over non-human antibodies in order to reduce the risk of a human anti-antibody response, e.g. a human anti-mouse antibody response in the case of a murine antibody. An example of a typical chimeric antibody is one in which the variable region sequences are murine sequences derived from immunization of a mouse, while the constant region sequences are human. In the case of a chimeric antibody, the non-human parts may be subjected to further alteration in order to humanize the antibody. As described elsewhere herein, the present invention is based on humanization of certain chimeric antibodies having murine variable region sequences.

The term "humanize" refers to the fact that where an antibody is wholly or partially of non-human origin, for example a murine antibody obtained from immunization of mice with an antigen of interest or a chimeric antibody based on such a murine antibody, it is possible to replace certain amino acids, in particular in the framework regions and constant domains of

the heavy and light chains, in order to avoid or minimize an immune response in humans. It is known that all antibodies have the potential for eliciting a human anti-antibody response, which correlates to some extent with the degree of "humanness" of the antibody in question. Although it is not possible to precisely predict the immunogenicity and thereby the human anti-antibody response of a particular antibody, non-human antibodies tend to be more immunogenic than human antibodies. Chimeric antibodies, where the foreign (usually rodent) constant regions have been replaced with sequences of human origin, have been shown to be generally less immunogenic than antibodies of fully foreign origin, and the trend in therapeutic antibodies is towards humanized or fully human antibodies. For chimeric antibodies or other antibodies of non-human origin, it is therefore preferred that they be humanized to reduce the risk of a human anti-antibody response.

For chimeric antibodies, humanization typically involves modification of the framework regions of the variable region sequences. Amino acid residues that are part of a complementarity determining regions (CDRs) will most often not be altered in connection with humanization, although in certain cases it may be desirable to alter individual CDR amino acid residues, for example to remove a glycosylation site, a deamidation site, an aspartate isomerization site or an undesired cysteine or methionine residue. N-linked glycosylation occurs by attachment of an oligosaccharide chain to an asparagine residue in the tripeptide sequence Asn-X-Ser or Asn-X-Thr, where X may be any amino acid except Pro. Removal of an N-glycosylation site may be achieved by mutating either the Asn or the Ser/Thr residue to a different residue, preferably by way of conservative substitution. Deamidation of asparagine and glutamine residues can occur depending on factors such as pH and surface exposure. Asparagine residues are particularly susceptible to deamidation, primarily when present in the sequence Asn-Gly, and to a lesser extent in other dipeptide sequences such as Asn-Ala. When such a deamidation site, in particular Asn-Gly, is present in a CDR sequence, it may therefore be desirable to remove the site, typically by conservative substitution to remove one of the implicated residues.

Numerous methods for humanization of an antibody sequence are known in the art; see e.g. the review by Almagro & Fransson (2008) *Front Biosci.* 13: 1619-1633. One commonly used method is CDR grafting, which for e.g. a murine-derived chimeric antibody involves identification of human germline gene counterparts to the murine variable region genes and grafting of the murine CDR sequences into this framework. CDR grafting may be based on the Kabat CDR definitions, although a more recent publication (Magdelaine-Beuzelin et al. (2007) *Crit Rev. Oncol Hematol.* 64: 210-225) has suggested that the IMGT® definition (the international ImMunoGeneTics information system®, www.imgt.org) may improve the result of the humanization (see Lefranc et al. (2003), IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains, *Dev. Comp Immunol.* 27, 55-77). Since CDR grafting may reduce the binding specificity and affinity, and thus the

biological activity, of a CDR-grafted non-human antibody, back mutations (sometimes referred to as "framework repair") may be introduced at selected positions of the CDR-grafted antibody, typically in the framework regions, in order to reestablish the binding specificity and affinity of the parent antibody. Identification of positions for possible back mutations can be performed using information available in the literature and in antibody databases. Amino acid residues that are candidates for back mutations are typically those that are located at the surface of an antibody molecule, while residues that are buried or that have a low degree of surface exposure will not normally be altered. An alternative humanization technique to CDR grafting and back mutation is resurfacing, in which non-surface exposed residues of non-human origin are retained, while surface residues are altered to human residues.

In certain cases, it may also be desirable to alter one or more CDR amino acid residues in order to improve binding affinity to the target epitope. This is known as "affinity maturation" and may optionally be performed in connection with humanization, for example in situations where humanization of an antibody leads to reduced binding specificity or affinity and it is not possible to sufficiently improve the binding specificity or affinity by back mutations alone. Various affinity maturation methods are known in the art, for example the *in vitro* scanning saturation mutagenesis method described by Burks et al. (1997) *PNAS USA*, vol. 94, pp. 412-417 and the stepwise *in vitro* affinity maturation method of Wu et al. (1998) *PNAS USA*, vol. 95, pp. 6037-6042.

Amino acid residues herein may be indicated by either the one-letter code or the three-letter code. Amino acid substitutions relative to a reference sequence may e.g. be indicated using the format "G44R", which indicates that a glycine residue in position 44 of a reference sequence has been mutated to an arginine residue. For example, in Table 2 below, "G44R" indicates a mutation of the glycine residue in a CDR-grafted antibody to an arginine residue. An amino acid residue written in the format "Arg44" indicates a particular residue in a particular position, i.e. in this case an arginine residue in position 44. Unless otherwise indicated, numbering of amino acid residues refers to the appended sequence listing.

As noted above, the present invention relates to humanized antibodies, more particularly to humanized antibodies based on certain chimeric parent antibodies described in WO 2012/059857. The humanized antibodies of the invention were developed using CDR grafting and back mutations, and in some cases alteration of unwanted sequence motifs, starting with selected chimeric anti-EGFR, anti-HER2 and anti-HER3 antibodies described in WO 2012/059857. The particular methods used to develop these humanized antibodies, as well as the results of functional evaluation of the humanized antibodies compared to the original chimeric antibodies from which they were developed, are described in the examples below. Strikingly, the data presented in the examples shows that mixtures containing a humanized antibody of the invention have an *in vitro* efficacy that is comparable to that of corresponding

mixtures of the original chimeric antibodies, demonstrating that the humanization process did not affect the inhibitory properties of these antibodies or their ability to function in combination with each other. The data also strongly suggests that the humanized antibody mixtures will also show an *in vivo* efficacy that is comparable to that of the original chimeric antibody mixtures described in WO 2012/059857.

The five-digit antibody numbers used herein, e.g. "antibody 10560", refer to the specific humanized antibodies described below, which have been prepared by CDR grafting based on a chimeric parent antibody. For example, antibody 10560 is an antibody with a heavy chain comprising the heavy chain variable region sequence (VH) set forth in SEQ ID NO:4 and a light chain comprising the light chain variable region sequence (VL) set forth in SEQ ID NO:5, and comprising substitutions (for example, back mutations) at certain positions compared to the original CDR-grafted antibody (see Table 3 and Figures 1-6). In the examples below, the antibodies also included a human kappa constant region sequence (SEQ ID NO:42 in WO 2012/059858 and US 2011/0217305, with an N-terminal Arg residue) and a human IGHG1 heavy chain constant region sequence (SEQ ID NO:44 in WO 2012/059858 and US 2011/0217305).

Particular humanized antibodies of the invention are described herein by way of an antibody number, i.e. 10292, 10460, 11294, 10560, 10704, 11302, 11145, 11249, 10738, 10810, 11006 or 11052. These are derived from the chimeric antibodies (murine variable regions, human constant regions) disclosed in WO 2012/059857 by CDR grafting and subsequent mutation at certain positions, primarily back mutations, as described in Example 1. Table 2 below outlines how the humanized antibodies of the invention are related to the chimeric parent antibodies disclosed in WO 2012/059857.

Table 2: Humanized and chimeric parent antibody numbers

Humanized antibody	Chimeric parent antibody
10292	1277
10460	1277
11294	1277
10560	1565
11302	1565
10704	4384
11249	4384
11145	4517
10738	5038
10810	5038
11006	5082
11052	5082

Table 3 below provides the SEQ ID NOs of exemplary humanized antibodies of the invention, as well as the individual substitutions (back mutations, and in certain cases mutation(s) to alter undesired sequence motifs) in the heavy chain (HC) and light chain (LC) compared to the original CDR-grafted antibody. The amino acid sequences of the heavy and light chains of the antibodies listed in Table 3 are provided in Figures 1-6 and in separate SEQ ID NOs enclosed in parentheses in Table 3. The CDR sequences in Figures 1-6 are indicated with shading.

Table 3: Sequence numbers and substitutions in selected humanized antibodies

Humanized Ab number	HC + LC SEQ ID NO. and substitutions
10292	HC: SEQ ID NO:1; G44R, M83V (SEQ ID NO:38) LC: SEQ ID NO:2; V19A, Y92F (SEQ ID NO:39)
10460	HC: SEQ ID NO:1; G44R, M83V, M104I (SEQ ID NO:40) LC: SEQ ID NO:3; F41Y, F51L, Y92F (SEQ ID NO:41)
11294	HC: SEQ ID NO:1; G44R, M83V, M104I (SEQ ID NO:42) LC: SEQ ID NO:3; G34L, F41Y, F51L, Y92F (SEQ ID NO:43)
10560	HC: SEQ ID NO:4; V20L, M481, V68A (SEQ ID NO:44) LC: SEQ ID NO:5; I75V, Y87F (SEQ ID NO:45)
11302	HC: SEQ ID NO:4; V20L, M481, G56L, V68A (SEQ ID NO:46) LC: SEQ ID NO:5; I75V, Y87F (SEQ ID NO:47)
10704	HC: SEQ ID NO:6; N55S, M70L, R72V, T74K, V79A (SEQ ID NO:48) LC: SEQ ID NO:7; P44V, I48M, F70Y (SEQ ID NO:49)
11249	HC: SEQ ID NO:6; N55S, R72V (SEQ ID NO:50) LC: SEQ ID NO:7; I48M, F70Y (SEQ ID NO:51)
11145	HC: SEQ ID NO:8; S49A, N74I, N77S (SEQ ID NO:52) LC: SEQ ID NO:9; D56T, F71Y, Y85S, V104L (SEQ ID NO:53)
10738	HC: SEQ ID NO:10; I49M, D55S, V68I (SEQ ID NO:54) LC: SEQ ID NO:11; Y36F, P44V, Y49F, T85I (SEQ ID NO:55)
10810	HC: SEQ ID NO:10; K44N, D55S, V93T (SEQ ID NO:56) LC: SEQ ID NO:11; Y36F, Y49F, F73L (SEQ ID NO:57)
11006	HC: SEQ ID NO:12; L46V, I49M, D55S, V72R (SEQ ID NO:58) LC: SEQ ID NO:13; I21V, I29T, P44V, Y87F (SEQ ID NO:59)
11052	HC: SEQ ID NO:12; H41F, L46V, I49M, D55S, V72R (SEQ ID NO:60) LC: SEQ ID NO:13; I21V, P44V, F71Y, Y87F, V104L (SEQ ID NO:61)

An indication that any of the numbered humanized antibodies listed in Table 2 may comprise "at least one additional substitution in any of the heavy chain and/or light chain amino acid

residues indicated as "Xaa" in Table 4" means that the antibodies may comprise additional substitutions in one or more "Xaa" residues other than the substitutions listed above in Table 3.

5 **Table 4: Sequences of selected humanized antibodies**

```

SEQ ID NO:1
<210> 1
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 1277 VH

<220>
<221> VARIANT
<222> (44)..(44)
<223> Xaa = Gly or Arg

<220>
<221> VARIANT
<222> (49)..(49)
<223> Xaa = Ser or Ala

<220>
<221> VARIANT
<222> (83)..(83)
<223> Xaa = Met or Val

<220>
<221> VARIANT
<222> (104)..(104)
<223> Xaa = Met or Ile

<400> 1

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1          5          10          15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Tyr Ser
          20          25          30

Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Xaa Leu Glu Trp Val
          35          40          45

Xaa Tyr Met Ser Ser Ala Gly Asp Val Thr Phe Tyr Ser Asp Thr Val
          50          55          60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr
65          70          75          80

Leu Gln Xaa Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

Val Arg His Arg Asp Val Ala Xaa Asp Tyr Trp Gly Gln Gly Thr Thr
          100          105          110

```

Val Thr Val Ser Ser
115

SEQ ID NO:2

<210> 2

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized 1277 VL

<220>

<221> VARIANT

<222> (13)..(13)

<223> Xaa = Ala or Val

<220>

<221> VARIANT

<222> (19)..(19)

<223> Xaa = Val or Ala

<220>

<221> VARIANT

<222> (33)..(33)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> VARIANT

<222> (34)..(34)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> VARIANT

<222> (42)..(42)

<223> Xaa = Gln or Leu

<220>

<221> VARIANT

<222> (48)..(48)

<223> Xaa = Ala or Ser

<220>

<221> VARIANT

<222> (83)..(83)

<223> Xaa = Leu or Val

<220>

<221> VARIANT

<222> (89)..(89)

<223> Xaa = Ala or Gly

<220>

<221> VARIANT

<222> (92)..(92)

<223> Xaa = Tyr or Phe

<220>

<221> VARIANT

<222> (108)..(108)

```

<223> Xaa = Val or Leu

<400> 2

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Xaa Ser Val Gly
1          5          10          15

Asp Arg Xaa Thr Ile Thr Cys Arg Ser Ser Gln Ser Leu Val His Ser
          20          25          30

Xaa Xaa Asn Thr Tyr Leu His Trp Tyr Xaa Gln Lys Pro Gly Lys Xaa
          35          40          45

Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
          50          55          60

Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
65          70          75          80

Ser Ser Xaa Gln Pro Glu Asp Phe Xaa Thr Tyr Xaa Cys Ser Gln Ser
          85          90          95

Thr His Val Pro Thr Phe Gly Gly Gly Thr Lys Xaa Glu Ile Lys
          100          105          110

```

SEQ ID NO:3

```

<210> 3
<211> 111
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized 1277A VL

```

```

<220>
<221> VARIANT
<222> (33)..(33)
<223> Xaa = Asn or Ser

```

```

<220>
<221> VARIANT
<222> (34)..(34)
<223> Xaa = Gly or Leu

```

```

<220>
<221> VARIANT
<222> (41)..(41)
<223> Xaa = Phe or Tyr

```

```

<220>
<221> VARIANT
<222> (42)..(42)
<223> Xaa = Gln or Leu

```

```

<220>
<221> VARIANT
<222> (51)..(51)
<223> Xaa = Arg or Leu

<220>
<221> VARIANT
<222> (92)..(92)
<223> Xaa = Tyr or Phe

<220>
<221> VARIANT
<222> (108)..(108)
<223> Xaa = Val or Leu

<400> 3

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly
1          5          10          15

Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20          25          30

Xaa Xaa Asn Thr Tyr Leu His Trp Xaa Xaa Gln Arg Pro Gly Gln Ser
35          40          45

Pro Arg Xaa Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50          55          60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65          70          75          80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Xaa Cys Ser Gln Ser
85          90          95

Thr His Val Pro Thr Phe Gly Gly Gly Thr Lys Xaa Glu Ile Lys
100         105         110

```

SEQ ID NO:4

```

<210> 4
<211> 121
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized 1565 VH

```

```

<220>
<221> VARIANT
<222> (20)..(20)
<223> Xaa = Val or Leu

```

```

<220>
<221> VARIANT

```

```

<222> (38)..(38)
<223> Xaa = Arg or Lys

<220>
<221> VARIANT
<222> (40)..(40)
<223> Xaa = Ala or Arg

<220>
<221> VARIANT
<222> (48)..(48)
<223> Xaa = Met or Ile

<220>
<221> VARIANT
<222> (55)..(55)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> VARIANT
<222> (56)..(56)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> VARIANT
<222> (68)..(68)
<223> Xaa = Val or Ala

<220>
<221> VARIANT
<222> (70)..(70)
<223> Xaa = Met or Leu

<220>
<221> VARIANT
<222> (72)..(72)
<223> Xaa = Arg or Val

<220>
<221> VARIANT
<222> (74)..(74)
<223> Xaa = Thr or Lys

<220>
<221> VARIANT
<222> (79)..(79)
<223> Xaa = Val or Ala

<400> 4

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1          5          10          15

Ser Val Lys Xaa Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr
          20          25          30

Trp Met Gln Trp Val Xaa Gln Xaa Pro Gly Gln Gly Leu Glu Trp Xaa
          35          40          45

```

Gly Asn Ile Asn Pro Ser Xaa Xaa Gly Thr Ser Phe Asn Glu Glu Phe
50 55 60

Lys Ser Arg Xaa Thr Xaa Thr Xaa Asp Xaa Ser Thr Ser Thr Xaa Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Gly Gly Leu Tyr Asp Gly Tyr Tyr Phe Asp Phe Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

SEQ ID NO:5

<210> 5
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 1565 VL

<220>
<221> VARIANT
<222> (4)..(4)
<223> Xaa = Leu or Met

<220>
<221> VARIANT
<222> (75)..(75)
<223> Xaa = Ile or Val

<220>
<221> VARIANT
<222> (87)..(87)
<223> Xaa = Tyr or Phe

<400> 5

Ala Ile Gln Xaa Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Asp Val Asp Thr Ala
20 25 30

Val Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Ser Arg Phe Ser Gly

50	55	60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Xaa Ser Ser Leu Gln Pro		
65	70	75 80
Glu Asp Phe Ala Thr Tyr Xaa Cys Gln Gln Tyr Ser Ser Tyr Pro Leu		
	85	90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys		
	100	105
SEQ ID NO:6		
<210> 6		
<211> 119		
<212> PRT		
<213> Artificial Sequence		
<220>		
<223> Humanized 4384 VH		
<220>		
<221> VARIANT		
<222> (38)..(38)		
<223> Xaa = Arg or Lys		
<220>		
<221> VARIANT		
<222> (48)..(48)		
<223> Xaa = Met or Ile		
<220>		
<221> VARIANT		
<222> (55)..(55)		
<223> Xaa = Asn or Ser		
<220>		
<221> VARIANT		
<222> (68)..(68)		
<223> Xaa = Val or Ala		
<220>		
<221> VARIANT		
<222> (70)..(70)		
<223> Xaa = Met or Leu		
<220>		
<221> VARIANT		
<222> (72)..(72)		
<223> Xaa = Arg or Val		
<220>		
<221> VARIANT		
<222> (74)..(74)		
<223> Xaa = Thr or Lys		
<220>		
<221> VARIANT		

```

<222> (79)..(79)
<223> Xaa = Val or Ala

<400> 6

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1          5          10          15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
          20          25          30

Trp Met His Trp Val Xaa Gln Ala Pro Gly Gln Gly Leu Glu Trp Xaa
          35          40          45

Gly Asn Ile Asn Pro Ser Xaa Gly Gly Thr Asn Tyr Asn Glu Lys Phe
          50          55          60

Lys Ser Arg Xaa Thr Xaa Thr Xaa Asp Xaa Ser Thr Ser Thr Xaa Tyr
65          70          75          80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

Ala Arg Ala Tyr Tyr Asp Phe Ser Trp Phe Val Tyr Trp Gly Gln Gly
          100          105          110

Thr Leu Val Thr Val Ser Ser
          115

```

SEQ ID NO:7

```

<210> 7
<211> 106
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized 4384 VL

```

```

<220>
<221> VARIANT
<222> (44)..(44)
<223> Xaa = Pro or Val

```

```

<220>
<221> VARIANT
<222> (48)..(48)
<223> Xaa = Ile or Met

```

```

<220>
<221> VARIANT
<222> (70)..(70)
<223> Xaa = Phe or Tyr

```

```

<220>
<221> VARIANT
<222> (72)..(72)
<223> Xaa = Phe or Leu

<220>
<221> VARIANT
<222> (86)..(86)
<223> Xaa = Tyr or Phe

<400> 7

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1          5          10          15

Asp Arg Val Thr Ile Thr Cys Arg Ser Ser Gln Asp Ile Ser Asn Tyr
          20          25          30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Xaa Lys Leu Leu Xaa
          35          40          45

Tyr Ile Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
          50          55          60

Gly Ser Gly Thr Asp Xaa Thr Xaa Thr Ile Ser Ser Leu Gln Pro Glu
65          70          75          80

Asp Ile Ala Thr Tyr Xaa Cys Gln Gln Gly Asn Thr Leu Pro Leu Thr
          85          90          95

Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
          100          105

```

SEQ ID NO:8

```

<210> 8
<211> 121
<212> PRT
<213> Artificial Sequence

```

```

<220>
<223> Humanized 4517 VH

```

```

<220>
<221> VARIANT
<222> (39)..(39)
<223> Xaa = Gln or Leu

```

```

<220>
<221> VARIANT
<222> (40)..(40)
<223> Xaa = Ala or Thr

```

```

<220>
<221> VARIANT

```

```

<222> (44)..(44)
<223> Xaa = Gly or Arg

<220>
<221> VARIANT
<222> (49)..(49)
<223> Xaa = Ser or Ala

<220>
<221> VARIANT
<222> (74)..(74)
<223> Xaa = Asn or Ile

<220>
<221> VARIANT
<222> (77)..(77)
<223> Xaa = Asn or Ser

<400> 8

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1          5          10          15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
          20          25          30

Gly Met Ser Trp Val Arg Xaa Xaa Pro Gly Lys Xaa Leu Glu Trp Val
          35          40          45

Xaa Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
          50          55          60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Xaa Ala Lys Xaa Ser Leu Tyr
65          70          75          80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

Ala Arg Lys Gly Asn Tyr Gly Asn Tyr Gly Lys Leu Ala Tyr Trp Gly
          100          105          110

Gln Gly Thr Thr Val Thr Val Ser Ser
          115          120

```

SEQ ID NO:9

```

<210> 9
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 4517 VL

```

```

<220>
<221> VARIANT
<222> (13) .. (13)
<223> Xaa = Ala or Val

<220>
<221> VARIANT
<222> (48) .. (48)
<223> Xaa = Ile or Val

<220>
<221> VARIANT
<222> (56) .. (56)
<223> Xaa = Asp or Thr

<220>
<221> VARIANT
<222> (71) .. (71)
<223> Xaa = Phe or Tyr

<220>
<221> VARIANT
<222> (84) .. (84)
<223> Xaa = Ala or Gly

<220>
<221> VARIANT
<222> (85) .. (85)
<223> Xaa = Thr or Ser

<220>
<221> VARIANT
<222> (104) .. (104)
<223> Xaa = Val or Leu

<400> 9

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Xaa Ser Val Gly
1          5          10          15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
          20          25          30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Xaa
          35          40          45

Tyr Ala Ala Thr Asn Leu Ala Xaa Gly Val Pro Ser Arg Phe Ser Gly
          50          55          60

Ser Gly Ser Gly Thr Asp Xaa Thr Leu Thr Ile Ser Ser Leu Gln Pro
65          70          75          80

Glu Asp Phe Xaa Xaa Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp
          85          90          95

```

Thr Phe Gly Gln Gly Thr Lys Xaa Glu Ile Lys
 100 105

SEQ ID NO:10

<210> 10
 <211> 120
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Humanized 5038 VH

<220>
 <221> VARIANT
 <222> (44)..(44)
 <223> Xaa = Lys or Asn

<220>
 <221> VARIANT
 <222> (49)..(49)
 <223> Xaa = Ile or Met

<220>
 <221> VARIANT
 <222> (55)..(55)
 <223> Xaa = Asp or Ser

<220>
 <221> VARIANT
 <222> (68)..(68)
 <223> Xaa = Val or Ile

<220>
 <221> VARIANT
 <222> (72)..(72)
 <223> Xaa = Val or Arg

<220>
 <221> VARIANT
 <222> (93)..(93)
 <223> Xaa = Val or Thr

<400> 10

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1 5 10 15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Gly
 20 25 30

Phe Tyr Trp Thr Trp Ile Arg Gln His Pro Gly Xaa Gly Leu Glu Trp
 35 40 45

Xaa Gly Phe Ile Ser Tyr Xaa Gly Ser Asn Asn Tyr Asn Pro Ser Leu
 50 55 60

Lys Asn Arg Xaa Thr Ile Ser Xaa Asp Thr Ser Lys Asn Gln Phe Ser
 65 70 75 80

Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Xaa Tyr Tyr Cys
 85 90 95

Ala Arg Gly Gly Gly Tyr Tyr Gly Asn Leu Phe Asp Tyr Trp Gly Gln
 100 105 110

Gly Thr Leu Val Thr Val Ser Ser
 115 120

SEQ ID NO:11

<210> 11
 <211> 107
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Humanized 5038 VL

<220>
 <221> VARIANT
 <222> (36)..(36)
 <223> Xaa = Tyr or Phe

<220>
 <221> VARIANT
 <222> (44)..(44)
 <223> Xaa = Pro or Val

<220>
 <221> VARIANT
 <222> (49)..(49)
 <223> Xaa = Tyr or Phe

<220>
 <221> VARIANT
 <222> (71)..(71)
 <223> Xaa = Phe or Tyr

<220>
 <221> VARIANT
 <222> (73)..(73)
 <223> Xaa = Phe or Leu

<220>
 <221> VARIANT
 <222> (85)..(85)
 <223> Xaa = Thr or Ile

<220>
 <221> VARIANT
 <222> (87)..(87)
 <223> Xaa = Tyr or Phe

<400> 11

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5				10						15	

Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg	Pro	Ser	Gln	Asp	Ile	Ser	Asn	Tyr
		20					25					30			

Val	Asn	Trp	Xaa	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Xaa	Lys	Leu	Leu	Ile
	35					40					45				

Xaa	His	Thr	Ser	Arg	Leu	His	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50				55					60					

Ser	Gly	Ser	Gly	Thr	Asp	Xaa	Thr	Xaa	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65				70				75						80	

Glu	Asp	Ile	Ala	Xaa	Tyr	Xaa	Cys	Gln	Gln	Gly	Ile	Thr	Leu	Pro	Trp
			85					90					95		

Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys
		100				105				

SEQ ID NO:12

<210> 12

<211> 118

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized 5082 VH

<220>

<221> VARIANT

<222> (41)..(41)

<223> Xaa = His or Phe

<220>

<221> VARIANT

<222> (46)..(46)

<223> Xaa = Leu or Val

<220>

<221> VARIANT

<222> (49)..(49)

<223> Xaa = Ile or Met

<220>

<221> VARIANT

<222> (55)..(55)

<223> Xaa = Asp or Ser

<220>

```

<221> VARIANT
<222> (68)..(68)
<223> Xaa = Val or Ile

<220>
<221> VARIANT
<222> (72)..(72)
<223> Xaa = Val or Arg

<220>
<221> VARIANT
<222> (86)..(86)
<223> Xaa = Val or Leu

<400> 12

Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1          5          10          15

Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Tyr Ser Ile Thr Ser Ala
          20          25          30

Tyr Tyr Trp Asn Trp Ile Arg Gln Xaa Pro Gly Lys Gly Xaa Glu Trp
          35          40          45

Xaa Gly Tyr Ile Gly Tyr Xaa Gly Arg Asn Thr Tyr Asn Pro Ser Leu
          50          55          60

Lys Asn Arg Xaa Thr Ile Ser Xaa Asp Thr Ser Lys Asn Gln Phe Ser
65          70          75          80

Leu Lys Leu Ser Ser Xaa Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys
          85          90          95

Ser Arg Glu Gly Asp Tyr Gly Tyr Ser Asp Tyr Trp Gly Gln Gly Thr
          100          105          110

Leu Val Thr Val Ser Ser
          115

```

SEQ ID NO:13

```

<210> 13
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized 5082 VL

<220>
<221> VARIANT
<222> (21)..(21)

```

<223> Xaa = Ile or Val

<220>

<221> VARIANT

<222> (29) .. (29)

<223> Xaa = Ile or Thr

<220>

<221> VARIANT

<222> (44) .. (44)

<223> Xaa = Pro or Val

<220>

<221> VARIANT

<222> (69) .. (69)

<223> Xaa = Thr or Ile

<220>

<221> VARIANT

<222> (71) .. (71)

<223> Xaa = Phe or Tyr

<220>

<221> VARIANT

<222> (87) .. (87)

<223> Xaa = Tyr or Phe

<220>

<221> VARIANT

<222> (104) .. (104)

<223> Xaa = Val or Leu

<400> 13

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	

Asp	Arg	Val	Thr	Xaa	Thr	Cys	Arg	Ala	Ser	Gln	Asp	Xaa	Asn	Asn	Tyr
		20						25					30		

Leu	Asn	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Ala	Xaa	Lys	Leu	Leu	Ile
		35					40					45			

Tyr	Tyr	Thr	Ser	Arg	Leu	Gln	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				

Ser	Gly	Ser	Gly	Xaa	Asp	Xaa	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75					80

Glu	Asp	Phe	Ala	Thr	Tyr	Xaa	Cys	Gln	Gln	Ser	Glu	Thr	Leu	Pro	Trp
				85					90					95	

Thr	Phe	Gly	Gln	Gly	Thr	Lys	Xaa	Glu	Ile	Lys
		100						105		

Amino acid sequence alignments of the CDR-grafted heavy and light chain variable regions of these humanized antibodies with the respective *in silico* designed sequence made up of original murine CDRs grafted into fully human framework regions are shown in Figures 1-6.

5

One aspect of the invention relates to particular humanized antibodies targeting EGFR, HER2 or HER3. These individual antibodies include the following:

10

- (a) a humanized anti-EGFR antibody comprising the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:2 or SEQ ID NO:3;
- (b) a humanized anti-EGFR antibody comprising the heavy chain variable region sequence of SEQ ID NO:4 and the light chain variable region sequence of SEQ ID NO:5;
- (c) a humanized anti-HER2 antibody comprising the heavy chain variable region sequence of SEQ ID NO:6 and the light chain variable region sequence of SEQ ID NO:7;
- (d) a humanized anti-HER2 antibody comprising the heavy chain variable region sequence of SEQ ID NO:8 and the light chain variable region sequence of SEQ ID NO:9;
- (e) a humanized anti-HER3 antibody comprising the heavy chain variable region sequence of SEQ ID NO:10 and the light chain variable region sequence of SEQ ID NO:11; and
- (f) a humanized anti-HER3 antibody comprising the heavy chain variable region sequence of SEQ ID NO:12 and the light chain variable region sequence of SEQ ID NO:13.

15

20

25

The above-outlined humanized antibodies typically include, in both the heavy chain variable region sequence and the light chain variable region sequence, one or more of the possible substitutions (primarily back mutations, but in certain cases also mutation to alter unwanted sequence motifs) set forth in Table 4 and in the examples and accompanying figures. The heavy chain variable region sequence and the light chain variable region sequence will typically each comprise two, three, four or five such substitutions.

30

Examples of a preferred anti-EGFR antibody (a) are antibodies comprising:

(i) a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44 and Val83, and a light chain variable region sequence (SEQ ID NO:2) comprising Ala19 and Phe92 [e.g., antibody 10292];

35

(ii) a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44, Val83 and Ile104, and a light chain variable region sequence (SEQ ID NO:3) comprising Tyr41, Leu51 and Phe92 [e.g., antibody 10460]; or

(iii) a heavy chain variable region sequence (SEQ ID NO:1) comprising Arg44, Val83 and Ile104, and a light chain variable region sequence (SEQ ID NO:3) comprising Leu34, Tyr41, Leu51 and Phe92 [e.g., antibody 11294].

The anti-EGFR antibody (a) may also be an antibody corresponding to antibody 10292, 10460, or 11294, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two, three or four of such "Xaa" residues. SEQ ID NO:2 includes Xaa in positions 33-34, since the CDR-grafted sequence has a deamidation site (Asn-Gly) in these positions. Although it is possible to perform substitutions in both positions, it is sufficient to alter only one of the positions in order to eliminate the deamidation site. The sequence will therefore typically include either Asn in position 33 or Gly in position 34.

An example of a preferred anti-EGFR antibody (b) is one comprising:

(i) a heavy chain variable region sequence (SEQ ID NO:4) comprising Leu20, Ile48 and Ala68, and a light chain variable region sequence (SEQ ID NO:5) comprising Val75 and Phe87 [e.g., antibody 10560]; or

(ii) a heavy chain variable region sequence (SEQ ID NO:4) comprising Leu20, Ile48, Leu56, and Ala68, and a light chain variable region sequence (SEQ ID NO:5) comprising Val75 and Phe87 [e.g., antibody 11302].

The anti-EGFR antibody (b) may also be an antibody corresponding to antibody 10560 or 11302, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two, three or four of such "Xaa" residues. SEQ ID NO:4 includes Xaa in positions 55-56, since the CDR-grafted sequence has a deamidation site (Asn-Gly) in these positions. Although it is possible to perform substitutions in both positions, it is sufficient to alter only one of the positions in order to eliminate the deamidation site. The sequence will therefore typically include either Asn in position 55 or Gly in position 56.

An example of a preferred anti-HER2 antibody (c) is one comprising:

(i) a heavy chain variable region sequence (SEQ ID NO:6) comprising Ser55, Leu70, Val72, Lys74 and Ala79, and a light chain variable region sequence (SEQ ID NO:7) comprising Val44, Met48 and Tyr70 [e.g., antibody 10704]; or

(ii) a heavy chain variable region sequence (SEQ ID NO:6) comprising Ser55 and Val72, and a light chain variable region sequence (SEQ ID NO:7) comprising Met48 and Tyr70 [e.g., antibody 11249].

The anti-HER2 antibody (c) may also be an antibody corresponding to antibody 10704 or 11249, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two,
 5 three or four of such "Xaa" residues.

An example of a preferred anti-HER2 antibody (d) is one comprising a heavy chain variable region sequence (SEQ ID NO:8) comprising Ala49, Ile74 and Ser77, and a light chain variable region sequence (SEQ ID NO:9) comprising Thr56, Tyr71, Ser85 and Leu104 [e.g., antibody
 10 11145]. The anti-HER2 antibody (d) may also be an antibody corresponding to antibody 11145, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two, three or four of such "Xaa" residues.

Examples of a preferred anti-HER3 antibody (e) are antibodies comprising a heavy chain variable region sequence (SEQ ID NO:10) comprising Met49, Ser55 and Ile68, or comprising Asn44, Ser55 and Thr93, and a light chain variable region sequence (SEQ ID NO:11) comprising Phe36, Val44, Phe49 and Ile85, or comprising Phe36, Phe49 and Leu73. Particular examples of such anti-HER3 antibodies are those comprising:

20 (i) a heavy chain variable region sequence (SEQ ID NO:10) comprising Met49, Ser55 and Ile68, and a light chain variable region sequence (SEQ ID NO:11) comprising Phe36, Val44, Phe49 and Ile85 [e.g., antibody 10738]; or

(ii) a heavy chain variable region sequence (SEQ ID NO:10) comprising Asn44, Ser55 and Thr93, and a light chain variable region sequence (SEQ ID NO:11) comprising Phe36,
 25 Phe49 and Leu73 [e.g., antibody 10810].

The anti-HER3 antibody (e) may also be an antibody corresponding to antibody 10738 or 10810, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two,
 30 three or four of such "Xaa" residues.

Examples of a preferred anti-HER3 antibody (f) are antibodies comprising:

(i) a heavy chain variable region sequence (SEQ ID NO:12) comprising Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence (SEQ ID NO:13) comprising
 35 Val21, Val44 and Phe87, and optionally Thr29 [e.g., antibody 11006]; or

(ii) a heavy chain variable region sequence (SEQ ID NO:12) comprising Phe41, Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence (SEQ ID NO:13) comprising Val21, Val44, Tyr71, Phe87 and Leu104 [e.g., antibody 11052].

The anti-HER3 antibody (f) may also be an antibody corresponding to antibody 11006 or 11052, but comprising at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in one, two, three or four of such "Xaa" residues.

It is well-known in the art that antibodies exist as different isotypes, such as the human isotypes IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2, or the murine isotypes IgG1, IgG2a, IgG2b, IgG3 and IgA. An antibody of the invention may be of any isotype, including IgG, IgM, IgE, IgA, or IgD.

Humanized Antibody Compositions

A further aspect of the invention relates to a recombinant antibody composition (or mixture) comprising at least two humanized antibodies of the invention directed against at least two different receptors selected from EGFR, HER2 and HER3. The terms "polyclonal antibody" or "mixture of [monoclonal] antibodies" refer to a composition of two or more different antibody molecules which are capable of binding to or reacting with different specific antigenic determinants on the same or on different antigens. In the context of the present invention, the individual antibodies of a mixture of antibodies bind to different antigenic determinants of at least two HER family receptors. In the case of antibody mixtures containing two different antibodies that bind to the same receptor, the individual antibodies preferably bind to different epitopes of that receptor, more preferably distinct and substantially non-overlapping epitopes.

The terms "pan-HER" or "pan-HER antibody composition" refer to a composition of antibody molecules which are capable of binding to at least two different antigens on at least two HER family receptors. In the context of the present invention, the individual antibodies of an antibody composition bind to different antigenic determinants of the HER family. The individual antibodies of the antibody composition may thus bind to EGFR and HER2, EGFR and HER3, HER2 and HER3, or EGFR, HER2 and HER3, preferably to the three receptors EGFR, HER2 and HER3.

The term "epitope" is used to describe a part of a larger molecule (e.g. antigen or antigenic site) having antigenic or immunogenic activity in an animal. An epitope having immunogenic activity is a portion of a larger molecule that elicits an antibody response in an animal. An epitope having antigenic activity is a portion of a larger molecule to which an antibody immunospecifically binds as determined by any method known in the art. Antigenic epitopes are not necessarily immunogenic. An antigen is a substance to which an antibody or antibody fragment immunospecifically binds, e.g. a toxin, virus, bacteria, protein or DNA. An antigen or antigenic site often has more than one epitope, unless it is very small, and is often capable of stimulating an immune response. Epitopes may be linear or conformational. A linear epitope generally consists of about 6 to 10 adjacent amino acids on a protein molecule that are

recognized by an antibody. In contrast, a conformational epitope consists of amino acids that are not arranged sequentially, but where an antibody recognizes a particular three-dimensional structure. When a protein molecule folds into a three-dimensional structure, the amino acids forming the epitope are juxtaposed, enabling the antibody to recognize the conformational epitope. In a denatured protein only linear epitopes are recognized. A conformational epitope, by definition, must be on the outside of the folded protein.

The term "distinct epitopes" refers to the fact that when two different antibodies of the invention bind distinct epitopes, there is less than 100% competition for antigen binding, preferably less than 80% competition for antigen binding, more preferably less than 50% competition for antigen binding, and most preferably as little competition as possible, such as less than about 25% competition for antigen binding. Antibodies capable of competing with each other for binding to the same antigen may bind the same or overlapping epitopes or may have a binding site in close vicinity of one another, so that competition is mainly caused by steric hindrance. An analysis for "distinct epitopes" of antibody pairs may be performed by methods known in the art, for example by way of binding experiments under saturating antibody conditions using either FACS (fluorescence activated cell sorting) or other flow cytometry analysis on cells expressing the relevant receptor antigen and individual fluorescent labeled antibodies, or by Surface Plasmon Resonance (SPR) using antigen captured or conjugated to a flow cell surface.

The distinct epitopes are preferably "non-overlapping" in the sense that two different antibodies in a composition of the invention that bind to the same receptor have a sufficiently low competition for antigen binding that the two antibodies are able to bind their respective epitopes simultaneously. It will be understood by persons skilled in the art that there can be different degrees of overlap, and that distinct epitopes can be considered to be "non-overlapping" in spite of the presence of some degree of competition, as long as the respective antibodies are able to substantially bind their epitopes. This is generally considered to be the case when the competition for antigen binding between two antibodies is less than about 50%. Methods for determining competition between antibodies are known in the art, for example using Surface Plasmon Resonance (SPR) as described e.g. in WO 2011/107957.

Antibodies binding to different epitopes on the same antigen can have varying effects on the activity of the antigen to which they bind, depending on the location of the epitope. An antibody binding to an epitope in an active site of the antigen may block the function of the antigen completely, whereas another antibody binding at a different epitope may have no or little effect on the activity of the antigen alone. Such antibodies may, however, still activate complement and thereby result in the elimination of the antigen-expressing cell, and may result in synergistic growth inhibitory effects when combined with one or more antibodies binding at different epitopes on the same antigen. In the context of the present invention, the

epitope is a portion of the extracellular domain of EGFR, HER2 or HER3 (either wild-type or mutated). An anti-EGFR antibody of the invention will thus bind to the extracellular domain of EGFR, an anti-HER2 antibody of the invention will bind to the extracellular domain of HER2, and an anti-HER3 antibody of the invention will bind to the extracellular domain of HER3.

5

Particular embodiments of this aspect of the invention include, with reference to humanized antibodies (a)-(f) outlined above, compositions comprising:

- anti-EGFR antibody (a) and anti-HER2 antibody (c);
- anti-EGFR antibody (a) and anti-HER2 antibody (d);
- 10 • anti-EGFR antibody (a) and anti-HER3 antibody (e);
- anti-EGFR antibody (a) and anti-HER3 antibody (f);
- anti-EGFR antibody (b) and anti-HER2 antibody (c);
- anti-EGFR antibody (b) and anti-HER2 antibody (d);
- anti-EGFR antibody (b) and anti-HER3 antibody (e);
- 15 • anti-EGFR antibody (b) and anti-HER3 antibody (f);
- anti-HER2 antibody (c) and anti-HER3 antibody (e);
- anti-HER2 antibody (c) and anti-HER3 antibody (f);
- anti-HER2 antibody (d) and anti-HER3 antibody (e); or
- anti-HER2 antibody (d) and anti-HER3 antibody (f).

20

In one embodiment, the invention relates to a recombinant antibody composition comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody, and at least one humanized anti-HER3 antibody.

25

In some embodiments, the invention relates to an antibody composition comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody, and at least one humanized anti-HER3 antibody, wherein:

the at least one humanized anti-EGFR antibody is selected from (a) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:2 or SEQ ID NO:3, and (b) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:4 and the light chain variable region sequence of SEQ ID NO:5;

the at least one humanized anti-HER2 antibody is selected from (c) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:6 and the light chain variable region sequence of SEQ ID NO:7, and (d) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:8 and the light chain variable region sequence of SEQ ID NO:9; and

the at least one humanized anti-HER3 antibody is selected from (e) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:10 and the light chain variable region sequence of SEQ ID NO:11, and (f) an antibody comprising the heavy chain

40

variable region sequence of SEQ ID NO:12 and the light chain variable region sequence of SEQ ID NO:13.

In the case of an antibody composition comprising one anti-EGFR antibody, one anti-HER2 antibody and one anti-HER3 antibody, the composition may thus comprise, with reference to humanized antibodies (a)-(f) outlined above:

- anti-EGFR antibody (a), anti-HER2 antibody (c), and anti-HER3 antibody (e);
- anti-EGFR antibody (a), anti-HER2 antibody (c), and anti-HER3 antibody (f);
- anti-EGFR antibody (a), anti-HER2 antibody (d), and anti-HER3 antibody (e);
- anti-EGFR antibody (a), anti-HER2 antibody (d), and anti-HER3 antibody (f);
- anti-EGFR antibody (b), anti-HER2 antibody (c), and anti-HER3 antibody (e);
- anti-EGFR antibody (b), anti-HER2 antibody (c), and anti-HER3 antibody (f);
- anti-EGFR antibody (b), anti-HER2 antibody (d), and anti-HER3 antibody (e); or
- anti-EGFR antibody (b), anti-HER2 antibody (d), and anti-HER3 antibody (f).

Examples of preferred compositions comprising one anti-EGFR antibody, one anti-HER2 antibody and one anti-HER3 antibody are, e.g.:

- antibodies 10292, 10704 and 10738;
- antibodies 10292, 10704 and 10810;
- antibodies 10292, 10704 and 11006;
- antibodies 10292, 10704 and 11052;
- antibodies 10460, 10704 and 10738;
- antibodies 10460, 10704 and 10810;
- antibodies 10460, 10704 and 11006;
- antibodies 10460, 10704 and 11052;
- antibodies 11294, 10704 and 10738;
- antibodies 11294, 10704 and 10810;
- antibodies 11294, 10704 and 11006; and
- antibodies 11294, 10704 and 11052 .

In a still more preferred embodiment, the antibody composition comprises six humanized antibodies, i.e. two humanized antibodies directed against each of the three receptors EGFR, HER2 and HER3, where each pair of antibodies that bind the same receptor bind to distinct and non-overlapping epitopes of that receptor. This may in particular be a composition comprising anti-EGFR antibodies (a) and (b), anti-HER2 antibodies (c) and (d), and anti-HER3 antibodies (e) and (f). In this case, one, two, three, four, five or all of the six antibodies may be selected from antibodies 10292, 10460, 11294, 10560, 11302, 10704, 11249, 11145, 10738, 10810, 11006 and 11052.

In a particular embodiment, the antibody composition comprises:

- (a) anti-EGFR antibody 10292, 10460, or 11294;

- (b) anti-EGFR antibody 10560 or 11302;
- (c) anti-HER2 antibody 10704 or 11249;
- (d) anti-HER2 antibody 11145;
- (e) anti-HER3 antibody 10738 or 10810; and
- (f) anti-HER3 antibody 11006 or 11052.

Alternatively, any one or more of the antibodies (a)-(f) in this embodiment may comprise at least one additional substitution in any of the heavy chain and/or light chain amino acid residues indicated as "Xaa" in Table 4, e.g. substitution in up to five or six of such "Xaa" residues per antibody for one or more of the antibodies in the composition, such as substitution in one, two, three or four of such "Xaa" residues per antibody for one or more of the antibodies in the composition.

In a preferred embodiment, the antibody composition comprises anti-EGFR antibodies 11294 and 11302, anti-HER2 antibodies 11249 and 11145, and anti-HER3 antibodies 10738 and 11052. The antibody composition may comprise (a) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:43 and the light chain variable region sequence of SEQ ID NO:44; (b) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:47 and the light chain variable region sequence of SEQ ID NO:48; (c) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:51 and the light chain variable region sequence of SEQ ID NO:52; (d) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:53 and the light chain variable region sequence of SEQ ID NO:54; (e) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:55 and the light chain variable region sequence of SEQ ID NO:56; and (f) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:61 and the light chain variable region sequence of SEQ ID NO:62.

Although it is possible for the individual antibodies of an antibody mixture of the invention to include antibodies of more than one isotype, they may all be of the same isotype.

Properties of the Humanized Antibodies and Antibody Compositions

The humanized antibodies of the invention bind to the HER- or EGFR-family members, EGFR, HER2, or HER3. The term "HER" stands for "Human Epidermal growth factor Receptor" and is often used interchangeably with the term "ErbB" to characterize the subgroup of the receptor tyrosine kinases (RTKs) consisting of the four members EGFR/ErbB, HER2/ErbB2, HER3/ErbB3 and HER4/ErbB4. Together, these four receptors constitute the "HER family" (or ErbB or EGFR family) receptors.

Binding of one or more antibodies of the invention, in particular a pan-HER antibody composition of the invention, to HER family receptors preferably inhibits the growth and proliferation of cells expressing the receptors (i.e. typically tumor cells). The mechanism(s)

involved may, for example, include one or more of the following: preventing receptor dimerization, preventing ligand binding, promoting internalization and degradation of the receptor, reducing tyrosine kinase domain (TKD) phosphorylation, reducing receptor signaling, and inducing phagocytosis, CDC and/or ADCC.

As used herein, the term "inhibits growth" (e.g., referring to cells) is intended to include any measurable decrease in the proliferation (increase in number of cells) or metabolism of a cell when contacted with an anti-HER family antibody or pan-HER antibody composition as compared to the growth of the same cells in the absence of the antibody or composition, e.g. inhibition of growth of a cell culture by at least about 10%, and preferably more, such as at least about 20% or 30%, more preferably at least about 40% or 50%, such as at least about 60%, 70%, 80%, 90%, 95% or 99%, or even about 100%. Growth inhibition can e.g. be determined in relevant cancer cell lines as described in the examples below.

Bispecific Binding Molecules

In a further aspect, the binding specificities of any two individual antibodies disclosed herein may be combined in one bispecific binding molecule. Such a bispecific binding molecule may have the binding specificities of two antibodies targeting two different receptors selected from EGFR, HER2 and HER3, or it may have the binding specificities of two antibodies targeting the same receptor. For example, a bispecific binding molecule may have the binding specificities of anti-EGFR antibodies (a) and (b), the binding specificities of anti-HER2 antibodies (c) and (d), or the binding specificities of anti-HER3 antibodies (e) and (f). More particularly, a bispecific binding molecule may e.g. have the binding specificities of (1) anti-EGFR antibody 10292, 10460, or 11294, and anti-EGFR antibody 10560 or 11302; (2) anti-HER2 antibody 10704 or 11249, and anti-HER2 antibody 11145; or (3) anti-HER3 antibody 10738 or 10810, and anti-HER3 antibody 11006 or 11052. The bispecific binding molecule may be a dual variable domain antibody, i.e. wherein the two arms of the antibody comprise two different variable domains, or may be in the form of an antibody fragment such as a bispecific Fab fragment or a bispecific scFv.

Nucleic Acid Molecules, Vector, and Production of Antibodies and Antibody Compositions of the Invention

Further aspects of the invention relate to nucleic acid molecules comprising a nucleotide sequence that encodes an antibody of the invention, in particular an antibody selected from the group consisting of antibodies 10292, 10460, 11294, 10560, 11302, 10704, 11249, 11145, 10738, 10810, 11006 and 11052, or encoding a heavy and/or light chain variable region sequence of such an antibody, as well as an expression vectors comprising such a nucleic acid molecule, and host cells comprising the nucleic acid molecule or expression vector, wherein said host cells are capable of expressing an antibody encoded by the nucleic acid molecule.

The term "vector" refers to a nucleic acid molecule into which a nucleic acid sequence can be inserted for transport between different genetic environments and/or for expression in a host cell. A vector that carries regulatory elements for transcription of the nucleic acid sequence (at least a suitable promoter) is referred to as an "an expression vector". The terms "plasmid" and "vector" may be used interchangeably. Expression vectors used in the context of the present invention may be of any suitable type known in the art, e.g. a plasmid or a viral vector.

An additional aspect of the invention relates to methods for producing humanized recombinant antibodies and compositions comprising the antibodies of the invention. One embodiment of this aspect of the invention relates to a method for producing an antibody as defined herein, comprising providing a host cell capable of expressing the antibody, cultivating said host cell under conditions suitable for expression of the antibody, and isolating the resulting antibody.

In a further embodiment, the invention relates to a method for producing a recombinant antibody composition comprising at least one humanized recombinant anti-EGFR antibody, at least one humanized recombinant anti-HER2 antibody and at least one humanized recombinant anti-HER3 antibody, the method comprising:

providing at least first, second and third host cells, wherein the first host cell is capable of expressing a recombinant anti-EGFR antibody of the invention, the second host cell is capable of expressing a recombinant anti-HER2 antibody of the invention, and the third host cell is capable of expressing a recombinant anti-HER3 antibody of the invention,

cultivating the first, second and third host cells under conditions suitable for expression of the anti-EGFR antibody, the anti-HER2 antibody and the anti-HER3 antibody, and

isolating the resulting antibodies.

An antibody or antibody composition of the present invention may be produced by methods generally known in the art for production of recombinant monoclonal or polyclonal antibodies. Thus, in the case of production of a single antibody of the invention, any method known in the art for production of recombinant monoclonal antibodies may be used. For production of an antibody composition of the invention comprising a mixture of antibodies, the individual antibodies may be produced separately, i.e. each antibody being produced in a separate bioreactor, or the individual antibodies may be produced together in single bioreactor. If the antibody composition is produced in more than one bioreactor, the purified antibody composition can be obtained by pooling the antibodies obtained from individually purified supernatants from each bioreactor. Various approaches for production of a polyclonal antibody composition in multiple bioreactors, where the cell lines or antibody preparations are combined at a later point upstream or prior to or during downstream processing, are described in WO 2009/129814 (incorporated by reference).

In the case of production individual antibodies in a single bioreactor, this may be performed e.g. as described in WO 2004/061104 or WO 2008/145133 (both of which are incorporated herein by reference). The method described in WO 2004/061104 is based on site-specific integration of the antibody coding sequence into the genome of the individual host cells, while
5 the method of WO 2008/145133 involves an alternative approach using random integration to produce antibodies in a single bioreactor.

Further information regarding methods suitable for preparing the antibodies and compositions of the invention may be found in WO 2012/059857 (incorporated by reference).

10

Therapeutic compositions

Another aspect of the invention is a pharmaceutical composition comprising as an active ingredient an antibody or antibody composition of the invention. Such compositions are intended for amelioration, prevention and/or treatment of cancer. The pharmaceutical
15 composition may be administered to a human or to a domestic animal or pet, but will typically be administered to humans.

The ratio between the individual antibodies in a therapeutic composition of the invention, or, in the case of individual antibodies of the invention being administered simultaneously,
20 sequentially or separately, will often be such that the antibodies are administered in equal amounts, but this need not necessarily be the case. Thus, a composition of the invention comprising two anti-EGFR family antibodies will often contain them in approximately a 1:1 ratio, and a composition comprising three anti-EGFR family antibodies will often contain them in approximately a 1:1:1 ratio. Similarly, an antibody composition comprising six antibodies,
25 two against each of the receptors EGFR, HER2 and HER3, will often contain them in approximately a 1:1:1:1:1:1 ratio. Depending on the characteristics of the individual antibodies, however, it may be desirable to use non-equal amounts of the different antibodies. Suitable ratios for the different anti-HER antibodies in compositions of the invention may be determined as described in WO 2010/040356 (incorporated herein by reference), which
30 describes methods for identifying and selecting the optimal stoichiometric ratio between chemical entities in a combinatorial drug product, e.g. a polyclonal antibody composition, to obtain a combinatorial drug with optimal potency and efficacy.

In addition to the humanized recombinant antibodies of the invention or binding fragments
35 thereof, the pharmaceutical composition will further comprise at least one pharmaceutically acceptable diluent, carrier or excipient. These may for example include preservatives, stabilizers, surfactants/wetting agents, emulsifying agents, solubilizers, salts for regulating the osmotic pressure and/or buffers. Solutions or suspensions may further comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose,

dextran, polyvinylpyrrolidone or gelatin. A suitable pH value for the pharmaceutical composition will generally be in the range of about 5.5 to 8.5, such as about 6 to 8, e.g. about 7, maintained where appropriate by use of a buffer.

5 Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer to e.g. cancer patients by conventional administration routes known in the art. Similarly, the pharmaceutical compositions of the invention may be prepared in a manner known *per se* for preparation of recombinant antibody compositions. For further information on formulation, administration, etc., see PCT/IB2011/054834.

Therapeutic uses of antibodies and compositions of the invention

The antibodies and compositions of the present invention may be used for the treatment or amelioration of a disease in a mammal, in particular treatment of cancer in humans. The term "treatment" as used herein refers to administration of an antibody or, preferably, antibody
15 composition of the invention in a sufficient amount to ease, reduce, ameliorate or eradicate (cure) symptoms or disease states. Administration of two or more pan-HER antibodies of the invention will generally be by way of simultaneous administration of the antibodies, preferably in the form of a composition containing all of the pan-HER antibodies to be used for treatment. However, it is also possible to administer two or more antibodies of the invention separately.

20 References herein to e.g. administration of a recombinant antibody composition comprising at least two anti-HER family antibodies should therefore be understood as encompassing not only administration of a composition comprising the at least two antibodies as such, but also separate administration of the antibodies. Combinations of two or more antibodies of the invention can thus be administered simultaneously, sequentially or separately. One
25 embodiment of the invention is a method of preventing, treating or ameliorating one or more symptoms associated with cancer in a human or other mammal, comprising administering an effective amount of the pharmaceutical antibody composition of the present invention to said mammal.

30 A particular embodiment relates to a method for treating a patient, typically a human patient, with a disorder characterized by expression or overexpression of or dependency on any one or more of the EGFR family receptors EGFR, HER2 and HER3, in particular cancer, the method comprising administering to said patient a recombinant antibody composition or pharmaceutical composition as defined herein. The term "HER dependency" refers to a cancer
35 cell with dependency on one or more of the HER family receptors for maintaining malignant properties such as proliferation, growth, motility, invasion, survival and/or chemo resistance. Dependency may be caused by receptor overexpression, receptor mutations, autocrine growth factor production, and/or cross-talk with other receptor systems.

In a further embodiment, the invention relates to a method for treating cancer in a patient, typically a human patient, having acquired resistance to treatment with an antibody and/or a tyrosine kinase inhibitor (TKI), the method comprising administering to said patient an effective amount of a recombinant antibody composition or pharmaceutical composition as defined herein.

Based upon a number of factors, the following tumor types in particular may be indicated for treatment with an antibody composition of the invention: breast, ovarian, gastric, colon, rectum, prostate, bladder, pancreas, melanoma, head and neck, and non-small cell lung cancer. Antibody compositions of the invention are contemplated to be particularly applicable to treatment of cancers that overexpress EGFR or HER2, for example certain epithelial cancers such as many breast cancers, ovarian cancers and gastric (stomach) cancers.

In one embodiment, antibody compositions of the invention are used to treat a patient with pancreatic cancer. The patient may have a KRAS mutation.

In one embodiment, the patient has not been treated for cancer previously. In another embodiment, the patient has been treated for cancer previously. The patient may have been treated with cetuximab, trastuzumab, or pertuzumab previously. The cancer in the patient may have acquired resistance to cetuximab, trastuzumab, or pertuzumab.

In connection with each of these indications, two main clinical pathways are contemplated, namely 1) adjunctive therapy in connection with at least one additional therapeutic treatment or 2) as a monotherapy.

1) Adjunctive therapy: In adjunctive therapy, also known as combination therapy, patients will be treated with antibodies of the present invention in combination with at least one additional therapeutic treatment, typically a chemotherapeutic or antineoplastic agent and/or radiation therapy. Alternatively or additionally, the composition of the invention may also be used in combination with a different anti-cancer antibody, e.g. an antibody targeting VEGF. The primary cancer targets listed above may thus be treated by administration of an antibody or composition of the invention in addition to standard first line and second line therapy. Protocol designs will address effectiveness as assessed e.g. by reduction in tumor mass as well as the ability to reduce usual doses of standard chemotherapy. Such dosage reductions may allow additional and/or prolonged therapy by reducing dose-related toxicity of the chemotherapeutic agent.

By combining the antibody compositions of the invention with agents known to induce terminal differentiation of cancer cells, the effect may be improved further. Such compounds may, for example, be selected from the group consisting of retinoic acid, trans-retinoic acids, cis-

retinoic acids, phenylbutyrate, nerve growth factor, dimethyl sulfoxide, active form vitamin D3, peroxisome proliferator-activated receptor gamma, 12-O-tetradecanoylphorbol 13-acetate, hexamethylene-bis-acetamide, transforming growth factor-beta, butyric acid, cyclic AMP, and vesnarinone. Preferably, the compound is selected from the group consisting of

5 retinoic acid, phenylbutyrate, all-trans-retinoic acid and active form vitamin D.

Pharmaceutical articles comprising an antibody composition of the invention and at least one chemotherapeutic or antineoplastic compound may be used as a combination treatment for the simultaneous, separate or successive administration in cancer therapy. The

10 chemotherapeutic compound may be any chemotherapeutic agent suitable for treatment of the particular cancer in question, for example an agent selected from the group consisting of alkylating agents, for example platinum derivatives such as cisplatin, carboplatin and/or oxaliplatin; plant alkoids, for example paclitaxel, docetaxel and/or irinotecan; antitumor antibiotics, for example doxorubicin (adriamycin), daunorubicin, epirubicin, idarubicin

15 mitoxantrone, dactinomycin, bleomycin, actinomycin, luteomycin, and/or mitomycin;; topoisomerase inhibitors such as topotecan; and/or antimetabolites, for example fluorouracil and/or other fluoropyrimidines.

It is also contemplated that antibody composition of the invention may be used in adjunctive

20 therapy in connection with tyrosine kinase inhibitors. These are synthetic, mainly quinazoline-derived, low molecular weight molecules that interact with the intracellular tyrosine kinase domain of receptors and inhibiting ligand-induced receptor phosphorylation by competing for the intracellular Mg-ATP binding site. Several tyrosine kinase inhibitors that block HER2 kinase are currently in clinical development. Some of these also target EGFR or other EGFR family

25 receptors. For a review of these TKIs see Spector et al. (2007) *Breast Cancer Res.* 9(2): 205. Pharmaceutical articles comprising an antibody composition of the invention and at least one TKI targeting HER2 may thus also be used as a combination treatment for the simultaneous, separate or successive administration in cancer therapy.

30 In other embodiments, the antibody compositions of the present invention may be used in combination with other antibody therapeutics, e.g. an antibody against VEGF (e.g. Avastin®). In yet other embodiments, the antibody compositions of the present invention may be used in combination with an agent known to stimulate cells of the immune system, such combination treatment leading to enhanced immune-mediated enhancement of the efficacy of the antibody

35 compositions of the invention. Examples of such immune-stimulating agents include recombinant interleukins (e.g. IL-21 and IL-2).

2) Monotherapy: In connection with the use of the antibody composition in accordance with the present invention in monotherapy of tumors, the antibody composition may be

administered to patients without concurrent use of a chemotherapeutic or antineoplastic agent, i.e. as a stand-alone therapy.

Immunoconjugates

Another option for therapeutic use of the compositions of the invention is in the form of immunoconjugates, i.e. antibodies conjugated to one or more anti-cancer agents. In particular in the case of compositions of the invention that bind distinct epitopes, it is contemplated that this may generate a cross-linked antibody-receptor lattice on the cell surface, thereby potentially resulting in an increased level of receptor internalization as compared to the use of a single monoclonal antibody. Conjugation of one or more of the individual antibodies of such a composition to one or more anti-cancer agents therefore has the potential to specifically and effectively deliver the conjugated anti-cancer agents to the interior of tumor cells, thereby augmenting the effect of the antibody composition of the invention to provide an improved tumor cell-killing activity.

Various types of anti-cancer agents may be conjugated to the antibodies of the invention, including cytotoxic agents (including conventional chemotherapy agents and other small molecule anti-cancer drugs), cytokines (in which case the conjugate may be termed an "immunocytokine"), toxins (in which case the conjugate may be termed an "immunotoxin") and radionuclides, and a few immunoconjugates have already been approved for clinical use. These include Zevalin® (a murine anti-CD20 antibody conjugated to ⁹⁰Y), Bexxar® (a murine anti-CD20 antibody conjugated to ¹³¹I) and Mylotarg® (a humanized anti-CD33 antibody conjugated to calicheamicin). Other immunoconjugates that have been tested in clinical trials include antibodies conjugated to e.g. doxorubicin or a maytansinoid compound. Immunotoxins that have been tested in clinical trials include several antibodies conjugated to a truncated *Pseudomonas* exotoxin A. An immunocytokine comprising a humanized EpCAM antibody conjugated to IL-2 has also been tested.

In the case of antibodies of the invention conjugated to cytotoxic agents, these may e.g. belong to any of the major classes of chemotherapy drugs, including alkylating agents (e.g. carboplatin, cisplatin, oxaliplatin), antimetabolites (e.g. methotrexate, capecitabine, gemcitabine), anthracyclines (e.g. bleomycin, doxorubicin, mitomycin-C) and plant alkaloids (e.g. taxanes such as docetaxel and paclitaxel, and vinca alkaloids such as vinblastine, vincristine and vinorelbine). Since the use of immunoconjugates specifically directs the anti-cancer agent to the tumors, and in particular to the interior of the tumor cells subsequent to internalization, immunoconjugates based on the antibodies of the invention may advantageously be based on highly cytotoxic agents such as calicheamicin or maytansine derivatives, or on toxins such as bacterial toxins (e.g. *Pseudomonas* exotoxin A, diphtheria toxin) or plant toxins (e.g. ricin).

The conjugated anti-cancer agent in an immunoconjugate is generally linked to the antibody by means of a labile linker that is relatively stable in serum but which allows release of the agent when the immunoconjugate is internalized into the target cell. Suitable linkers include, for example, chemical linkers that are stable at neutral pH in serum but are subjected to acid hydrolysis in the mildly acidic conditions within the lysosomes subsequent to internalization, disulfide linkers that are cleaved by intracellular thiols, and peptide linkers that are stable in serum but which are subjected to enzymatic cleavage in intracellular compartments.

Various conjugation arrangements can be envisioned in compositions containing two or more antibodies of the invention. For example, with two antibodies it would be possible to conjugate the antibodies to two or more different anti-cancer drugs or to conjugate one antibody to a prodrug which is activated by an agent such as an enzyme conjugated to the other antibody. The general concept of antibody-directed enzyme prodrug therapy (ADEPT) has been described for monoclonal antibodies, where a prodrug is activated by an enzyme targeted to the tumor by a mAB-enzyme conjugate, but the present invention may provide an opportunity for tailoring this approach to particular conditions. It may thus be possible to specifically increase tumor cell killing while sparing or reducing damage to normal tissues.

For further information on anti-cancer immunoconjugates, see Wu et al. (2005) *Nature Biotechnology* 23(9):1137-1146; Schrama et al. (2006) *Nature Reviews/Drug Discovery* 5:147-159; and Rohrer (2009) *chimica oggi/Chemistry Today* 27(5):56-60.

Compositions of the invention comprising antibodies directed against two or more EGFR family receptors may contain a single antibody in the form of an immunoconjugate, or they may contain two or more antibodies in the form of an immunoconjugate, e.g. one or possibly two immunoconjugates targeting each of the receptors EGFR, HER2 and HER3.

Dose and Route of Administration

The antibody compositions of the invention will be administered in an effective amount for treatment of the condition in question, i.e. at dosages and for periods of time necessary to achieve a desired result. A therapeutically effective amount may vary according to factors such as the particular condition being treated, the age, sex and weight of the patient, and whether the antibodies are being administered as a stand-alone treatment or in combination with one or more additional anti-cancer treatments.

An effective amount for tumor therapy may be measured by its ability to stabilize disease progression and/or ameliorate symptoms in a patient, and preferably to reverse disease progression, e.g. by reducing tumor size. The ability of an antibody or composition of the invention to inhibit cancer may be evaluated by *in vitro* assays, e.g. as described in the examples, as well as in suitable animal models that are predictive of the efficacy in human

tumors. Suitable dosage regimens will be selected in order to provide an optimum therapeutic response in each particular situation, for example, administered as a single bolus or as a continuous infusion, and with possible adjustment of the dosage as indicated by the exigencies of each case.

5

While specific dosing for antibodies in accordance with the invention has not yet been determined, certain dosing considerations can be determined through comparison with a similar product (e.g. a monoclonal antibody directed against HER2 or EGFR) that has been approved for therapeutic use. It is thus contemplated that an appropriate dosage of an antibody composition of the invention will be similar to the recommended dosage for the anti-HER2 monoclonal antibody trastuzumab (Herceptin®) or the anti-EGFR monoclonal antibody panitumumab (Vectibix®). Depending on the particular condition, Herceptin® is administered (by way of infusion) for treatment of breast cancer at either an initial dose of 4 mg/kg and subsequent weekly doses of 2 mg/kg, or an initial dose of 8 mg/kg and subsequent doses of 6 mg/kg every three weeks, while Vectibix® is administered at a dose of 6 mg/kg every 14 days.

20

25

It is contemplated that a suitable dose of an antibody composition of the invention will be in the range of 0.1-100 mg/kg, such as about 0.5-50 mg/kg, e.g. about 1-20 mg/kg. The antibody composition may for example be administered in a dosage of at least 0.25 mg/kg, e.g. at least 0.5 mg/kg, such as at least 1 mg/kg, e.g. at least 1.5 mg/kg, such as at least 2 mg/kg, e.g. at least 3 mg/kg, such as at least 4 mg/kg, e.g. at least 5 mg/kg; and e.g. up to at most 50 mg/kg, such as up to at the most 30 mg/kg, e.g. up to at the most 20 mg/kg, such as up to at the most 15 mg/kg. Administration will normally be repeated at suitable intervals, e.g. once every week, once every two weeks, once every three weeks, or once every four weeks, and for as long as deemed appropriate by the responsible doctor, who may optionally increase or decrease the dosage as necessary.

30

35

Three distinct delivery approaches are contemplated for delivery of the antibodies of the invention. Conventional intravenous delivery will presumably be the standard delivery technique for the majority of tumors. However, in connection with tumors in the peritoneal cavity, such as tumors of the ovaries, biliary duct, other ducts, and the like, intraperitoneal administration may prove favourable for obtaining high dose of antibody at the tumor and to minimize antibody clearance. Similarly, certain solid tumors possess vasculature that is appropriate for regional perfusion. Regional perfusion may allow the obtainment of a high dose of the antibody at the site of a tumor and minimise short term clearance of the antibody.

40

As with any protein or antibody infusion-based therapeutic product, safety concerns are related primarily to (i) cytokine release syndrome, i.e. hypotension, fever, shaking, chills, (ii) the development of an immunogenic response to the protein (i.e. development of human

antibodies by the patient to the recombinant antibody product), and (iii) toxicity to normal cells that express the HER family receptors, e.g. many epithelial cells. Standard tests and follow-up procedures are utilised to monitor any such safety concerns.

5 Diagnostic Uses and Compositions

The antibodies of the present invention also are useful in diagnostic processes (e.g., *in vitro*, *ex vivo*). For example, the antibodies can be used to detect and/or measure the level of EGFR, HER2, or HER3 in a sample from a patient (e.g., a tissue sample, or a body fluid sample such as an inflammatory exudate, blood, serum, bowel fluid, saliva, or urine). Suitable
10 detection and measurement methods include immunological methods such as flow cytometry, enzyme-linked immunosorbent assays (ELISA), chemiluminescence assays, radioimmunoassay, and immunohistology. The invention further encompasses kits (e.g., diagnostic kits) comprising the antibodies described herein.

15 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention. All publications and other references mentioned herein are
20 incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Although a number of documents are cited herein, this citation does not constitute an admission that any of these documents forms part of the common general knowledge in the art. Throughout this specification and embodiments, the word "comprise," or variations such as "comprises" or "comprising" will be understood to imply
25 the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers. The materials, methods, and examples are illustrative only and not intended to be limiting.

The following examples are meant to illustrate the methods and materials of the present
30 invention. Suitable modifications and adaptations of the described conditions and parameters normally encountered in the art which are obvious to those skilled in the art are within the spirit and scope of the present invention. The terms "antigen-binding fragment" and "antigen-binding portion" are used interchangeably herein.

EXAMPLES**Example 1: Humanization of chimeric antibodies****5 Identification of acceptor frameworks and critical positions for mutation**

The method chosen for the humanization was based on complementarity determining region (CDR) grafting followed by back mutation of critical residues using a combinatorial library approach, where all combinations of up to 13 back mutations were evaluated simultaneously.

10 The CDRs of the donor murine antibodies were grafted into the closest human V-region acceptor framework, which was found by comparing the V region amino acid sequences of the donor antibodies with the human germline repertoire of V and J region sequences (IMGT reference directory). The closest germline V and J regions identified for each antibody are shown in Table 5 below.

15 For 1277VL, the closest human germline V-region was IGKV2-30*02. However, since the IGKV2 family is rarely used in the human repertoire, a second acceptor framework was also selected from the IGKV1 family. Each of the two frameworks were used for generation of a VL back mutation library and combined with the single 1277 VH back mutation library.

20 Since CDR grafting alone may not be sufficient to recreate the binding specificity and affinity, and thus biological activity, of a rodent antibody, back mutations may have to be introduced at critical positions. Potentially critical positions include those that are somatically hypermutated in the donor antibody, positions that may be in direct contact with the antigen or influencing CDR structure (structure determining residues or Vernier zone residues), positions in the
25 VH/VL interface or responsible for the VH/VL packing angle, and positions that are occupied by statistically rare (as compared to the antibody repertoire) or structurally unfavorable residues. These positions can be identified using information available in the literature and in antibody databases (e.g., Padlan (1994) Mol.Immunol. 31: 169-217; Honegger and Plückthun (2001) J.Mol.Biol. 309: 657-670; <http://www.bioc.uzh.ch/antibody>; Martin and Thornton (1996) J.Mol.Biol. 263: 800-815; <http://www.bioc.uzh.ch/antibody>; Foote and Winter (1992) J.Mol.Biol. 224: 487-499), or by performing structural modeling of the *in silico* grafted sequence. A combination of these two approaches was used to identify potentially critical positions for back mutation in each of the antibodies.

35 In addition to the back mutation positions, exposed unwanted sequence motifs in the CDRs were also identified. These motifs included sites for asparagine deamidation (Asn-Gly), aspartate isomerization (Asp-Gly) and methionine oxidation. The identified sequence motifs were altered by conservative substitution or replacement with a frequently occurring amino acid residue at one of the positions (as opposed to back mutation to the murine sequence).
40

A maximum of 13 critical positions were identified and included in the library design for each antibody (Table 5). The number of positions was selected on the basis of the size of the resulting back mutation libraries. For example, if 13 positions are varied between two different amino acids (e.g. human or murine residue) this yields 8192 variants when combined into one molecular library. The location of the identified positions in each antibody is shown in the appended sequence listing, where amino acid residues indicated by "Xaa" are potentially critical positions selected for mutation.

Table 5: Design of libraries for humanization

Library (specificity)	Heavy chain human germline genes and number of positions for mutation			Light chain human germline genes and number of positions for mutation		
	V	J	Number of critical positions*	V	J	Number of critical positions*
1277 (EGFR)	3-48*03	6*01	4	1-39*03	4*01	9
1277A (EGFR)	3-48*03	6*01	4	2-30*02	4*01	6
1565 (EGFR)	1-46*03	4*01	10	1-13*02	4*01	3
4384 (HER2)	1-46*03	5*01	8	1-33*01	4*01	5
4517 (HER2)	3-21*02	6*01	6	1D-39*01	4*01	7
5038 (HER3)	4-31*03	4*01	7	1-33*01	1*01	6
5082 (HER3)	4-31*03	4*01	6	1D-39*01	4*01	7

*Number of positions where back mutations were introduced or unwanted sequence motifs altered.

Generation of back mutation libraries

Back mutation libraries for each VH and VL sequence were synthesized by PCR gene assembly of overlapping DNA oligos spanning 60-80 base pairs of the sequence. The light chain constant region was added by overlap extension PCR to generate full-length light chain genes.

Molecular libraries of humanized antibody variants were prepared by sub-cloning of the VH and light chain libraries for each antibody into a mammalian expression vector followed by transient expression of individual antibody variants in HEK293 cells in 384-well format as described elsewhere (Meijer et al. (2009) Methods Mol Biol. 525:261-77). Expression supernatants were harvested and used for screening.

Off-rate screening of humanization libraries

The library expression supernatants were screened in a sandwich ELISA employing IgG capture by anti-human IgG Fc coated at low density followed by detection with monovalent biotinylated antigen. This ELISA setup allowed for sensitive and reliable ranking of binding affinity without interference from avidity effects or varying expression levels of individual clones. In total, 24 384-well plates were used for each library screening, corresponding to 8832 individual wells and a library sampling of approximately 1 ($p=0.65$ for retrieving a distinct library member). 5 μ l of each library expression supernatant was incubated with coated anti-human IgG Fc capture antibodies at 4°C overnight to ensure that all supernatants, regardless of antibody expression level, reached equilibrium binding. Next, wells were washed and biotinylated antigen (human EGFR, HER2 or HER3; Sino Biological, Beijing, P.R. China; biotinylated in-house) was added at a concentration previously determined to be sufficient for saturation of the chimeric antibody standards. The plates were washed and the antigen was allowed to dissociate from the captured antibodies for a predetermined time interval depending on the measured dissociation of the chimeric parent antibody standard. Finally, streptavidin-peroxidase polymer (Sigma) was added and the plates were developed using TMB-plus substrate (Kem-En-Tec Diagnostics, Taastrup, Denmark).

Approximately 100 hits from each library that yielded an OD signal similar to or higher than that of the chimeric parent antibody were subjected to off-rate ranking using an Octet® QK384 instrument (Fortebio, Menlo Park, CA). Protein G biosensors (Fortebio) were used for capturing of antibody from 40 μ l of expression supernatant followed by incubation with human or cynomolgus antigen at 200 nM. Human antigens were obtained from Sino Biologicals and cynomolgus antigens were produced in-house by transient expression in CHO or HEK293 cells (Koefoed et al. (2011) mAbs, 3:6, 1-12). Subsequently, the biosensors were incubated in PBS and the dissociation of antigen was recorded for 20 min to allow for a reliable determination of the dissociation rates. The responses were globally fitted to a Langmuir 1:1 binding model for calculation of dissociation constants. Overall, multiple hits from each library were found to have dissociation rates from both human and cynomolgus antigen similar to or slower than that of the parent antibody.

Sequence analysis

Plasmids encoding the hits selected for off-rate ranking were subjected to DNA sequencing (MWG Biotech, Ebersberg, Germany), and the obtained sequences were aligned and compared to the *in silico* generated CDR-grafted V regions. Alignments of selected hits are shown in Figures 1-6. All the hits from the screening of the initial libraries based on antibodies 1277 and 1565 were found to have retained the deamidation site (Asn-Gly) in CDRL1 and CDRH2, respectively, thus indicating the importance of the motif for the interaction with the target. However, only a single replacement mutation (Asn to Ser) was attempted in both cases, and it is quite likely that binding variants devoid of the sequence motif can be generated by saturated mutagenesis of one or both positions that make up the motif. Screening of the

libraries generated by PCR-based saturated mutagenesis of the deamidation sites yielded hits devoid of this unwanted sequence motif (Figure 1 and 2). Potently binding antibody variants devoid of unwanted sequence motifs were found in all the other libraries.

Between four and ten hits from each library screening were selected on the basis of retained or improved binding to human and cynomolgus antigen, the number of back-mutations and absence of unwanted sequence motifs for expression in larger scale and purification by protein A chromatography. One of the humanized variants, antibody 11006, was found to have a fortuitous mutation in CDRL1 (I29T; SEQ ID NO:13 and Figure 6) that was not part of the library design, but was nevertheless selected for expression due to improved dissociation rate and removal of an aspartate isomerization site in CDRH2.

Kinetic binding analysis of humanized variants by surface plasmon resonance

Kinetic binding analysis of the purified humanized variants was performed on a ProteOn™ XPR36 biosensor (BioRad, USA) employing an IgG capture assay as described by Canziani et al. (Anal. Biochem. (2004) 325:301-307) that allows for measurement of antibody affinities of whole IgG molecules against soluble antigen under monovalent conditions. Briefly, approximately 5000 resonance units (RU) of a monoclonal mouse anti-human IgG Fc antibody (GE Healthcare, Denmark) was conjugated to a GLC chip surface (BioRad, USA) according to the manufacturer's instructions, followed by capture of individual antibodies of the invention or a negative control on the anti-Fc sensor surface. The densities of captured antibodies were optimized for each clone, so that the binding of the highest antigen concentration employed in the assay did not exceed ~30 RU. Next, 250 µl monovalent antigen (Sino Biologicals) was injected at a flow rate of 50 µl/min in serial threefold dilutions from 100 nM stock to generate response curves. The chip surface was regenerated between cycles by stripping the captured antibody/antigen complexes off the surface with a 10-second injection of 3 M MgCl₂ (GE Healthcare, Denmark) repeated three times. Finally, binding responses were fitted to a Langmuir 1:1 binding model for calculation of the on-rate (kon or ka), off-rate (koff or kd) and affinity (KD) constants using double referencing. The results of the kinetic binding analysis show that the selected variants have retained or even improved affinity for the human and cynomolgus antigen as compared to the chimeric parent antibodies (Table 6).

Table 6: Binding affinity of chimeric parent antibodies and humanized antibodies

Ab ID	Source library (specificity)	Human antigen			Cynomolgus antigen		
		k_a (M ⁻¹ s ⁻¹)	k_d (s ⁻¹)	K_D (M)	k_a (M ⁻¹ s ⁻¹)	k_d (s ⁻¹)	K_D (M)
1277	chimeric (EGFR)	9.4E+05	3.5E-04	3.7E-10	6.6E+05	3.9E-04	5.9E-10
10292	1277 (EGFR)	1.5E+06	4.8E-04	3.2E-10	7.9E+05	2.7E-04	3.5E-10
10460	1277A (EGFR)	1.3E+06	5.3E-04	4.1E-10	9.7E+05	5.2E-04	5.3E-10
11294	1277A (EGFR)	3.4E+05	1.8E-04	5.3E-10	3.7E+05	2.1E-04	5.6E-10

1565	chimeric (EGFR)	1.7E+06	5.8E-04	3.5E-10	5.8E+05	1.6E-02	2.8E-08
10560	1565 (EGFR)	1.7E+06	4.6E-04	2.7E-10	8.9E+05	2.7E-03	3.1E-09
11302	1565 (EGFR)	4.9E+05	9.6E-05	2.0E-10	4.2E+05	4.9E-04	1.2E-09
4384	chimeric (HER2)	4.0E+05	3.0E-04	7.5E-10	1.8E+05	5.0E-04	2.9E-09
10704	4384 (HER2)	3.6E+05	1.4E-04	3.9E-10	1.9E+05	2.7E-04	1.4E-09
11249	4384 (HER2)	2.2E+05	1.1E-04	5.0E-10	1.5E+05	3.8E-04	2.5E-09
4517	chimeric (HER2)	2.6E+05	2.9E-04	1.1E-09	2.3E+05	8.6E-04	3.7E-09
11145	4517 (HER2)	1.27E+05	1.24E-04	9.8E-10	5.3E+04	6.3E-04	1.2E-08
5038	chimeric (HER3)	3.0E+05	4.8E-04	1.6E-09	4.6E+05	4.1E-04	8.9E-10
10738	5038 (HER3)	2.6E+05	1.9E-04	7.5E-10	5.4E+05	2.9E-04	5.4E-10
10810	5038 (HER3)	1.9E+05	2.0E-04	1.1E-09	4.7E+05	3.4E-04	7.1E-10
5082	chimeric (HER3)	9.1E+05	7.3E-05	8.0E-11	1.7E+06	1.6E-04	9.8E-11
11006	5082 (HER3)	7.4E+05	<2E-6	ND*	1.5E+06	8.7E-05	5.9E-11
11052	5082 (HER3)	8.7E+05	1.6E-04	1.8E-10	1.3E+06	2.6E-04	1.9E-10

*KD could not be determined due to a very slow off-rate. Estimated to be in the picomolar range.

In vitro functional evaluation of humanized variants

Humanized antibody variants were tested for functional effect in a viability assay in combination with a chimeric "partner antibody" in an antibody mixture containing two antibodies against different epitopes of a particular target (where "partner antibody" refers to the fact that antibody1277 variants (anti-EGFR) were tested together with the chimeric anti-EGFR antibody 1565, antibody 4384 variants (anti-HER2) were tested in combination with the chimeric anti-HER2 antibody 4517, and so forth) to determine if the functional synergy between the two antibodies targeting the same receptor was preserved after humanization. Each humanized variant was tested in two cell lines and compared to the parental mixture of two chimeric antibodies and to a negative control antibody. The cell lines used were selected on the basis of their previously determined receptor-dependency, i.e., A431NS epidermoid, H358 non-small cell lung, and FaDu head and neck cancers for EGFR, OE19 esophageal and BT474 breast cancer for HER2, and MDA-MB-175 VII and MCF-7 breast cancer for HER3. In addition, a combination of six humanized variants (11294, 11302, 11249, 11145, 10738 and 11052; Humanized Pan-HER) was tested in a number of cell lines and compared to the combination of the six chimeric antibodies (1277, 1565, 4384, 4517, 5038 and 5082; Chimeric Pan-HER). The cell lines used, N87 gastric, FaDu head and neck, A431NS epidermoid, OE19 esophageal, HN5 head and neck, MDA-MB-175 VII breast and MFE-280 endometrial cancer, were selected on the basis of their previously determined dependency on the HER family receptors.

Prior to performing the viability assay the appropriate antibodies and antibody mixtures were diluted to a final total antibody concentration of 100 µg/ml in appropriate media supplemented with 0.5-2% FBS and 1% P/S (penicillin/streptomycin), yielding a final total antibody concentration of 50 µg/ml in the well containing the highest antibody concentration. A threefold serial dilution of the antibodies was then performed in a 384-well plate, followed by addition of relevant numbers of cells to the experimental wells. The MCF-7 cells were also stimulated with 1 nM heregulin beta. The plates were incubated for 4 days in a humidified incubator at 37°C. WST-1 reagent (Roche Applied Science, Mannheim, Germany) was added to the plates and the plates were incubated for 1-3 h at 37°C. Plates were transferred to an orbital plate shaker for one h and the absorbance was measured at 450 and 620 nm (reference wavelength) using an ELISA reader. The percentage of metabolically active cells (MAC) is calculated as a percentage of the untreated control as follows:

$$\%MAC = \left(\frac{(OD_{exp.} - OD_{medium})}{(OD_{untreat.} - OD_{medium})} \right) \times 100$$

The *in vitro* activity of selected humanized antibody variants is shown in Figures 7-15 and 17-19. The results show that all of the selected humanized variants display an anti-proliferative effect when combined with their chimeric or humanized partner that is very similar to the effect of the relevant mixture of the two chimeric parent antibodies. Furthermore, the combination of six humanized variants also displays an effect very similar to the effect of the combination of the six chimeric parent antibodies (Figure 20).

Specificity of humanized variants (cross-reactivity)

The chimeric parent antibodies and selected humanized variants were tested for binding to EGFR, HER2 and HER3 from humans, cynomolgus monkeys and mice, as well as human and murine HER4, to determine whether the humanization had introduced any changes in the cross-reactivity pattern.

Antibody-antigen binding was measured by ELISA with coated antigens. Human antigens were obtained from Sino Biologicals. All other antigens were produced in-house by transient expression in CHO or HEK293 cells. Chimeric and humanized antibodies, as well as an isotype control antibody, were incubated with the coated antigens at different concentrations. After wash, bound antibodies were detected by HRP- (horse radish peroxidase)-conjugated secondary antibodies. The OD signal from 40 nM antibody, measured at 450 nm using an ELISA reader, was scored from negative (-; OD<0.1) to strongly positive (+++; OD>2.5).

The results, shown in the table in Figure 16, demonstrate that cross-reactivity between the respective human and cynomolgus antigens is conserved in all humanized antibody variants,

and that no new reactivity to members of the epidermal growth factor receptor family has been introduced.

Summary and conclusions

5 A number of humanized variants of the chimeric anti-EGFR, anti-HER2 and anti-HER3 antibodies disclosed in PCT/IB2011/054834 were produced by screening of CDR-grafted libraries generated by back mutation of potentially critical framework positions and in some cases by alteration of unwanted CDR sequence motifs. Approximately 100 hits from each library selected for binding affinity to the relevant target antigen were subjected to off-rate
10 ranking, and variants with a dissociation rate similar to or slower than that of the parent chimeric antibody were selected and sequenced. Between four and ten hits from each library screening were selected on the basis of retained or improved binding to human and cynomolgus antigen, number of back-mutations and absence of unwanted sequence motifs for larger scale expression and purification. Selected purified humanized antibody variants were
15 subjected to a kinetic binding analysis to determine binding affinity to human and cynomolgus antigen, to *in vitro* functional analysis in a viability assay in combination with a chimeric partner antibody binding to a different epitope of the same receptor, and to a cross-reactivity assay.

20 Each of the humanized variant antibodies 10292, 10460, 11294, 10560, 11302, 10704, 112449, 11145, 10738, 10810, 11006 and 11052 were found to exhibit functional properties that were very similar to those of the original chimeric parent antibody from which they were derived, including:

- similar or higher binding affinity;
- 25 • similar or slower dissociation rate;
- binding to the same human and cynomolgus antigen combined with lack of binding to the mouse antigen or to other EGFR family receptors; and
- highly similar anti-proliferative effects in two different cell lines when tested in a functional *in vitro* assay in combination with the chimeric partner antibody.

30 These results thus demonstrate that the humanized antibody variants of the invention have functional characteristics that are highly similar to the respective parent chimeric antibodies from which they are derived. This strongly suggests that mixtures of the humanized antibodies of the invention, e.g. mixtures containing one or two such antibodies against each of the EGFR
35 family receptors EGFR, HER2 and HER3, can be expected to demonstrate anti-cancer effects *in vivo* that are similar to the effects of the mixtures of the parent chimeric antibodies described in PCT/IB2011/054834.

EXAMPLE 2: Two monoclonal antibodies against non-overlapping epitopes on EGFR, HER2 or HER3 display synergistic in vitro growth inhibitory activity and effectively induce target down-regulation

Antibodies against non-overlapping epitopes on EGFR (i.e., 1277 and 1565), HER2 (i.e., 4384 and 4517), and HER3 (i.e., 5038 and 5082) as illustrated in Figure 21A, were tested for their ability to inhibit the growth and proliferation of the cancer cell lines A431NS, HCC202, and MDA-MB-175-VII, respectively, using a viability assay. Antibody treatments consisted of antibodies to each receptor administered either alone or in the following combinations: 1277 and 1565 mixture, 4384 and 4517 mixture, and 5038 and 5082 mixture. Cellular damage will inevitably result in loss of the ability of the cell to maintain and provide energy for metabolic cell function and growth. Metabolic activity assays are based on this premise and usually measure mitochondrial activity. The Cell Proliferation Reagent WST-1 (Roche Cat. No 11 644 807 001) is a ready-to-use substrate that measures the metabolic activity of viable cells. It is assumed that the metabolic activity correlates with the number of viable cells. In this example, the WST-1 assay was used to measure the number of metabolically active cells after treatment of cancer cells with different concentrations of antibodies for 96 hours.

Prior to performing the WST-1 assay, the appropriate antibodies and antibody mixes were diluted to a final total antibody concentration of 100 µg/ml in appropriate media supplemented with 2% of FBS and 1% P/S yielding a final total antibody concentration of 50 µg/ml in the well containing the highest antibody concentration. A threefold serial dilution of the antibodies was then performed. Relevant numbers of cells were then added to the experimental wells in a 384-well plate. The plates were incubated for 4 days in a humidified incubator at 37°C. WST-1 reagent was then added to the plates and the plates were incubated for one hour at 37°C. Plates were transferred to an orbital plate shaker for one hour and the absorbance was measured at 450 and 620 nm (reference wavelength) using an ELISA reader. The amount of metabolically active cells (MAC) is calculated as a percentage of the untreated control as follows:

$$\%MAC = \left(\frac{(OD_{exp.} - OD_{media})}{(OD_{untreat.} - OD_{media})} \right) \times 100$$

The in vitro effects of antibody treatment showed that mixtures of antibodies are superior to the individual antibodies to each of the three HER receptors tested (Figure 21B). Furthermore, analysis of EGFR, HER2 and HER3 levels in cell lysates isolated from antibody treated A431NS, HCC202 and MDA-MB-175-VII cells (20 µg/ml total antibody for each treatment for 48 hours) by Western Blot analysis showed that antibody treated cells exhibited reduced levels of EGFR, HER2 and HER3 compared to untreated cells (Figure 21C).

This example demonstrates that two antibodies against EGFR, HER2 or HER3 display synergistic in vitro growth inhibitory activity and effectively induce target down-regulation.

EXAMPLE 3: Pan-HER is broadly inhibitory in a large number of cell lines of different tissue origin and genetic background

Mixtures of antibodies against non-overlapping epitopes on EGFR, HER2, and/or HER3 were tested for their ability to inhibit the growth and proliferation of a broad range of cancer cell lines. The effects of treatment with Pan-HER (a mixture of six monoclonal antibodies against EGFR, HER2 and HER3; antibodies 1277, 1565, 4384, 4517, 5038, and 5082), antibody mixtures targeting two HER family members (i.e., EGFR and HER2, EGFR and HER3, and HER2 and HER3), and antibody mixtures targeting one HER family member (i.e., EGFR, HER2 and HER3) were measured in the following cell lines: HN5, MDA-MB175-VII, HCC827, N87, A431NS, FaDu, OE19, SW948, BT474, RMG-1, TE11, GEO, H358, CALU-3, H292, HCC202, LS174T, ZR-75-30, H1975, KYSE520, AU-565, CAPAN-1, IGR-OV1, OE33, PK-1, CFPAC-1, BxPC3, A431, SW1463, COLO678, H820, COLO680N, ASPC1, HCC1937, H661, MFE-280, OVCAR-3, OVCAR-5, SK-BR-3, SW403, OVCAR-8, RL95-2, RMUG-S, SW837, T84, CAPAN-2, GP5d, CaCO2, BT20, MDA-MB-468, DU145, A549, CAL-120, EBC1, H1993, H226, HEC-108, LoVo, Panc08.13, RT-112, U2-OS, DLD-1, SKOV3, H460, KATOIII, MDA-MB-134-VI, MKN-45, PANC-1, RT-4, SNU-16, A2058, MCF7, SW480. Characterization of the receptor phosphorylation levels of EGFR, HER2 and HER3 in these 73 cell lines using PathScan RTK Signaling Antibody Arrays (Cell Signaling Technology) demonstrated elevated HER family activation (Figure 22).

Effects of antibody treatments in over 70 cancer cell lines (out of more than 100 cell lines tested) on metabolic activity were determined after 96 hours incubation using a similar WST-1 assay as described in Example 2. Results showed that Pan-HER is broadly inhibitory in a large number of cancer cell lines of different tissue origin and genetic background in the presence of Heregulin (Figure 24), EGF (Figure 25), or neither ligand (Figure 23). "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. These results further demonstrated that simultaneous targeting of three receptors provided broader efficacy than targeting of a single receptor or any combination of two receptors in the HER family.

EXAMPLE 4: Pan-HER effectively inhibits ligand-induced proliferation

To determine if antibody mixtures are efficacious in the presence of EGFR and HER3 ligands, antibody mixtures against one, two or three HER family receptors were tested for their ability to inhibit the growth and proliferation of pancreatic cancer cell lines in the presence of Heregulin, EGF, or neither ligand. The effects of treatment with Pan-HER (a mixture of six monoclonal antibodies against EGFR, HER2 and HER3; antibodies 1277, 1565, 4384, 4517, 5038, and 5082), antibody mixtures targeting two HER family members (i.e.,

EGFR and HER2, EGFR and HER3, and HER2 and HER3), and antibody mixtures targeting one HER family member (i.e., EGFR, HER2 and HER3) were measured on the following cell lines: CAPAN-1, PK-1, CFPAC-1, BxPC 3, ASPC1, CAPAN-2, Panc08.13, PANC-1, KP4, MiaPaca-2 and PSN1). The mutation status of these cell lines is shown in Figure 26. The ability of antibodies

5 mixtures against one, two or three HER family receptors to inhibit the growth and proliferation of a wide variety of cancer cell lines in the presence of Heregulin, EGF, or neither ligand was also tested (Figures 23-25). Cells were exposed to medium containing antibodies and ligands for 96 hours (ligand and antibody were added simultaneously to the cells). Metabolic activity was determined after 96 hours incubation using a similar WST-1 assay as described in

10 Example 2. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082. Pan-Her exhibited effective

15 inhibition of a wide variety of cancer cell lines in the presence of EGF or Heregulin.

EXAMPLE 5: Pan-HER maintains inhibitory effect in cells with acquired resistance to approved therapeutic antibodies

Pan-HER (a mixture of six monoclonal antibodies against EGFR, HER2 and HER3; antibodies

20 1277, 1565, 4384, 4517, 5038, and 5082) was tested for its ability to inhibit the growth and proliferation of HN5, OE19 and MDA-MB-175-VII cell lines or cell pools with acquired resistance to cetuximab, trastuzumab, or pertuzumab, respectively. Cetuximab resistant HN5 cell lines were generated as described in Example 11. Trastuzumab resistant OE19 cells and pertuzumab resistant MDA-MB-175-VII cells were established by exposing parental cells to

25 increasing concentrations of trastuzumab [10-100 µg/ml] and pertuzumab [1-50 µg/ml] respectively, during a period of eight months and 12 months respectively. Cells were split once or twice a week in order to keep cells in exponential growth. The level of resistance was tested every month in a WST-1 viability assay as described in Example 2, until a pool of resistant cells was established. Single cell clones of trastuzumab resistant OE19 cells were generated

30 through limited dilution cloning of the acquired trastuzumab resistant pool of OE19 cells as described in Example 11.

Metabolic activity was determined after 96 hours incubation using a similar WST-1 assay as described in Example 2. Pan-HER-treated resistant cells as well as parental cells exhibited

35 reduced levels of metabolic activity (Figure 28). In contrast, metabolic activity was reduced in parental HN5, OE19 and MDA-MB-175-VII cells, but unaltered in resistant clones treated with cetuximab, trastuzumab, or pertuzumab, respectively. This example demonstrates that Pan-HER maintains inhibitory effect in cells with acquired resistance to approved therapeutic antibodies.

EXAMPLE 6: Pan-HER effectively prevents compensatory receptor up-regulation in vitro

To determine if compensatory receptor up-regulation occurs as a result of treatment with antibody mixtures of the present invention, EGFR, HER2 and HER3 levels were measured in whole cell lysates from H292 and OVCAR8 cell lines after antibody treatment (20 µg/ml) for 48 hour by western blot analysis. The effects of treatment with Pan-HER (a mixture of six monoclonal antibodies against EGFR, HER2 and HER3; antibodies 1277, 1565, 4384, 4517, 5038, and 5082) and antibody mixtures targeting one HER family member (i.e., EGFR (antibodies 1277, 1565, or 1277+1565), HER2 (antibodies 4384, 4517, or 4384+4517) and HER3 (antibodies 5038, 5082, or 5038+5082)) were determined. β-Actin was used as a loading control. Results showed that anti-EGFR treatment lead to HER2 upregulation in H292 cells (Figure 29, top; cetuximab lane, 1277, 1565, and 1277 +1565 lanes), and anti-HER3 treatment lead to HER2 up-regulation in OVCAR-8 (Figure 29, bottom; MM-121 lane, 5038, 5082, and 5038 + 5082 lanes), while Pan-HER treatment lead to the downregulation of EGFR, HER2 and HER3 (Figure 29; Pan-Her lanes). These results demonstrated that Pan-HER effectively induced simultaneous down-regulation of all three targets and prevented compensatory receptor up-regulation, a potential mechanism for acquiring resistance.

EXAMPLE 7: Synergistic effect of targeting multiple HER family receptors in BxPC-3 (pancreatic cancer) xenograft model

To evaluate the efficacy of antibody mixtures against EGFR, HER2, HER3 and combinations of two and three receptor targets in xenograft model of human cancer, BxPC-3 (pancreatic cancer) xenograft models were treated with antibody mixtures and the effect on tumor size assayed.

In this assay, BxPC-3 pancreatic cancer cells were inoculated into mice. In brief, 5x10⁶ BxPC3 cells were inoculated subcutaneously into the left flank of eight to ten week old female athymic nude mice. Tumors were measured thrice weekly with calipers and tumor volume in mm³ was calculated according to the formula: (width)² x length x 0.5. At an average tumor size of 140 mm³ the mice were randomized and treatment initiated. The mice were treated with thrice weekly intraperitoneal injections of 50 mg/kg (10 injections in total) followed by an observation period. Graphical representations of tumor volume data were presented as means ± SEM.

Results showed that Pan-HER (antibodies 1277, 1565, 4384, 4517, 5038, and 5082) effectively suppressed tumor growth in the BxPC-3 xenograft model (Figure 30; N=7/group; treatment period indicated by the light grey area on the graph). A clear synergy was observed when targeting EGFR and HER3 as well as EGFR and HER2, with the former combination being most efficient at controlling growth of the BxPC3 tumor xenografts. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of

antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082. Furthermore, EGFR and HER2 down-regulation by Pan-HER in vivo was confirmed by immunohistochemistry on tissue sections from tumors resected 3 days after withdrawal of treatment (Figure 31).

EXAMPLE 8: Synergistic effect of targeting multiple HER family receptors in Calu-3 (NSCLC) xenograft model

To evaluate the efficacy of antibody mixtures against EGFR, HER2, HER3 and combinations of two and three receptor targets in xenograft models of human cancer, the Calu-3 (NSCLC) xenograft model were treated with antibody mixtures and the effect on tumor size assayed. In this assay, Calu-3 NSCLC cells were inoculated into mice. In brief, 1×10^7 Calu-3 cells were inoculated subcutaneously into the left flank of eight to ten week old female athymic nude mice. Tumors were measured thrice weekly with calipers and tumor volume in mm^3 was calculated according to the formula: $(\text{width})^2 \times \text{length} \times 0.5$. At an average tumor size of 170 mm^3 the mice were randomized and treatment initiated. The mice were treated with thrice weekly intraperitoneal injections of 50 mg/kg (8 injections in total). Graphical representations of tumor volume data were presented as means $\pm$ SEM.

Results showed that Pan-HER (antibodies 1277, 1565, 4384, 4517, 5038, and 5082) effectively suppressed tumor growth in the Calu-3 xenograft model (Figure 32; N=5/group; treatment period indicated by the light grey area on the graph). The results show a synergistic effect of targeting EGFR, HER2 and HER3 simultaneously whereas no clear synergy could be observed when targeting EGFR and HER2 or EGFR and HER3 compared to the anti-tumor response of EGFR mono-targeting. "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

EXAMPLE 9: Pan-HER effectively prevents compensatory receptor up-regulation *in vivo*

To determine if prevention of compensatory receptor up-regulation occurs in vivo as a result of treatment with antibody mixtures of the present invention, EGFR, HER2 and HER3 levels were measured in antibody-treated BxPC-3 tumor lysates by Western Blot analysis. The effects of treatment with Pan-HER (a mixture of six monoclonal antibodies against EGFR, HER2 and HER3; antibodies 1277, 1565, 4384, 4517, 5038, and 5082), antibody mixtures targeting two HER family members (i.e., EGFR and HER2, EGFR and HER3, and HER2 and HER3), and antibody mixtures targeting one HER family member (i.e., EGFR, HER2 and HER3) were

determined. β -Actin was used as a loading control. Results showed that anti-EGFR treatment lead to EGFR downregulation (Figure 33 top), anti-HER2 treatment lead to HER2 downregulation (Figure 33 top), and anti-HER3 treatment lead to HER3 downregulation (Figure 33 top). Relative quantification of the Western blot band intensities showed that HER2 was significantly up-regulated in response to anti-HER3 treatment (Figure 33; bottom). In contrast, Pan-HER treatment resulting in the simultaneous and effective downregulation of EGFR, HER2 and HER3 (Figure 33 top; green boxes and Figure 33 bottom). "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3" refers to a mixture of antibodies 4384, 4517, 5038, and 5082. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

This example demonstrated that Pan-HER is capable of effectively inducing simultaneous down-regulation of all three targets and preventing compensatory receptor up-regulation in vivo.

EXAMPLE 10: Synergistic effect of targeting multiple HER family receptors in patient-derived KRAS mutated pancreatic tumor xenograft models

To evaluate the in vivo efficacy of antibody mixtures against EGFR, HER2, HER3 and combinations of two and three receptor targets, patient-derived tumor xenograft models of KRAS mutated pancreatic cancer (START Discovery, San Antonio, TX) were treated with antibody mixtures and the effect on tumor size assayed.

In this assay, patient-derived pancreatic cancer cells were inoculated into mice. In brief, viable resected patient tumor material was implanted in immunocompromised mice and serially passaged in vivo. At a tumor volume of 100-200 mm³, animals were randomized into treatment and control groups and dosing was initiated. Dosing schedule: 50 mg/kg i.p. three times weekly, 10 doses in total (day 0-20). N=5/group. Data are presented as means $\pm$ SEM. Asterix indicates first day with $p < 0.05$. The statistically significant difference in treatment response between the groups was maintained throughout the study period.

Results showed that Pan-HER effectively suppressed tumor growth in hard-to-treat patient-derived models of pancreatic cancer. (Figure 34; N=5/group). Furthermore, deconvolution studies revealed strong synergy of EGFR and HER2 targeting in the ST179 xenograft model and of EGFR and HER3, and to a lesser extent of EGFR and HER2, targeting in the ST383 xenograft model (Figure 35; N=7-8/group; treatment period indicated by the light grey area on the graph). "EGFR" refers to a mixture of antibodies 1277 and 1565. "HER2" refers to a mixture of antibodies 4384 and 4517. "HER3" refers to a mixture of antibodies 5038 and 5082. "EGFR+HER2" refers to a mixture of antibodies 1277, 1565, 4384, and 4517. "EGFR+HER3" refers to a mixture of antibodies 1277, 1565, 5038, and 5082. "HER2+HER3"

refers to a mixture of antibodies 4384, 4517, 5038, and 5082. "Pan-HER" refers to a mixture of antibodies 1277, 1565, 4384, 4517, 5038, and 5082.

Table 7: Patient-derived xenograft models of pancreatic cancer

Model	KRAS mut.	p53 mut.	Erlotinib resistant	Cet. resp. (20 mg/kg)	Other
ST383	G12D	wt	Yes	ND	
ST204	G12D	wt	ND	PD	
ST334	G12D	R273C	Yes	PD	Trastuzumab resist.
ST385	G12D	G245S	Yes	PD	
STS059	G12D	K120R	Yes	ND	
STS058	G12D	R273C	Yes	ND	
STS021	G12R	wt	No	ND	
ST179	G12V	wt	ND	ND	
STS064	G12V	Y234C	ND	ND	
ST191	G12S	wt	Yes	PD	

wt: wild-type, PD: Progressive disease, ND: Not determined.

EXAMPLE 11: Acquired Cetuximab resistant HN5 clones show decreased total levels of EGFR together with high EGFR activity

Cetuximab resistant HN5 clones were established by exposing parental HN5 cells to increasing concentrations of cetuximab [1-100 µg/ml] during a period of six months. Cells were split twice a week in order to keep cells in exponential growth. The level of resistance to cetuximab was tested every month in a WST-1 viability assay as described in Example 2 until a pool of cetuximab resistant cells was established. Single cell clones were generated through limited dilution cloning of the acquired cetuximab resistant pool of HN5 cells. 0.5 cells/well were plated in 384 well plates. Growth and proliferation of single cell colonies was followed using Novartis Cellavista Imager. The most resistant individual clones, HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14, were selected for further characterization (Figure 36).

Viability:

The level of cetuximab resistance of individual clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 was tested in a WST-1 viability assay as previously described in Example 1. Briefly, cells were treated with cetuximab at a range of concentrations and assayed 96 hours later. Unlike parental HN5 cells, resistant clones were viable with increasing concentrations of cetuximab treatment (Figure 37).

Cetuximab binding to fixed cells:

The binding strength of cetuximab to parental HN5 and resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 was determined. Binding curves were generated by plotting fluorescence signals that were normalized to the number of cells (DRAQ-5 staining) and cetuximab concentrations. The results demonstrate that while half-maximal binding (i.e.,

EC50 value) of cetuximab was unaltered, maximal binding was decreased in the resistant clones compared to parental cells (Figure 38).

EGFR Expression and Signaling:

The relative surface levels of EGFR were determined in parental HN5 and resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14. Briefly, cells were stained with anti-EGFR-FITC (abcam, #11400) or an isotype control (abcam, #18446) and the relative fluorescence of live cells quantified by flow cytometry. The relative surface levels of EGFR were lower in cetuximab resistant HN5 clones compared to the parental cells (Figure 39).

The response of cetuximab resistant clones to EGF stimulation was tested. The total levels of EGFR, levels of phosphorylated EGFR and downstream signaling molecules were determined in parental HN5 and resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14. Parental HN5 cells and cetuximab resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14 were untreated or stimulated with 1nM EGF for 15 min before harvesting. Lysates were fractionated on SDS-PAGE followed by Western Blotting for EGFR, the phosphorylated EGFR species pEGFR (Tyr1068), pEGFR(Tyr1045), pEGFR(Tyr1173), pEGFR(Tyr992), pEGFR(Thr669), and pEGFR(Ser1046/1047), and the signalling molecules AKT, pAKT (Ser473), ERK1/2, pERK1/2(Thr202/Tyr204) (Figures 40 and 41). β -Actin was used as a loading control. Results showed that the total levels of EGFR and phosphorylated EGFR were lower in cetuximab resistant HN5 clones compared to the parental cells (Figure 40). The results also showed a decreased level of pEGFR(Ser1046/1047) in the cetuximab resistant clones, indicating that the feedback mechanism regulating EGFR is less active in the cetuximab resistant clones (Figure 40). Stimulation with EGF induced a stronger activation of pAKT and pERK1/2 in the cetuximab resistant clones compared to parental HN5 cells (Figure 41). Together, these results demonstrate that EGFR is still active in the cetuximab resistant clones, although EGFR expression is decreased compared to parental HN5 cells.

EXAMPLE 12: Antibody mixtures targeting EGFR overcome cetuximab resistance through efficient EGFR internalization followed by degradation of the receptor

A mixture of antibodies targeting non-overlapping epitopes on EGFR was tested for its ability to partially overcome the cetuximab induced resistance in cetuximab resistant HN5 clones HN5 CR2 and HN5 CR14. Parental HN5, HN5 CR2, and HN5 CR14 cells were treated with EGFR-LNA™ (EGFR targeting Locked Nucleic Acid, Exiqon), Cetuximab or EGFR-2mix (antibodies 1277 and 1565) for 48 hours. Growth and proliferation was measured using a WST-1 assay as described in Example 2 and quantification of the effects were plotted with data points representing a mean $\pm$ SEM (n=4) (Figure 42). EGFR-LNA, and EGFR-2mix both induced a similar reduction in cell viability. These results demonstrated that a mixture of antibodies targeting non-overlapping epitopes on EGFR partially overcame the cetuximab

induced resistance and that the cetuximab resistant clones remain dependent on EGFR for growth and proliferation (Figure 42).

The levels of EGFR in cells treated with EGFR-LNA, cetuximab or EGFR-2mix for 48 hour was determined by fractionating cellular lysates on a SDS-PAGE followed by Western Blotting for EGFR. The results showed that efficient EGFR internalization followed by lysosomal degradation of the receptor was induced in antibody treated resistant cells (Figure 43), and thus providing a mechanism for the ability of the antibody mixture targeting EGFR overcome cetuximab resistance.

EXAMPLE 13: Cetuximab resistant HN5 clones escape treatment through HER3 and IGF1R

The observed level of inhibition of the resistant clones by the anti-EGFR mixture did not, however, induce as efficient growth inhibition as in the parental cells, suggesting that alternative receptor tyrosine kinases (RTKs) may be involved in the mechanism of acquired cetuximab resistance. To test the role of HER3 activity in parental HN5 and resistant clones HN5 CR2, HN5 CR6, HN5 CR13, and HN5 CR14, cells were treated with a mixture of two EGFR antibodies (antibodies 1277 and 1565), a mixture of two HER3 antibodies (antibodies 5038 and 5082), a mixture of two EGFR and two HER3 antibodies (antibodies 1277, 1565, 5038 and 5082), or cetuximab for 48 hours. Growth and proliferation was measured using a WST-1 assay as described in Example 2 and quantification of the effects were plotted with data points representing as a mean $\pm$ SEM (n=6). The results showed superior effects of the mixture containing antibodies targeting both HER3 and EGFR compared to effects induced by the EGFR antibody mixture alone. These results support the hypothesis of involvement of alternative RTKs in the acquired cetuximab resistance (Figure 44). The dose response curves of parental HN5 and resistant HN5 CR2 cells to the antibody mixtures are shown in Figure 45A and B.

The involvement of HER3 in the acquired resistance to cetuximab shown here indicates the plasticity of the RTK family as a mechanism of acquired resistance to cetuximab in vitro.

Table 8: Sequences of selected chimeric antibodies

Antibody 1277: VH nucleotide sequence

cgcgccgaag tgcagctggt ggagtctggg ggaggcttag tgaagcctgg agagtccttg
aaactctcct gtgcagcctc tggattcgct ttcagttact ctgacatgtc ttgggttcgc
cagactccgg agaagaggct ggagtgggtc gcatacatga gtagtgctgg tgatgtcacc
ttctattcag acactgtgaa gggccgattc accatctcca gagacaatgc caagaacacc
ctgtatctgc aagtgagcag tctgaagtct gaggacacag ccatatatta ctgtgtaaga
caccgggacg tggctatgga ctactggggt caaggaacct cagtcaccgt ctcg (SEQ ID NO: 14)

Antibody 1277: VH amino acid sequence

Arg Ala Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro

Gly Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser
 Tyr Ser Asp Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu
 Trp Val Ala Tyr Met Ser Ser Ala Gly Asp Val Thr Phe Tyr Ser Asp
 Thr Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr
 5 Leu Tyr Leu Gln Val Ser Ser Leu Lys Ser Glu Asp Thr Ala Ile Tyr
 Tyr Cys Val Arg His Arg Asp Val Ala Met Asp Tyr Trp Gly Gln Gly
 Thr Ser Val Thr Val Ser (SEQ ID NO: 15)

Antibody 1277: light chain nucleotide sequence

10 ctagccgatg ttgtgatgac ccagactcca ctctccctgc ctgtcagtct tggagatcaa
 gcctccatct cttgcagatc tagtcagagc cttgtacaca gtaatggaaa cacctattta
 cattgggtacc tgcagaagcc aggccagtct ccaaagctcc tgatctacaa agtttccaac
 cgattttctg ggggtcccaga cagggtcagt ggcagtggat cagggacaga ttccacactc
 aagatcagca gagtggaggc tgaggatctg ggagtttatt tctgctctca aagtacacat
 15 gttccgacgt tcggtggagg caccaagctg gaaatcaaac gaactgtggc tgcaccatct
 gtcttcatct tcccgccatc tgatgagcag ttgaaatctg gaactgcctc tgttgtgtgc
 ctgctgaata acttctatcc cagagaggcc aaagtacagt ggaaggtgga taacgcctc
 caatcgggta actccagga gagtgtcaca gagcaggaca gcaaggacag cacctacagc
 ctgagcagca cctgacgct gagcaaagca gactacgaga aacacaaagt ctacgcctgc
 20 gaagtcaccc atcagggcct gagctcgccc gtcacaaaga gcttcaacag gggagagtgt (SEQ ID NO: 16)

Antibody 1277: light chain amino acid sequence

Leu Ala Asp Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser
 Leu Gly Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val
 25 His Ser Asn Gly Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly
 Gln Ser Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly
 Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
 Lys Ile Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Ser
 Gln Ser Thr His Val Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
 30 Lys Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
 Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn
 Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu
 Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp
 Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr
 35 Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser
 Ser Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 17)

Antibody 1565: VH nucleotide sequence

ggcgcgccga ggtccaactg caacagtctg ggactgaatt ggtgaagcct ggggcttcag
 40 tgatactgtc ctgtaaggcc tctggctaca ccttcaccag ctactggatg cagtgggtga

agcagaggcc tggacaaggc cttgagtgga ttggaaatat taatcctagc aatggtggaa
 ctagtttcaa tgaggagttc aagagtaggg ccacactgac ttagacaaa tctccagta
 cagcctacat gcaactcagc agcctgacat ctgaggactc tgcggtctat tattgtgcaa
 gagacggggg cctttacgac ggatactact ttgacttctg gggccaaggc accactctca
 5 cagtctcgag (SEQ ID NO: 18)

Antibody 1565: VH amino acid sequence

Arg Ala Glu Val Gln Leu Gln Gln Ser Gly Thr Glu Leu Val Lys Pro
 Gly Ala Ser Val Ile Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 10 Ser Tyr Trp Met Gln Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu
 Trp Ile Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Ser Phe Asn Glu
 Glu Phe Lys Ser Arg Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr
 Ala Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr
 Tyr Cys Ala Arg Asp Gly Gly Leu Tyr Asp Gly Tyr Tyr Phe Asp Phe
 15 Trp Gly Gln Gly Thr Thr Leu Thr Val Ser (SEQ ID NO: 19)

Antibody 1565: light chain nucleotide sequence

gctagccaac attgtgatga cacagtctca caaatcatg tccacattaa taggagccag
 ggtctccatc acctgcaagg ccagtcagga tgtggatacg gctgtagcct ggtatcaaca
 20 gaaaccaggt caatctcta aattattaat ttattgggca tccacccggc acactggagt
 ccctgatcgc ttcacaggca gtggatctgg gacagatttc tctctcaccg ttagcaatgt
 gcagtctgag gacttaacag attatttctg tcagcaatat agcagctatc ctctcacgtt
 cgggtgctggg accaagctgg agctgaaacg aactgtggct gcaccatctg tcttcatctt
 cccgccatct gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa
 25 cttctatccc agagaggcca aagtacagtg gaaggtggat aacgcctcc aatcgggtaa
 ctcccaggag agtgtcacag agcaggacag caaggacagc acctacagcc tcagcagcac
 cctgacgctg agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca
 tcagggcctg agctcgcccg tcacaaagag cttcaacagg ggagagtgtt aataagcggc
 cgc (SEQ ID NO: 20)

Antibody 1565: light chain amino acid sequence

Leu Ala Asn Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Leu
 Ile Gly Ala Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Asp
 Thr Ala Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu
 35 Leu Ile Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe
 Thr Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr Val Ser Asn Val
 Gln Ser Glu Asp Leu Thr Asp Tyr Phe Cys Gln Gln Tyr Ser Ser Tyr
 Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 40 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg

Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 5 Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 21)

Antibody 4384: VH nucleotide sequence

cagggtgcagc tgcagcagcc tggcacagag ctggtgaaac ctggcgctc cgtgaagctg
 tcttgcaagg cctccggcta caccttcacc tccactgga tgcactgggt gaaacagcgg
 10 cctggacagg gcctggaatg gatcggcaac atcaaccct ccaacggcgg caccaactac
 aacgagaagt tcaagtcccg ggccaccctg accgtggaca aggcctctc caccgctac
 atgcagctgt cctccctgac ctccgaggac tccgccgtgt actactgccc cagagcctac
 tacgacttca gttggttcgt gtactggggc cagggcaccc tggtgacagt ctcg (SEQ ID NO: 22)

15 Antibody 4384: VH amino acid sequence

Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Lys Pro Gly Ala
 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser His
 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile
 Gly Asn Ile Asn Pro Ser Asn Gly Gly Thr Asn Tyr Asn Glu Lys Phe
 20 Lys Ser Arg Ala Thr Leu Thr Val Asp Lys Ala Ser Ser Thr Ala Tyr
 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 Ala Arg Ala Tyr Tyr Asp Phe Ser Trp Phe Val Tyr Trp Gly Gln Gly
 Thr Leu Val Thr Val Ser (SEQ ID NO: 23)

25 Antibody 4384: light chain nucleotide sequence

gatatccaga tgaccagac ctctccagc ctgtccgct cctgggcca cagagtgacc
 atctctgcc ggtctccca ggacatctc aactacctga actggtatca gcagaaaccc
 gacggcaccg tgaagctgct gatgtacatc tcccggtgc actccggcgt gccctccaga
 ttctccggct ctggctccgg caccgagtac tcctgacca tcagcaacct ggaacaggaa
 30 gatatcgcta cctactctg tcagcagggc aacaccctgc cctgacctt cggcgctggc
 accaagctgg aactgaagcg gaccgtggc gctccctccg tgttcatctt cccaccctcc
 gacgagcagc tgaagtccgg caccgctcc gtggtgtgcc tgctgaacaa cttctacccc
 cgcgaggcca aggtgcagtg gaaggtggac aacgccctgc agtccggcaa ctcccaggaa
 tccgtgaccg agcaggactc caaggacagc acctactccc tgtctccac cctgacctg
 35 tccaaggccg actacgagaa gcacaagggtg tacgctgcg aagtgacca ccagggcctg
 tccagccccg tgaccaagtc cttcaaccgg ggcgagtgc (SEQ ID NO: 24)

Antibody 4384: light chain amino acid sequence

Asp Ile Gln Met Thr Gln Thr Ser Ser Ser Leu Ser Ala Ser Leu Gly
 40 Asp Arg Val Thr Ile Ser Cys Arg Ser Ser Gln Asp Ile Ser Asn Tyr

Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Met
 Tyr Ile Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
 Gly Ser Gly Thr Glu Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln Glu
 Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Leu Thr
 5 Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Thr Val Ala Ala Pro
 Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly Thr
 Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys
 Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln Glu
 Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser
 10 Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala
 Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe
 Asn Arg Gly Glu Cys (SEQ ID NO: 25)

Antibody 4517: VH nucleotide sequence

15 gaagtgcagc tgggtggaatc tggcggcgac ctggtgaaac ctggcggctc cctgaagctg
 tctcgcccg cctccggctt caccttctcc agctacggca tgcctgggt gcgactgacc
 cccgacaagc ggctggaatg ggtggcaacc atctccggcg gaggtccta cacctactac
 cccgactccg tgaagggccg gttcaccatc tcccgggata tcgccaagtc caccctgtac
 ctgcagatgt cctccctgaa gtccgaggac accgccgtgt actactgcgc ccggaagggc
 20 aactacggca attacggcaa gctggcctac tggggccagg gcacctccgt gacagtctcg (SEQ ID NO: 26)

Antibody 4517: VH amino acid sequence

Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
 25 Gly Met Ser Trp Val Arg Leu Thr Pro Asp Lys Arg Leu Glu Trp Val
 Ala Thr Ile Ser Gly Gly Gly Ser Tyr Thr Tyr Tyr Pro Asp Ser Val
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Ile Ala Lys Ser Thr Leu Tyr
 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 Ala Arg Lys Gly Asn Tyr Gly Asn Tyr Gly Lys Leu Ala Tyr Trp Gly
 30 Gln Gly Thr Ser Val Thr Val Ser (SEQ ID NO: 27)

Antibody 4517: light chain nucleotide sequence

gatatccaga tgaccagtc ccccgccctc ctgtccgtgt ctgtgggcga gacagtgacc
 atcacctgtc gggcctccga gaacatctac tccaacctgg cctggatatca gcaggaacag
 35 ggcaagtccc ccagctgct ggtgtacgcc gccaccaatc tggccgacgg cgtgccctcc
 agattctccg gctctggctc cggcaccag tactccctga agatcaactc cctgcagtc
 gaggacttcg gctctacta ctgcagcac ttctggggca cccctggac ctcggcgga
 ggcaccaagc tggaaatcaa gcggaccgtg gccgctccct ccgtgttcat cttcccaccc
 tccgacgagc agctgaagtc cggcaccgcc tccgtggtgt gcctgctgaa caactctac
 40 ccccgcgagg ccaaggtgca gtggaaggtg gacaacgccc tgcagagcgg caactcccag

gaatccgtga ccgagcagga ctccaaggac agcacctact ccctgtcctc caccctgacc
ctgtccaagg ccgactacga gaagcacaag gtgtacgcct gcgaagtgac ccaccagggc
ctgtccagcc ccgtgaccaa gtccttcaac cggggcgagt gc (SEQ ID NO: 28)

5 Antibody 4517: light chain amino acid sequence

Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Val Ser Val Gly
Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Asn
Leu Ala Trp Tyr Gln Gln Glu Gln Gly Lys Ser Pro Gln Leu Leu Val
Tyr Ala Ala Thr Asn Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly
10 Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn Ser Leu Gln Ser
Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp Gly Thr Pro Trp
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
15 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
Phe Asn Arg Gly Glu Cys (SEQ ID NO: 29)

20

Antibody 5038: VH nucleotide sequence

cgcgccgagg tgaagctggg tgagtcagga cctggcctcg tgaaaccttc tcagtctctg
tctctcacct gctctgtcac tggctactcc atcaccagtg gtttttactg gacctggatc
cggcagtttc caggcaacaa attggaatgg atgggcttca taagctacga tggtagcaat
25 aactacaacc catctctcaa aaatcgaatc tccatcactc gtgacacatc taagaaccag
tttttctga agttgaattc tgtgactact gaggacacag ccacatatta ctgtgcaaga
ggcggaggct actatggtaa cctctttgac tactggggcc aaggcaccac tctcacagtc
tcga (SEQ ID NO: 30)

30 Antibody 5038: VH amino acid sequence

Arg Ala Glu Val Lys Leu Val Glu Ser Gly Pro Gly Leu Val Lys Pro
Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr
Ser Gly Phe Tyr Trp Thr Trp Ile Arg Gln Phe Pro Gly Asn Lys Leu
Glu Trp Met Gly Phe Ile Ser Tyr Asp Gly Ser Asn Asn Tyr Asn Pro
35 Ser Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
Phe Phe Leu Lys Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr
Tyr Cys Ala Arg Gly Gly Gly Tyr Tyr Gly Asn Leu Phe Asp Tyr Trp
Gly Gln Gly Thr Thr Leu Thr Val Ser (SEQ ID NO: 31)

40 Antibody 5038: light chain nucleotide sequence

ctagccgata ttgtgatgac tcaaactaca tcttcctgt cgcctctct gggagacaga
 gtcaccatca gttgcaggcc aagtcaggac attagcaatt atgtaaactg gtttcagcag
 aaaccagggtg gaactgttaa gtcctgatc ttccacacat caagattaca ctcaggagtc
 ccatcaaggt tcagtggcag tgggtctgga acagattatt ctctacccat tagcacccctg
 5 gaacaggaag atattgccat ttacttttgc caacagggtt ttacgcttcc gtggacgttc
 ggtggcggca ccaagctgga aataaaacga actgtggctg caccatctgt cttcatcttc
 ccgccatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac
 ttctatccca gagaggccaa agtacagtgg aagggtggata acgcccctca atcgggtaac
 tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc
 10 ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga agtcacccat
 cagggcctga gctcgcccggt cacaaagagc ttcaacaggg gagagtgtta ataagcggcc (SEQ ID NO: 32)

Antibody 5038: light chain amino acid sequence

Leu Ala Asp Ile Val Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser
 15 Leu Gly Asp Arg Val Thr Ile Ser Cys Arg Pro Ser Gln Asp Ile Ser
 Asn Tyr Val Asn Trp Phe Gln Gln Lys Pro Gly Gly Thr Val Lys Leu
 Leu Ile Phe His Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe
 Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Thr Leu
 Glu Gln Glu Asp Ile Ala Ile Tyr Phe Cys Gln Gln Gly Ile Thr Leu
 20 Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 25 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 33)

Antibody 5082: VH nucleotide sequence

cgcgccgagg tgcagctgaa ggagtcagga cctggcctcg tgaaaccttc tcagtctctg
 30 tctctcacct gctctgtcac cggctactcc atcaccagtg cttattactg gaactggatc
 cggcagtttc caggaaacaa agtggaatgg atgggctaca taggctacga tggctgtaat
 acctacaacc catctctcaa aaatcgaatc tccatcactc gtgacacatc taagaaccag
 tttttcctga aattgaattc tctgactact gaggacacag ccacatatta ttgttcaaga
 35 gaggggggact acggttactc tgactactgg ggccaaggca ccactctcac agtctcga (SEQ ID NO: 34)

Antibody 5082: VH amino acid sequence

Arg Ala Glu Val Gln Leu Lys Glu Ser Gly Pro Gly Leu Val Lys Pro
 Ser Gln Ser Leu Ser Leu Thr Cys Ser Val Thr Gly Tyr Ser Ile Thr
 40 Ser Ala Tyr Tyr Trp Asn Trp Ile Arg Gln Phe Pro Gly Asn Lys Val

Glu Trp Met Gly Tyr Ile Gly Tyr Asp Gly Arg Asn Thr Tyr Asn Pro
 Ser Leu Lys Asn Arg Ile Ser Ile Thr Arg Asp Thr Ser Lys Asn Gln
 Phe Phe Leu Lys Leu Asn Ser Leu Thr Thr Glu Asp Thr Ala Thr Tyr
 Tyr Cys Ser Arg Glu Gly Asp Tyr Gly Tyr Ser Asp Tyr Trp Gly Gln
 5 Gly Thr Thr Leu Thr Val Ser (SEQ ID NO: 35)

Antibody 5082: light chain nucleotide sequence

ctagccgata ttgtgatgac gcaagctaca tctcctctgt ctgcctctct gggagacaga
 gtcaccgtca gttgcagggc aagtcaggac attaacaatt atttaaattg gtatcagcag
 10 aagccagatg gaactgttaa actcctgata tactacacat caagattaca gtcaggagtc
 ccatcaaggt tcagtggcag tgggtctgga atagattatt ctctcacat tagcaacctg
 gagcaggaag atttgtcac ttacttttgc caacagagtg aaacgcttcc gtggacgttc
 ggtggaggca ccaagctgga gctgaaacga actgtggctg caccatctgt ctcatcttc
 ccgcatctg atgagcagtt gaaatctgga actgcctctg ttgtgtgcct gctgaataac
 15 ttctatocca gagaggccaa agtacagtgg aagggtggata acgcccctca atcgggtaac
 tcccaggaga gtgtcacaga gcaggacagc aaggacagca cctacagcct cagcagcacc
 ctgacgctga gcaaagcaga ctacgagaaa cacaaagtct acgcctgcga agtcacccat
 cagggcctga gctcgcccgt cacaaagagc ttcaacaggg gagagtgtta ataagcggcc (SEQ ID NO: 36)

20 Antibody 5082: light chain amino acid sequence

Leu Ala Asp Ile Val Met Thr Gln Ala Thr Ser Ser Leu Ser Ala Ser
 Leu Gly Asp Arg Val Thr Val Ser Cys Arg Ala Ser Gln Asp Ile Asn
 Asn Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu
 Leu Ile Tyr Tyr Thr Ser Arg Leu Gln Ser Gly Val Pro Ser Arg Phe
 25 Ser Gly Ser Gly Ser Gly Ile Asp Tyr Ser Leu Thr Ile Ser Asn Leu
 Glu Gln Glu Asp Phe Val Thr Tyr Phe Cys Gln Gln Ser Glu Thr Leu
 Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu Lys Arg Thr Val
 Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys
 Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg
 30 Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn
 Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser
 Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys
 Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr
 Lys Ser Phe Asn Arg Gly Glu Cys (SEQ ID NO: 37)

What is claimed is:

1. A recombinant antibody composition comprising at least one humanized anti-EGFR antibody or an antigen-binding fragment thereof, at least one humanized anti-HER2
5 antibody or an antigen-binding fragment thereof, and at least one humanized anti-HER3 antibody or an antigen-binding fragment thereof.

2. The antibody composition of claim 1, wherein:
the at least one humanized anti-EGFR antibody is selected from

10 (a) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:1 and the light chain variable region sequence of SEQ ID NO:3 or SEQ ID NO:2, and

(b) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:4 and the light chain variable region sequence of SEQ ID NO:5;

15 the at least one humanized anti-HER2 antibody is selected from

(c) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:6 and the light chain variable region sequence of SEQ ID NO:7, and

(d) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:8 and the light chain variable region sequence of SEQ ID NO:9; and

20 the at least one humanized anti-HER3 antibody is selected from

(e) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:10 and the light chain variable region sequence of SEQ ID NO:11, and

25 (f) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:12 and the light chain variable region sequence of SEQ ID NO:13.

3. The antibody composition of claim 2, comprising

(a) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:43 and the light chain variable region sequence of SEQ ID NO:44;

30 (b) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:47 and the light chain variable region sequence of SEQ ID NO:48;

(c) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:51 and the light chain variable region sequence of SEQ ID NO:52;

- (d) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:53 and the light chain variable region sequence of SEQ ID NO:54;
- (e) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:55 and the light chain variable region sequence of SEQ ID NO:56;
- 5 and
- (f) an antibody comprising the heavy chain variable region sequence of SEQ ID NO:61 and the light chain variable region sequence of SEQ ID NO:62.

4. The antibody composition of claim 2, comprising anti-EGFR antibodies (a) and
10 (b), anti-HER2 antibodies (c) and (d), and anti-HER3 antibodies (e) and (f).

5. The antibody composition of claim 2, comprising:

- (i) anti-EGFR antibody (a), anti-HER2 antibody (c), and anti-HER3 antibody (e);
- (ii) anti-EGFR antibody (a), anti-HER2 antibody (c), and anti-HER3 antibody (f);
- 15 (iii) anti-EGFR antibody (a), anti-HER2 antibody (d), and anti-HER3 antibody (e);
- (iv) anti-EGFR antibody (a), anti-HER2 antibody (d), and anti-HER3 antibody (f);
- (v) anti-EGFR antibody (b), anti-HER2 antibody (c), and anti-HER3 antibody (e);
- (vi) anti-EGFR antibody (b), anti-HER2 antibody (c), and anti-HER3 antibody (f);
- (vii) anti-EGFR antibody (b), anti-HER2 antibody (d), and anti-HER3 antibody (e);

20 or

- (viii) anti-EGFR antibody (b), anti-HER2 antibody (d), and anti-HER3 antibody (f).

6. The antibody composition of any of the preceding claims, wherein the anti-EGFR antibody (a) comprises:

- 25 (i) a heavy chain variable region sequence comprising SEQ ID NO:1 that has Arg44, Val83 and Ile104, and a light chain variable region sequence comprising SEQ ID NO:3 that has Leu34, Tyr41, Leu51 and Phe92;

- (ii) a heavy chain variable region sequence comprising SEQ ID NO:1 that has Arg44, Val83 and Ile104, and a light chain variable region sequence comprising SEQ ID NO:3 that
30 has Tyr41, Leu51 and Phe92; or

- (iii) a heavy chain variable region sequence comprising SEQ ID NO:1 that has Arg44 and Val83, and a light chain variable region sequence comprising SEQ ID NO:2 that has Ala19 and Phe92.

7. The antibody composition of any of the preceding claims, wherein the anti-EGFR antibody (b) comprises:

(i) a heavy chain variable region sequence comprising SEQ ID NO:4 that has
5 Leu20, Ile48 and Ala68, and a light chain variable region sequence comprising SEQ ID NO:5
that has Val75 and Phe87; or

(ii) a heavy chain variable region sequence comprising SEQ ID NO:4 that has
Leu20, Ile48, Leu56, and Ala68, and a light chain variable region sequence comprising SEQ
ID NO:5 that has Val75 and Phe87.

10 8. The antibody composition of any of the preceding claims, wherein the anti-HER2 antibody (c) comprises:

(i) a heavy chain variable region sequence comprising SEQ ID NO:6 that has
Ser55, Leu70, Val72, Lys74 and Ala79, and a light chain variable region sequence comprising
15 SEQ ID NO:7 that has Val44, Met48 and Tyr70; or

(ii) a heavy chain variable region sequence comprising SEQ ID NO:6 that has
Ser55 and Val72, and a light chain variable region sequence comprising SEQ ID NO:7 that
has Met48 and Tyr70.

20 9. The antibody composition of any of the preceding claims, wherein the anti-HER2 antibody (d) comprises a heavy chain variable region sequence comprising SEQ ID
NO:8 that has Ala49, Ile74 and Ser77, and a light chain variable region sequence comprising
SEQ ID NO:9 that has Thr56, Tyr71, Ser85 and Leu104.

25 10. The antibody composition of any of the preceding claims, wherein the anti-HER3 antibody (e) comprises a heavy chain variable region sequence comprising SEQ ID
NO:10 that has Met49, Ser55 and Ile68, or Asn44, Ser55 and Thr93, and a light chain variable
region sequence comprising SEQ ID NO:11 that has Phe36, Val44, Phe49 and Ile85, or has
Phe36, Phe49 and Leu73.

30 11. The antibody composition of any of the preceding claims, wherein the anti-HER3 antibody (f) comprises:

(i) a heavy chain variable region sequence comprising SEQ ID NO:12 that has Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence comprising SEQ ID NO:13 that has Val21, Thr29, Val44, and Phe87; or

(ii) a heavy chain variable region sequence comprising SEQ ID NO:12 that has Phe41, Val46, Met49, Ser55 and Arg72, and a light chain variable region sequence comprising SEQ ID NO:13 that has Val21, Val44, Tyr71, Phe87 and Leu104.

12. The antibody composition of claim 2, comprising three, four, five, or six antibodies.

13. The antibody composition of claim 2, comprising:

(a) anti-EGFR antibody 10292, 10460, or 11294;

(b) anti-EGFR antibody 10560 or 11302;

(c) anti-HER2 antibody 10704 or 11249;

(d) anti-HER2 antibody 11145;

(e) anti-HER3 antibody 10738 or 10810; and

(f) anti-HER3 antibody 11006 or 11052.

14. A pharmaceutical composition comprising a humanized recombinant antibody composition according to any of claims 1-13 and at least one pharmaceutically acceptable diluent, carrier or excipient.

15. The pharmaceutical composition comprising the antibody composition of claim 3 and at least one pharmaceutically acceptable diluent, carrier or excipient.

16. The pharmaceutical composition of claim 14 or 15, wherein at least one antibody in the composition is an immunoconjugate wherein the antibody is conjugated to an anti-cancer agent.

17. A humanized anti-EGFR antibody whose heavy and light chain amino acid sequences comprise:

SEQ ID NOs:43 and 44, respectively,

SEQ ID NOs:38 and 39, respectively,

SEQ ID NOs:41 and 42, respectively,
SEQ ID NOs:45 and 46, respectively, or
SEQ ID NOs:47 and 48, respectively,
or an antigen-binding fragment thereof.

5

18. A humanized anti-HER2 antibody whose heavy and light chain amino acid sequences comprise:

SEQ ID NOs:51 and 52, respectively,
SEQ ID NOs:49 and 50, respectively, or
10 SEQ ID NOs:53 and 54, respectively,

or an antigen-binding fragment thereof.

19. A humanized anti-HER3 antibody whose heavy and light chain amino acid sequences comprise:

15 SEQ ID NOs:55 and 56, respectively,
SEQ ID NOs:57 and 58, respectively,
SEQ ID NOs:59 and 60, respectively, or
SEQ ID NOs:61 and 62, respectively,

or an antigen-binding fragment thereof.

20

20. A nucleic acid molecule comprising a nucleotide sequence that encodes the heavy chain, or the light chain, or both, of an antibody or antigen-binding fragment of any of claims 17-19.

25 21. An expression vector comprising a nucleic acid molecule according to claim 20.

22. A host cell comprising a nucleic acid molecule according to claim 21 or an expression vector according to claim 21, wherein said host cell is capable of expressing the
30 antibody or antigen-binding fragment encoded by said nucleic acid molecule.

23. A method for producing an antibody, comprising providing a host cell according to claim 22, cultivating said host cell under conditions suitable for expression of the antibody, and isolating the resulting antibody.

5 24. A method for producing a recombinant antibody composition comprising at least one humanized recombinant anti-EGFR antibody, at least one humanized recombinant anti-HER2 antibody and at least one humanized recombinant anti-HER3 antibody, the method comprising:

10 providing at least first, second and third host cells, wherein the first host cell is capable of expressing a recombinant anti-EGFR antibody as defined in claim 17, the second host cell is capable of expressing a recombinant anti-HER2 antibody as defined in claim 18, and the third host cell is capable of expressing a recombinant anti-HER3 antibody as defined in claim 18,

15 cultivating the first, second and third host cells under conditions suitable for expression of the anti-EGFR antibody, the anti-HER2 antibody and the anti-HER3 antibody, and isolating the resulting antibodies.

25 25. A method for treating cancer in a patient, the method comprising administering to said patient a recombinant antibody composition according to any of claims 1-13 or a pharmaceutical composition according to claim 14 or 15.

26. A method for treating a patient with a disorder characterized by expression or overexpression of EGFR, HER2 and/or HER3, the method comprising administering to said patient a recombinant antibody composition according to any of claims 1-13 or a pharmaceutical composition according to claim 14 or 15.

27. A method for treating cancer in a patient having acquired resistance to treatment with an antibody and/or a tyrosine kinase inhibitor, the method comprising administering to said patient an effective amount of a recombinant antibody composition according to any of claims 1-13 or a pharmaceutical composition according to claim 14 or 15.

28. A method for inhibiting cancer growth in a patient, the method comprising administering to said patient a recombinant antibody composition according to any of claims 1-13 or a pharmaceutical composition according to claim 14 or 15.

5 29. A method for reducing EGFR, HER2, or HER3 expression, or preventing EGFR, HER2, or HER3 up-regulation in a cancer patient, comprising administering to the patient a recombinant antibody composition according to any of claims 1-13 or a pharmaceutical composition according to claim 14 or 15.

10 30. The method of any one of claims 25-29, wherein the patient has pancreatic, bone, colon, endometrial, or urinary tract cancer.

31. The method of claim 30, wherein the patient has pancreatic cancer and a KRAS mutation.

15 32. The method of any one of claims 25-31, wherein at least one of the antibodies is conjugated to an anti-cancer agent.

20 33. The method of claim 32, wherein the anti-cancer agent is a cytotoxic agent, a cytokine, a toxin, or a radionuclide.

34. The method of any one of claims 25-33, wherein the patient has not been treated for cancer previously.

25 35. The method of any one of claims 25-33, wherein the patient has been treated for cancer previously.

36. The method of claim 35, wherein the patient has been treated with cetuximab, trastuzumab, or pertuzumab previously.

30 37. The method of claim 36, wherein cancer in the patient has acquired resistance to cetuximab, trastuzumab, or pertuzumab.

Figure 1

		20		40	
			CDR1		
1277_CDRgrafted-H	EVQLVESGGGLVQPGGSLRLSCAASGFAFSYSDMSWVRQAPGKGL				45
10292					R. 45
10460 & 11294					R. 45
		60		80	
			CDR2		
1277_CDRgrafted-H	EWVSYMSSAGDVTFYSDTVKGRFTISRDNAKNSLYLQMNSLRAED				90
10292				V.....	90
10460 & 11294				V.....	90
		100			
			CDR3		
1277_CDRgrafted-H	TAVYYCVRHRDVAMDYWGQGTTVTVSS				117
10292					117
10460 & 11294					117

		20		40	
			CDR1		
1277_CDRgrafted-L	DIQMTQSPSSLSASVGDRVTITCRSSQSLVHSNGNTYLHWYQQKP				45
10292				A.....	45
		60		80	
			CDR2		
1277_CDRgrafted-L	GKAPKLLIYKVSNRFSGVPSRFSGSGSGTDFTLTISSLOPEDFAT				90
10292					90
		100			
			CDR3		
1277_CDRgrafted-L	YYCSQSTHVPTFGGGTKVEIK				111
10292	.F.....				111

		20		40	
			CDR1		
1277A_CDRgrafted-L	DVVMTQSPLSLPVTLGQPASISCRSSQSLVHSNGNTYLHWFOQRP				45
10460				Y.....	45
11294				L.....Y.....	45
		60		80	
			CDR2		
1277A_CDRgrafted-L	GQSPRRLIYKVSNRFSGVPSRFSGSGSGTDFTLKISRVEAEDVGV				90
10460	L.....				90
11294	L.....				90
		100			
			CDR3		
1277A_CDRgrafted-L	YYCSQSTHVPTFGGGTKVEIK				111
10460	.F.....L....				111
11294	.F.....				111

Figure 2

		20		40	
			CDR1		
1565_CDRgrafted-H	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYWMQWVRQAPGQGL				45
10560	L.....				45
11302	L.....				45
		60		80	
			CDR2		
1565_CDRgrafted-H	EWMGNINPSNGGTSFNEEFKSRVTMTRDTSTSTVYMELSSLRSED				90
10560	..I.....A.....				90
11302	..I.....L.....A.....				90
		100		120	
			CDR3		
1565_CDRgrafted-H	TAVYYCARDGGLYDGYFDFWGQGTLLVTVSS				121
10560					121
11302					121

		20		40	
			CDR1		
1565_CDRgrafted-L	AIQLTQSPSSLSASVGDRVITCKASQDVDTAVAWYQOKPGKAPK				45
10560 & 11302					45
		60		80	
			CDR2		
1565_CDRgrafted-L	LLIYWASTRHTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQ			CDR3	90
10560 & 11302	V.....F.....				90
		100			
			CDR3		
1565_CDRgrafted-L	YSSYPLTFGGGTKVEIK				107
10560 & 11302					107

Figure 3

		20 	CDR1	40 	
4384_CDRgrafted-H	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSHWMHWVRQAPGQGL				45
10704					45
11249					45
		60 	CDR2	80 	
4384_CDRgrafted-H	EWNGNINPSNGGTNYNEKFKSRVTMTRDTSTSTVYMELSSLRSED				90
10704	S.....L.V.K.....A.....				90
11249	S.....V.....				90
		100 	CDR3		
4384_CDRgrafted-H	TAVYYCARAYYDFSWFVYWGQGTLVTVSS				119
10704					119
11249					119

		20 	CDR1	40 	
4384_CDRgrafted-L	DIQMTQSPSSLSASVGDRVTITCRSSQDISNYLNWYQQKPGKAPK				45
10704	V.				45
11249					45
		60 	CDR2	80 	CDR3
4384_CDRgrafted-L	LLIYISRLHSGVPSRFSGSGSGTDFTFTISSLPEDIATYYCQQG				90
10704	..M.....Y.....				90
11249	..M.....Y.....				90
		100 	CDR3		
4384_CDRgrafted-L	NTLPLTFGGGTKVEIK				106
10704					106
11249					106

Figure 4

		20		40	
			CDR1		
4517_CDRgrafted-H	EVQLVESGGGLVKPGGSLRLSCAASGFTFS				45
11145					45
		60		80	
			CDR2		
4517_CDRgrafted-H	EWVSTISGGGSYTYYPDSVKGRFTISRDN				90
11145	...A.....I...S.....				90
		100		120	
			CDR3		
4517_CDRgrafted-H	TAVYYCARKGNYGKLAYWGQGTTVT				121
11145					121

		20		40	
			CDR1		
4517_CDRgrafted-L	DIQMTQSPSSLSASVGDRVTITCRASENIYS				45
11145					45
		60		80	
			CDR2		
4517_CDRgrafted-L	LLIYAATNLADGVPSRFSGSGSGTDFTLTIS				90
11145	T.....Y.....S.....				90
		100			
			CDR3		
4517_CDRgrafted-L	FWGTPWTFGQGTKVEIK				107
11145	L....				107

Figure 5

		20		40	
			CDR1		
5038_CDRgrafted-H	QVQLQESGPGLVKPSQTL	SLTCTVSGYSITSGFY	WTWIRQHPGKG	45	
10738				45	
10810				N	45
		60		80	
			CDR2		
5038_CDRgrafted-H	LEWIGFISYDGSNNYNPSL	KNRVTISVDTSKNQFSLKL	SSVTAAD	90	
10738	...M...S.....I.....			90	
10810	S.....			90	
		100		120	
			CDR3		
5038_CDRgrafted-H	TAVYYCARGGGYYGNLFDY	WGQGT	LVTVSS	120	
10738				120	
10810	...T.....			120	

		20		40	
			CDR1		
5038_CDRgrafted-L	DIQMTQSPSSLSASVGDRV	ITCRPSQDISNYVNWYQQK	PGKAPK	45	
10738			F.....V	45	
10810			F.....	45	
		60		80	
			CDR2		
5038_CDRgrafted-L	LLIYHISRLHSGVPSRFS	SGSGSGTDFTFTISSLPED	IATYYCQQ	90	
10738	...F.....I.....			90	
10810	...F.....L.....			90	
		100			
			CDR3		
5038_CDRgrafted-L	GITLPWTFGQGTKVEIK	107			
10738		107			
10810		107			

Figure 6

		20		40	
			CDR1		
5082_CDRgrafted-H	QVQLQESGPGLVKPSQTL	SLTCTVSGYS	ITSAYYWNWIRQHPGKG		45
11006					45
11052				F	45
		60		80	
			CDR2		
5082_CDRgrafted-H	LEWIGY	IGYDGRNTYNPSLKNRVT	ISVDTSKNQFSLKLSSVTAAD		90
11006	V..M.....S.....R.....				90
11052	V..M.....S.....R.....				90
		100			
			CDR3		
5082_CDRgrafted-H	TAVYYCS	REGDYGYS	DYWGQGT	LVTVSS	118
11006					118
11052					118

		20		40	
			CDR1		
5082_CDRgrafted-L	DIQMTQSPSSLSASVGDRVT	ITCRASQD	INNYLNWYQQKPGKAPK		45
11006	V.....T.....V.....				45
11052	V.....V.....V.....				45
		60		80	
			CDR2		
5082_CDRgrafted-L	LLIYYT	SR	LQSGVPSRFS	SGSGSGTDFTLT	ISSLPEDFATYYCQQ
11006					F
11052				Y	F
		100			
			CDR3		
5082_CDRgrafted-L	SETLPWTF	GQGT	KVEIK		107
11006					107
11052	L.....				107

Figure 7







Figure 8

Figure 9





Figure 10







Figure 11

Figure 12







Figure 13

Figure 14





Figure 15





Figure 16

Ab ID	Source library (specificity)	ELISA reactivity											
		hu EGFR	cy EGFR	mu EGFR	hu HER2	cy HER2	mu HER2	hu HER3	cy HER3	mu HER3	hu HER4	mu HER4	
1277	chimeric (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
10292	1277 (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
10460	1277A (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
11294	1277A (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
1565	chimeric (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
10560	1565 (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
11302	1565 (EGFR)	+++	+++	-	-	-	-	-	-	-	-	-	
4384	chimeric (HER2)	-	-	-	+++	+++	-	-	-	-	-	-	
10704	4384 (HER2)	-	-	-	+++	+++	-	-	-	-	-	-	
4517	chimeric (HER2)	-	-	-	+++	+++	-	-	-	-	-	-	
11145	4517 (HER2)	-	-	-	+++	+++	-	-	-	-	-	-	
5038	chimeric (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
10738	5038 (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
10810	5038 (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
5082	chimeric (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
11006	5082 (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
11052	5082 (HER3)	-	-	-	-	-	-	+++	+++	-	-	-	
Neg	Isotype control	-	-	-	-	-	-	-	-	-	-	-	

Figure 17







Figure 18



Figure 19




Figure 20

Figure 21

A



B



C




Figure 22




Figure 23

	Origin	Subtype	Cell line	Pan-HER	EGFR+HER2	EGFR+HER3	HER2+HER3	EGFR	HER2	HER3	Cetuximab	Trastuzumab	MM-121	Negative control
1	Breast	Ductal Carcinoma	MDA-MB-175-VII	10	50	25	25	90	65	35	90	65	30	100
2	Head and Neck	HNSCC	HN5	10	10	10	100	12	100	100	10	100	95	105
3	Lung	Adenocarcinoma	HCC827	11	17	14	87	22	100	100	9	100	95	94
4	Gastric	Carcinoma	N87 (NCI-N87)	14	14	78	21	88	21	81	83	41	88	100
5	Skin	Epidermoid carcinoma	A431NS	16	29	23	66	49	87	100	98	100	74	100
6	Head and Neck	Pharyngeal Squamous cell carcinoma	FaDu	16	16	15	83	28	90	80	30	93	79	104
7	Gastric	Adenocarcinoma	OE19	20	20	80	20	85	25	100	100	45	85	100
8	Breast	Ductal Carcinoma	MDA-MB-175-VII	20	75	35	45	90	75	55	90	70	50	105
9	Skin	Epidermoid carcinoma	A431-NS	20	30	25	80	75	100	80	90	90	85	110
10	Colon	Rectal adenocarcinoma	SW948	25	28	25	54	21	49	53	23	44	56	71
11	Ovary	Adenocarcinoma	RMG-1	25	20	15	30	25	75	95	20	30	70	75
12	Breast	Carcinoma	BT474	25	25	80	30	110	30	75	100	30	85	120
13	Oesophagus	Squamous cell carcinoma	TE11	28	25	26	76	62	74	85	71	100	81	100
14	Colon		GE0	28	29	25	72	20	81	105	27	87	97	90
15	Lung	Adenocarcinoma	H358 (NCI-H358)	31	42	33	64	51	87	90	55	75	84	94
16	Lung	Adenocarcinoma	CALU-3	35	35	45	100	55	80	100	55	87	90	100
17	Gastric	Adenocarcinoma	OE19	35	40	85	40	85	40	100	85	55	90	90
18	Lung	MuocoeipidermoidCarcinoma	H292 (NCI-H292)	36	37	38	96	38	95	95	39	81	90	98
19	Breast	Ductal Carcinoma	HCC202	39	46	82	57	96	66	88	83	63	90	90
20	Colon	Adenocarcinoma	LS-174T	43	24	24	72	21	68	77	28	63	79	67
21	Breast	Ductal Carcinoma	ZR-75-30	44	55	80	70	85	50	75	85	40	70	95
22	Lung	Adenocarcinoma	H1975 (NCI-H1975)	46	44	50	100	70	100	84	79	84	83	100
23	Oesophagus	Squamous cell carcinoma	KYSE520	48	51	47	71	62	100	100	59	100	100	100
24	Breast	Adenocarcinoma	AU565	52	68	80	81	83	79	100	100	60	80	100
25	Ovary	Adenocarcinoma	IGR-OV1	55	30	40	80	45	80	90	45	55	110	80
26	Breast	Adenocarcinoma	AU-565	55	55	75	55	90	55	80	100	75	95	100
27	Pancreas	Adenocarcinoma	CAPAN-1	55	50	55	100	65	90	90	65	60	65	100
28	Oesophagus	Adenocarcinoma (lower third)	OE33	56	90	91	97	70	100	96	81	100	100	100
29	Pancreas	Carcinoma	PK-1	56	75	57	83	88	93	79	83	83	80	99
30	Pancreas	Adenocarcinoma, ductal	CFFAC-1	60	60	55	95	75	95	90	75	95	90	100
31	Pancreas	Carcinoma	BxPC3	65	72	55	44	100	75	66	100	94	63	100
32	Colon	Rectal adenocarcinoma	SW1463	65	45	90	110	65	100	100	65	115	115	120
33	Skin	Epidermoid carcinoma	A-431	65	55	55	90	85	100	85	90	100	85	100
34	Colon	Carcinoma	COLO678	65	61	54	100	53	96	96	62	84	93	100
35	Lung	Adenocarcinoma	H820 (NCI-H820)	65	63	60	77	89	76	66	100	90	82	100
36	Oesophagus	Squamous cell carcinoma	COLO680N	66	59	65	88	70	99	100	73	94	100	100
37	Pancreas	Adenocarcinoma	ASPC1	67	49	55	93	65	100	75	78	100	76	100
38	Breast	Carcinoma	HCC1937	68	61	63	88	84	89	86	78	85	87	94
39	Colon	Colorectal adenocarcinoma	SW403	70	50	55	100	80	80	95	65	80	80	115
40	Ovary	Adenocarcinoma	OVCAR-3	70	75	85	90	80	90	90	75	80	85	100
41	Ovary	Adenocarcinoma	OVCAR-5	70	80	70	95	70	95	85	75	80	95	100
42	Lung	Large cell carcinoma	H661 (NCI-H661)	70	60	100	80	105	85	80	100	85	85	110
43	Breast	Adenocarcinoma	SK-BR-3	70	77	70	80	100	80	80	90	73	80	105
44	Endometrium	Adenocarcinoma	MFE-280	70	70	85	70	105	70	70	100	70	65	100
45	Ovary	Adenocarcinoma	OVCAR-8	71	84	69	103	100	100	75	77	86	75	97
46	Endometrium	Carcinoma	RL95-2	72	64	72	72	92	93	89	76	100	91	97
47	Colon	Rectal adenocarcinoma	SW937	75	85	80	115	75	100	105	80	95	105	115
48	Colon	Colorectal carcinoma	T84	75	70	55	90	65	100	100	85	100	100	100
49	Ovary	Cystadenocarcinoma	RMUG-S	75	75	65	100	75	100	100	85	90	100	120
50	Lung	Adenocarcinoma	A549	75	70	63	88	81	75	65	78	99	52	100
51	Pancreas	Carcinoma	CAPAN-2	76	73	75	99	84	100	100	76	94	100	99
52	Colon	Adenocarcinoma	GF5d	80	100	66	105	70	97	100	61	85	110	109
53	Colon	Adenocarcinoma	CaCO2	80	70	70	100	75	95	95	75	90	85	95
54	Breast	Carcinoma	BT20	81	69	64	97	72	100	100	60	101	95	99
55	Breast	Adenocarcinoma	MDA-MB-468	81	80	77	86	85	103	113	80	96	95	94
56	Prostate	Carcinoma	DU145	82	83	75	102	82	103	106	92	100	99	110
57	Lung	Squamous cell carcinoma, Mesothelioma	H226 (NCI-H226)	85	100	95	100	95	100	100	95	100	95	100
58	Pancreas	Adenocarcinoma	Panc08.13	85	90	100	110	95	110	110	85	100	95	100
59	Urinary tract	Carcinoma	RT-112	85	85	85	100	85	90	100	80	85	100	100
60	Lung	Adenocarcinoma	A549	85	100	95	100	115	105	105	80	85	90	105
61	Lung	Squamous cell carcinoma	EBC1	85	100	95	105	100	100	95	70	75	75	95
62	Bone	Osteosarcoma	U2-OS	85	90	90	90	95	95	95	80	85	105	95
63	Endometrium	Endometrial Adenocarcinoma	HEC-108	85	100	100	105	100	100	105	85	90	95	110
64	Breast	Adenocarcinoma	CAL-120	85	95	95	100	90	90	90	90	90	100	100
65	Colon	Adenocarcinoma	LoVo	85	80	80	100	90	100	90	80	85	90	100
66	Lung	Adenocarcinoma	H1993 (NCI-H1993)	85	100	105	110	105	95	95	90	95	90	95
67	Colon	Colorectal adenocarcinoma	DLD-1	87	98	94	100	100	96	100	100	97	100	96
68	Ovary	Adenocarcinoma	SKOV3	87	87	83	83	100	100	100	100	95	113	115
69	Urinary tract	Carcinoma	RT-4	90	75	80	85	90	90	90	70	85	95	100
70	Gastric	Adenocarcinoma	MKN-45	90	100	90	85	90	100	90	90	95	95	90
71	Pancreas	Ductal carcinoma	PANC-1	90	90	85	95	90	85	85	90	95	100	100
72	Gastric	Carcinoma	SNU-16	90	100	90	90	90	90	90	80	75	95	100
73	Gastric	Gastric carcinoma	KATOIII	90	100	85	90	100	100	85	105	110	80	110
74	Breast	Ductal carcinoma	MDA-MB-134-VI	90	75	90	100	99	90	87	80	91	99	102
75	Lung	Large cell carcinoma	H460 (NCI-H460)	90	90	80	75	90	90	85	90	95	105	85
76	Breast	Adenocarcinoma	MCF7	95	90	90	100	104	90	95	90	95	100	95
77	Skin	Melanoma	A2058	95	90	100	100	100	95	90	95	90	90	90
78	Colon	Adenocarcinoma	SW480	95	105	113	99	105	100	99	105	121	115	100
79	Colon	Colorectal carcinoma	LS1034	96	83	94	85	94	96	83	96	100	99	87

Figure 24

	Origin	Subtype	Cell line	Pan-HER	EGFR+HER2	EGFR+HER3	HER2+HER3	EGFR	HER2	HER3	Cetuximab	Trastuzumab	MM-121	Negative control
1	Breast	Ductal Carcinoma	MDA-MB-175-VH	13	75	25	30	120	60	50	120	100	50	150
2	Lung	Adenocarcinoma	HCC827	15	43	19	75	75	100	79	31	89	79	90
3	Head and Neck	HNSCC	HN5	15	15	25	100	65	125	115	100	165	120	95
4	Head and Neck	Pharyngeal Squamous cell carcinoma	FaDu	18	20	23	85	110	120	100	96	90	85	100
5	Breast	Carcinoma	HCC1937	20	51	36	75	75	100	95	95	100	97	106
6	Skin	Epidermoid carcinoma	A431-NS	20	60	35	75	75	100	80	90	100	80	115
7	Oesophagus	Squamous cell carcinoma	TE11	20	51	38	70	75	100	95	95	100	97	106
8	Breast	Ductal Carcinoma	MDA-MB-175-VH	25	95	60	50	125	95	75	115	120	85	140
9	Ovary	Adenocarcinoma	RMG-1	25	100	30	40	130	150	140	135	105	105	180
10	Colon		GEO	29	80	40	120	130	125	120	130	125	125	150
11	Lung	Adenocarcinoma	H358 (NCI-H358)	30	58	37	96	100	76	67	85	73	65	90
12	Gastric	Carcinoma	N87 (NCI-N87)	30	130	110	25	210	125	95	180	125	100	250
13	Lung	Mucopidermoid Carcinoma	H292 (NCI-H292)	32	64	59	94	89	119	116	131	139	118	150
14	Oesophagus	Squamous cell carcinoma	KYSE520	34	41	41	81	47	100	80	90	85	89	108
15	Colon	Adenocarcinoma	LS-174T	40	41	49	95	50	113	111	126	122	112	144
16	Gastric	Adenocarcinoma	OE19	40	130	115	50	160	130	105	150	140	80	150
17	Lung	Adenocarcinoma	CALU-3	45	120	50	85	150	160	160	125	155	75	200
18	Colon	Carcinoma	COLO678	48	74	60	80	106	120	115	130	130	93	125
19	Gastric	Adenocarcinoma	OE19	50	80	130	50	160	140	115	105	120	120	170
20	Lung	Adenocarcinoma	H820 (NCI-H820)	51	72	60	66	117	109	61	107	108	71	140
21	Breast	Carcinoma	BT474	55	130	110	50	150	130	110	130	140	115	170
22	Pancreas	Adenocarcinoma	CAPAN-1	55	110	70	100	160	110	90	150	150	95	210
23	Pancreas	Carcinoma	PK-1	57	85	62	82	97	105	87	100	100	80	105
24	Pancreas	Adenocarcinoma	ASPC1	58	70	64	105	200	179	90	205	160	95	240
25	Endometrium	Carcinoma	RL95-2	60	75	85	100	83	120	100	80	120	120	100
26	Pancreas	Carcinoma	BxPC3	60	55	65	70	120	68	60	125	100	60	120
27	Oesophagus	Squamous cell carcinoma	COLO680N	60	55	70	95	110	115	115	120	120	100	140
28	Pancreas	Carcinoma	CAPAN-2	62	70	75	94	75	75	81	77	68	70	100
29	Skin	Epidermoid carcinoma	A-431	65	80	70	100	133	110	160	110	95	85	100
30	Endometrium	Adenocarcinoma	MFE-280	65	65	65	70	110	100	65	95	75	55	100
31	Breast	Ductal Carcinoma	HCC202	70	110	110	90	91	105	112	121	120	115	97
32	Colon	Adenocarcinoma	CaCO2	70	100	75	90	100	100	85	100	100	90	120
33	Ovary	Cystadenocarcinoma	RMLG-S	70	100	95	90	105	110	105	115	110	110	140
34	Colon	Colorectal carcinoma	T84	75	65	60	75	100	95	80	100	100	95	100
35	Ovary	Adenocarcinoma	OVCAR-8	75	105	97	97	104	100	95	100	107	88	101
36	Pancreas	Adenocarcinoma	Panc02.13	75	80	80	90	110	115	105	110	115	95	120
37	Pancreas	Adenocarcinoma, ductal	CFPAC-1	75	95	80	100	175	120	110	160	145	90	170
38	Colon	Rectal adenocarcinoma	SW1463	75	95	80	120	150	120	100	145	125	110	175
39	Breast	Adenocarcinoma	MDA-MB-468	79	87	71	92	82	138	118	85	146	106	134
40	Endometrium	Endometrial Adenocarcinoma	HEC-108	80	105	110	220	90	100	110	90	65	95	100
41	Breast	Adenocarcinoma	CAL-120	80	80	80	95	85	85	80	85	70	75	100
42	Ovary	Adenocarcinoma	IGR-OV1	80	120	140	150	60	85	125	120	120	130	105
43	Colon	Rectal adenocarcinoma	SW837	80	125	105	120	150	120	130	145	130	125	165
44	Urinary tract	Carcinoma	RT-4	80	110	80	100	200	100	100	135	135	105	180
45	Oesophagus	Adenocarcinoma (lower third)	OE33	80	105	87	86	122	110	87	120	130	94	140
46	Ovary	Adenocarcinoma	SKOV3	82	69	81	117	87	99	116	110	106	117	112
47	Pancreas	Ductal carcinoma	PANC-1	85	70	70	100	100	80	80	75	85	70	95
48	Colon	Adenocarcinoma	LoVo	86	100	100	110	110	110	105	105	100	100	115
49	Colon	Colorectal adenocarcinoma	SW403	85	140	90	100	280	190	120	260	185	160	280
50	Prostate	Carcinoma	DU145	86	107	96	103	117	100	100	110	98	100	98
51	Lung	Adenocarcinoma	H1437 (NCI-H1437)	88	85	102	95	101	100	90	113	115	95	110
52	Lung	Squamous cell carcinoma, Mesothelioma	H226 (NCI-H226)	90	105	100	90	100	100	100	100	105	100	110
53	Gastric	Gastric carcinoma	KATOIII	90	115	95	90	115	100	95	110	110	100	110
54	Bone	Osteosarcoma	U2-OS	90	100	90	100	100	100	100	100	100	105	120
55	Ovary	Adenocarcinoma	OVCAR-3	90	130	130	110	115	140	145	120	145	135	130
56	Urinary tract	Carcinoma	RT-112	90	120	95	100	150	130	100	140	120	110	140
57	Breast	Ductal Carcinoma	ZR-75-30	90	120	130	120	120	125	120	115	160	130	150
58	Colon	Colorectal carcinoma	LS1034	90	111	85	72	140	109	90	170	151	99	155
59	Breast	Adenocarcinoma	MCF7	90	200	170	120	220	165	130	220	205	135	220
60	Lung	Squamous cell carcinoma	H520 (NCI-H520)	94	95	100	105	95	95	100	103	84	107	105
61	Skin	Melanoma	A2058	95	95	95	95	90	100	95	95	100	100	85
62	Gastric	Carcinoma	SNU-5	95	80	90	95	100	90	90	95	95	100	100
63	Ovary	Epithelial serous carcinoma, pleural effusion	COV504	95	100	100	105	110	105	160	95	110	110	110
64	Lung	Squamous cell carcinoma	EBC1	95	110	110	120	110	105	105	80	100	95	120
65	Lung	Adenocarcinoma	A549	95	100	100	115	115	105	110	85	80	105	135
66	Breast	Adenocarcinoma	AU-565	95	160	130	105	150	150	125	130	130	135	145
67	Ovary	Adenocarcinoma	OVCAR-5	95	105	95	115	140	140	130	120	130	120	155
68	Brain	Glioblastoma	SKMG3	96	92	86	73	100	96	95	96	93	87	88
69	Breast	Adenocarcinoma	SK-BR-3	98	130	130	105	120	114	108	120	125	115	130
70	Colon	Adenocarcinoma	GP5d	100	120	90	112	150	125	120	150	156	122	171
71	Breast	Ductal carcinoma	MDA-MB-134-VI	105	112	112	100	143	100	106	140	120	88	152
72	Prostate	Carcinoma	LncAP FGC	105	105	110	120	180	150	160	190	155	85	200
73	Urinary tract	Urinary bladder transitional carcinoma	BFTC-905	110	150	100	95	200	180	110	180	175	100	160
74	Breast	Carcinoma	CAL-51	119	142	160	143	159	149	156	150	146	153	155
75	Colon	Adenocarcinoma	SW620	124	123	120	115	140	120	120	150	148	132	152
76	Ovary	Adenocarcinoma	OVCAR-4	135	200	220	220	250	250	280	260	220	175	300

Figure 25

	Origin	Subtype	Cell line	Pan-HER	EGFR+HER2	EGFR+HER3	HER2+HER3	EGFR	HER2	HER3	Cetuximab	Trastuzumab	MM-121	Negative control
1	Breast	Ductal Carcinoma	MDA-MB175-VII	10	50	20	40	85	70	55	90	75	50	115
2	Colon	Adenocarcinoma	LS-174T	13	23	18	114	20	118	95	51	108	120	135
3	Gastric	Carcinoma	N87 (NCI-N87)	15	15	90	215	95	230	240	115	195	200	270
4	Head and Neck	Pharyngeal Squamous cell carcinoma	FaDu	17	20	17	100	31	98	89	77	83	85	94
5	Breast	Ductal Carcinoma	MDA-MB175-VII	20	65	35	65	90	80	80	90	80	65	105
6	Gastric	Adenocarcinoma	OE19	25	20	85	70	80	60	130	90	85	100	130
7	Ovary	Adenocarcinoma	RMG-I	25	25	25	170	25	180	190	90	185	175	170
8	Lung	Adenocarcinoma	H358 (NCI-H358)	27	30	29	66	36	69	81	80	95	92	97
9	Colon		GEO	27	35	30	144	23	133	113	100	139	137	136
10	Breast	Carcinoma	BT474	30	30	80	25	120	35	75	100	35	70	105
11	Gastric	Adenocarcinoma	OE19	35	40	90	90	90	90	110	105	95	105	120
12	Lung	Adenocarcinoma	CALU-3	35	40	45	170	55	140	140	65	140	140	165
13	Lung	MucoepidermoidCarcinoma	H292 (NCI-H292)	39	36	34	142	38	137	129	107	133	136	139
14	Pancreas	Adenocarcinoma	ASPC1	39	42	39	153	49	148	143	73	148	142	163
15	Colon	Rectal adenocarcinoma	SW948	44	35	44	210	26	83	111	103	200	175	300
16	Breast	Carcinoma	HCC1937	45	56	58	96	78	94	97	98	87	95	103
17	Breast	Ductal Carcinoma	HCC202	49	58	81	98	88	113	117	87	112	113	126
18	Lung	Adenocarcinoma	H820 (NCI-H820)	53	48	58	90	74	48	76	76	108	102	114
19	Colon	Rectal adenocarcinoma	SW1463	55	60	70	150	65	145	130	75	115	130	155
20	Esophagus	Adenocarcinoma (lower third)	OE33	57	81	72	105	53	75	108	72	93	100	98
21	Pancreas	Carcinoma	BxPC3	58	65	57	93	100	95	91	100	105	103	100
22	Endometrium	Adenocarcinoma	MFE-2B0	60	65	60	70	95	75	65	95	75	60	95
23	Pancreas	Adenocarcinoma	CAPAN-1	60	50	50	130	55	135	130	80	140	140	140
24	Esophagus	Squamous cell carcinoma	COLO680N	61	49	61	151	58	149	155	128	164	138	150
25	Prostate	Carcinoma	DU145	65	71	69	100	66	97	90	94	100	100	100
26	Colon	Adenocarcinoma	CaCO2	65	65	65	110	60	90	100	75	105	105	120
27	Pancreas	Carcinoma	PK-1	67	76	66	80	88	70	70	87	88	71	94
28	Colon	Carcinoma	COLO678	68	67	59	126	48	129	115	115	117	102	107
29	Endometrium	Carcinoma	RL95-2	68	69	78	125	87	166	158	118	150	129	130
30	Breast	Adenocarcinoma	SK-BR-3	73	81	89	87	90	90	88	75	95	100	96
31	Pancreas	Carcinoma	CAPAN-2	75	69	74	93	71	91	76	62	85	86	99
32	Gastric	Gastric carcinoma	KATOIII	75	85	80	90	100	100	80	95	100	85	100
33	Ovary	Cystadenocarcinoma	RMUG-S	75	70	65	100	85	100	100	100	105	100	115
34	Pancreas	Adenocarcinoma	Panc08.13	75	90	95	130	90	130	130	80	140	120	125
35	Ovary	Adenocarcinoma	OVCAR-3	75	75	95	125	90	135	135	115	125	130	135
36	Ovary	Adenocarcinoma	IGR-OV1	75	50	75	130	65	150	150	80	190	180	150
37	Pancreas	Adenocarcinoma, ductal	CFPAC-1	75	65	60	160	85	155	160	95	155	165	160
38	Lung	Adenocarcinoma	H1437 (NCI-H1437)	75	89	73	88	82	85	102	84	87	106	97
39	Ovary	Adenocarcinoma	OVCAR-8	77	71	62	85	81	85	78	96	83	95	98
40	Colon	Adenocarcinoma	GP5d	78	87	84	164	62	141	155	112	115	167	192
41	Colon	Adenocarcinoma	LoVo	80	85	90	90	90	90	85	90	90	90	95
42	Pancreas	Ductal carcinoma	PANC-1	80	80	90	90	90	90	85	85	90	90	100
43	Colon	Colorectal carcinoma	T84	80	70	60	110	75	100	100	65	115	125	115
44	Lung	Large cell carcinoma	H661 (NCI-H661)	80	75	90	85	100	90	90	95	95	95	120
45	Colon	Rectal adenocarcinoma	SW837	80	95	85	155	80	130	135	100	125	130	150
46	Ovary	Adenocarcinoma	SKOV3	81	83	88	127	88	130	121	91	102	127	129
47	Breast	Carcinoma	BT20	85	77	77	93	78	98	95	88	94	91	91
48	Lung	Adenocarcinoma	H1993 (NCI-H1993)	85	90	90	95	85	90	90	85	90	95	100
49	Gastric	Carcinoma	SNU-16	85	100	100	105	75	100	100	70	90	90	100
50	Breast	Adenocarcinoma	MCF7	85	110	125	105	80	110	135	100	100	110	130
51	Muscle	Rhabdomyosarcoma	RD	85	85	100	120	100	100	105	90	110	125	145
52	Colon	Adenocarcinoma	HT29	90	85	90	105	100	90	90	70	90	105	100
53	Breast	Carcinoma	MDA-MB-157	90	95	100	100	90	100	105	100	95	95	100
54	Ovary	Adenocarcinoma	OVCAR-5	90	75	80	115	85	120	120	95	120	110	115
55	Urinary tract	Carcinoma	RT-112	90	100	90	130	95	135	150	125	130	135	130
56	Colon	Colorectal adenocarcinoma	SW403	90	65	70	120	75	110	125	100	100	105	150
57	Urinary tract	Carcinoma	RT-4	90	75	75	140	70	160	150	110	155	170	170
58	Breast	Ductal carcinoma	MDA-MB-134-VI	95	85	85	100	110	90	90	88	88	90	95
59	Breast	Carcinoma	MDA-MB-453	95	95	75	90	100	100	90	95	70	75	100
60	Lung	Squamous cell carcinoma	H520 (NCI-H520)	95	92	105	92	93	99	91	93	93	93	104
61	Lung	Squamous cell carcinoma	EBC1	95	95	100	100	85	105	95	65	90	100	115
62	Urinary tract	Urinary bladder transitional carcinoma	BFTC-905	95	90	95	110	100	105	110	100	110	110	115
63	Colon	Carcinoma	HCT-116	97	81	92	99	98	100	86	92	91	101	96
64	Breast	Carcinoma	CAL-51	100	99	105	144	105	147	144	123	133	126	144
65	Prostate	Carcinoma	LncAP FGC	100	90	90	180	120	130	125	110	130	120	175
66	Lung	Adenocarcinoma	A549	105	100	100	100	105	125	130	110	100	120	140
67	Lung	Squamous cell carcinoma	H1703 (NCI-H1703)	107	95	109	273	98	225	300	119	238	230	322
68	Lung	Large cell carcinoma, lymph node metastasis	H1299 (NCI-H1299)	110	105	105	130	105	125	125	110	150	110	150
69	Ovary	Adenocarcinoma	OVCAR-4	110	80	85	210	95	200	205	120	200	220	250
70	Breast	Adenocarcinoma	AU-565	115	60	75	75	100	115	120	50	95	125	125
71	Lung	Squamous cell carcinoma, Mesothelioma	H226 (NCI-H226)	135	140	140	175	130	165	135	135	165	170	175

Figure 26





Figure 27


Figure 28


Figure 29

Figure 30





Figure 31

Figure 32




Figure 33





Figure 34

Figure 35





Figure 36


Figure 37


Figure 38


Figure 39


Figure 40


Figure 41

Figure 42

**LNA-EGFR and anti-EGFR mAb 2mix
induce similar reduction in cell viability**




Figure 43





Figure 44

Figure 45A




Figure 45B




Figure 1

		20		40	
			CDR1		
1277_CDRgrafted-H	EVQLVESGGGLVQPGGSLRLSCAASG		EFSTSDMSWVRQAPGKGL	45	
10292				R	45
10460 & 11294				R	45
		60		80	
	CDR2				
1277_CDRgrafted-H	EWVSY	SSAGDV	FYS	DTVKG	RFTISR
					DN
					AKNSLY
					LQMNSL
					RAED
90					
10292				V	90
10460 & 11294				V	90
		100			
	CDR3				
1277_CDRgrafted-H	TAVYYC	VRHRDV	AND	WGQGT	TVTVSS
117					
10292					117
10460 & 11294					117

		20		40	
			CDR1		
1277_CDRgrafted-L	DIQMTQSPSSLSASVGDRVTITCRSS		QS	VHSNGNT	YLHWYQQKP
45					
10292				A	45
		60		80	
	CDR2				
1277_CDRgrafted-L	GKAPKLLIY	KVSNR	FSGVPSR	FSGSGSGT	DFTLTIS
					SLOPED
					FAT
90					
10292					90
		100			
	CDR3				
1277_CDRgrafted-L	YYCS	QSTHVP	TFGGG	TKVEIK	111
111					
10292	.F.....				111

		20		40	
			CDR1		
1277A_CDRgrafted-L	DVVM	TQSP	LSLP	VTLG	QPASIS
					SCRSS
					QS
					VHSNGNT
					YLHWFQ
					QQR
45					
10460					Y
45					
11294					L
45					Y
		60		80	
	CDR2				
1277A_CDRgrafted-L	GQSP	RRLLIY	KVSNR	FSGVPSR	FSGSGSGT
					DFTLKI
					SRVEA
					EDVGV
90					
10460					L
90					
11294					L
90					
		100			
	CDR3				
1277A_CDRgrafted-L	YYCS	QSTHVP	TFGGG	TKVEIK	111
111					
10460	.F.....				L
111					
11294	.F.....				111